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ABSTRACT
Background
In 2011, The Centers for Medicare and Medicaid Services (CMS) has introduced
a bundled payment reform along with a Quality Incentive Program (QIP) to bring
efficiency in End stage renal disease (ESRD) care. The QIP rates facilities using clinical
and reporting criteria, but misses out on patient outcomes. It penalizes facilities not
achieving a target score by 0-2% of payments. The small facilities are expected to be
impacted more by a reduction in payments. We determined the association between
ESRD facility size and QIP scores and the association between QIP scores and patient
survival.
Methods
We used the Medicare dialysis facility compare, facility level impact and QIP
files; United State Renal Data System (USRDS) facility and patient data and Area health
resource (AHRF) file. We restricted the data to 2013, the most recent year for which all
data were available.
For the first objective, we aggregated the USRDS patient data by facility.
Merging the above data yielded 5,193 facility records. We measured facility size by
number dialysis stations. Given a non-linear relationship between QIP sores and dialysis
stations, we categorized stations into three categories including small (≤10), medium (1125) and large
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(>25). We used a multivariable generalized linear model to determine the association
between QIP scores and facility size.
In the objective 2, we included 96,102 incident ESRD patients from January
2013- December 2013, using USRDS patient files. We determined 1-year patient survival
among incident patients who survived the first 90 days. A multivariable Cox proportional
hazard model was run to estimate the association between QIP scores and patient.

Result
The medium and large size facilities scored higher on QIP than small facilities.
Facilities in South, offering peritoneal dialysis, having higher number of Hispanics
patient and county populations scored higher on QIP. However, the facilities with a
higher average distance between patients and facility, a higher proportion of black
population in a facility or county scored lower. Further, patients in facilities scoring < 60
showed a higher mortality than patients in facilities scoring ≥ 95.

Conclusion
We found small facilities scored lower by the QIP than medium and large
facilities. Further, facilities performing lower on the QIP criteria demonstrated lower
patient survival. Our finding that a higher black population in a facility or in the county is
associated with lower QIP scores warrants more research
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CHAPTER I: INTRODUCTION
1.1

THE U.S. HEALTHCARE SYSTEM AND ESRD CARE
The U.S. spends more on healthcare than any other country (Health at a Glance

2011: OECD Indicators, 2011; Woolf & Aron, 2013). However, it lags behind many
wealthier nations, both in life expectancy and quality of care (The Commonwealth Fund,
2015; Woolf & Aron, 2013). The US spent $3.2 trillion on health care in 2015, 17.8% of
gross domestic product (GDP) (Martin, Hartman, Washington, Catlin, & Team, 2016).
Trends show a continuing rise in cost of care, more so, during the past two decades
(Dieleman et al., 2016). The rising health care costs have affected both private and public
health insurance programs. Medicare, being the largest public insurer, is expected to
utilize 8% of the GDP in 2020, an unprecedented consumption of a single program
(Thorpe, Ogden, & Galactionova, 2010). Therefore, the Centers for Medicare and
Medicaid Programs (CMS) is focused on bringing healthcare delivery reforms.
Some diseases are more costly to treat than the others. An example of such
disease is end-stage renal disease (ESRD). Given its high cost, Centers for Medicare and
Medicaid Services (CMS) included ESRD as a first disease based eligibility in 1972. In
other words, ESRD patients are enrolled in Medicare, irrespective of their age. When the
ESRD legislation was being debated in 1972, the estimated cost was $22-25K per patient
per treatment year in the most expensive setting (hospital) (Richard A. Rettig, 1991).
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ESRD patients require kidney transplantation or frequent dialysis to survive
(Levey & Coresh, 2012). Kidney transplantation is a more permanent and cost effective
treatment than dialysis, however, a majority of patients remain on dialysis due to the
unavailability of kidneys or mismatch in kidney tissues (Garcia, Harden, & Chapman,
2012). Dialysis entails a long treatment with a high recurring cost (National Kidney and
Urologic Diseases Information Clearinghouse, 2013). In 2011, total Medicare
expenditure by modality included, $24.3 billion for hemodialysis; $1.5 billion for
peritoneal dialysis and $2.9 billion for kidney transplants (United States Renal Data
System, 2013). The majority of the End-stage renal disease (ESRD) patients are covered
by Medicare or jointly by Medicare and Medicaid programs (Wetmore, Rigler, Mahnken,
Mukhopadhyay, & Shireman, 2009).
Initially, Medicare reimbursed the cost of ESRD treatment, laboratory services
and drugs, using fee-for-service (FFS) methods (Watnick et al., 2012). The fee-forservice (FFS) payment mechanism and growth in the eligible population increased the
total ESRD care cost to Medicare. Further, the lifespans of ESRD patients have also
increased due to the discovery and use of new treatment modalities (A. W. Williams,
2015). Currently, ESRD patients account for a disproportionate share of Medicare
expenditures – ESRD patients comprise about 1% Medicare patient population, however,
consume 7% of the program expenditures (Ojo, 2014; The American Society of
Nephrology, 2014). The rise in overall healthcare cost and, more specifically, the ESRD
care cost, resulted in Medicare seeking more efficient payment models.

2

1.2

INITIAL COST CONTAINMENT: NARROW BUNDLE PROGRAM
In 1983, the program promulgated the ESRD bundled payment model – also called

narrow bundle payments (Chambers, Weiner, Bliss, & Neumann, 2013). Medicare paid
$130 per dialysis treatment, however, kept reimbursing facilities for the provider’s fee,
laboratory tests and medications by FFS method (Watnick, et al., 2012). Consequently,
the providers started prescribing more medications to ESRD patients. The higher
erythropoiesis stimulating agent (ESA) was one such example. This drug improves
hemoglobin levels among anemic ESRD patients. In 2005, 40% of facility payment were
mainly driven by ESA — a separately billable drug (Weiner & Watnick, 2010). Epoetin
and darbepoetin are the two approved ESAs. Epoetin had become a revenue generator,
consuming $2 billion in Medicare costs in the same year (Steinbrook, 2007).

1.3

MODIFICATION: EXPANDED BUNDLE PAYMENT
Realizing the ever increasing cost of the program, Medicare implemented a

prospective payment system with an expanded bundle payment in 2011 (Iglehart, 2011;
Medicare & Medicaid Services 2010). Using new PPS, CMS pays a predetermined
Medicare payment to cove items and services in a dialysis care episode . The composite
rate covers routine laboratory The services included intravenous drugs, laboratory
services, supplies and capital-related costs related to providing maintenance dialysis
(Iglehart, 2011). The expanded bundle makes an average payment of $230 per dialysis
episode, This cost was calculated after adjusting for patient characteristics, including,
age, body size and acute/chronic health conditions (Medicare & Medicaid Services 2010;
Swaminathan, Mor, Mehrotra, & Trivedi, 2012). However, physicians were still
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reimbursed by FFS method. At the end of 2011, the majority of the dialysis facilities
were paid through PPS (Iglehart, 2011).

1.4

POTENTIAL RISKS OF THE EXPANDED BUNDLE PROGRAM
The expanded bundle was designed to bring down cost, however, experts raised

concerns about the negative effects of fixed payment (Kristensen & Wish, 2010; Weiner
& Watnick, 2010). For instance, to mitigate financial risks, dialysis facilities can
undertreat, cherry pick, stint services and increase referrals to ensure financial solvency
(Chambers, et al., 2013; Iglehart, 2011; Kristensen & Wish, 2010; Swaminathan, et al.,
2012). Such reactions to cost saving can result in higher patient complications,
hospitalization, readmissions and mortality due to poor quality of health care (Iglehart,
2011).
The agency theory attempts to explicate the relationship between principal and agent
in a marketplace. The bundled payment is likely to affect the relationship between
principal and agent. A provider (dialysis facilities) acts as an agent, while a patient acts as
a principal (Eisenhardt, 1989; Lee & Zenios, 2012). Under financial constraints, the
agent tries to save cost (Eisenhardt 1989). The principal remains unable to assess agent’s
performance and has no control over the quality of service rendered by an agent.
Therefore, cost savings reforms that are not coupled with quality assessment can result in
lower quantity and quality of service (Landon et al., 2007; Sekhri, 2000).
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1.5

ESRD QUALITY PROGRAM
Researchers raised concerns about the possibility of service quality and quantity

decline after the expanded bundle (Chambers, et al., 2013; Kristensen & Wish, 2010).
Considering the concerns and taking lessons from the past, Medicare included the Quality
Incentive Program (QIP) as part of the Medicare ESRD Program in Medicare
Improvement for Patient and Provider Act, 2008 (Medicare & Medicaid Services 2011).
In 2011, the program was formally implemented after the initiation of expanded bundled
payment. Initially, the QIP tracked the facility performance using indicators: proportion
of patients with hemoglobin (Hgb) levels <10 g/dl, Hgb ≥ 12 g/dl and urea reduction ratio
of ≥ 65% average over a year (Fishbane & Hazzan, 2012). Over years, the program
added more indicators including, clinical measures (proportion of patients with
arteriovenous fistula (AVF) and the proportion of patients with catheter for more than 90
days of dialysis initiation) and reporting factors (Table 2.1). The presence of mature AVF
decreases the risk of infections associated with dialysis.
CMS penalizes facilities scoring lower than the target score on QIP by 0-2% of the
payments (Center for Medicare and Medicaid Services, 2012b). Table 2.1 presents the
summary of the clinical measures, reporting measures and scoring criteria. Chapter II
includes more details on indicators and performance calculation and criteria.
Generally, the experience with pay for performance is mixed (James, 2012).
Researchers have also questioned whether the QIP will improve the patient outcomes
(Watnick, et al., 2012; A. W. Williams, 2015). The program was implemented as an
uncontrolled pilot – using a “one size fit all” strategy without an initial pilot or
effectiveness study (A. W. Williams, 2015). Moss and Davison criticized the program’s
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narrow clinical focus, rather than a focus on achieving overall health of the patient (Moss
& Davison, 2015). QIP includes easy to measure laboratory indicators (Moss & Davison,
2015; Nissenson, 2013). However, both Moss et al. and Nissenson et al. reviewed studies
based on specific measures included in the QIP criteria rather than the studies that the
QIP criteria. The QIP criteria include a collection of clinical and reporting measures.
Therefore, a key unanswered question is the relationship between QIP scores and actual
patient outcomes including patient survival.

1.6

FACTORS ASSOCIATED WITH ESRD QUALITY PERFORMANCE
In addition to Medicare quality incentives, facility factors such as chain

affiliation, for-profit status, number of dialysis stations and patient to staff ratio influence
facility performance and health outcomes (Straube, 2014; Yan, Norris, Xin, et al., 2013;
Yue Zhang, 2015). Zhang et al. reported for-profit and chain affiliated facilities rendering
better service quality (Yue Zhang, 2015).
QIP is more likely to increase financial constraints of small dialysis facilities (A.
W. Williams, 2015). QIP can limit the ability of smaller facilities to receive medication
discounts, establish their own pharmacy and laboratory services and administer electronic
health records (Slinin & Ishani, 2013). The few studies that have addressed the
association between size and quality have reported mixed results. For instance, while
Eisenstein et al. and Yan et al. reported that smaller facilities are associated with a higher
patient mortality (Eisenstein et al., 2008; Yan, Norris, Xin, et al., 2013, ) Zhang et al.
reported such facilities perform better (Yue Zhang, 2015). Zhang and associates surmised
that a higher focus on producing results in larger facilities losing their sight on
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performance. Notably, the definition of size also varies in the literature. Yan et al. and
Zhang et al. used number of stations, while Eisenstein et al. used number of treatments to
measure facility size.
CMS payment reforms are expected to impact small size facilities adversely
(Chambers, et al., 2013; A. W. Williams, 2015). Rural dialysis facilities are more likely
smaller in size (Medicare Payment Advisory Commission (US), 2015); treat a low patient
volume; render fewer treatments; operate on fewer dialysis stations and generate lower
profit margin, compared with urban facilities (Eisenstein et al., 2008; Medicare Payment
Advisory Commission (US), 2015; O'hare, Johansen, & Rodriguez, 2006; Yan, Norris,
Xin, et al., 2013).
In 2012, CMS rebased the bundle payments, further reducing per treatment
payment by $30 (Wish, Johnson, & Wish, 2014). Rebasing was expected to further
aggravate financial constraints of rural facilities. CMS proposed Low Volume Payment
Adjustments (LVPA) for rural and low volume facilities. However, recent reports
indicate discrepancies in financial adjustments, causing under adjustment or no
adjustment (United States Government Accountability Office, 2013). Low operating
margins are associated with poor quality of care (Ly, Jha, & Epstein, 2011). Therefore,
we hypothesize that small size dialysis facilities are more likely to render a poor quality
of dialysis services.
1.7

RATIONALE
Performance scores were designed by CMS to improve the quality of the program

in the face of increased risk of compromised quality. Facility, patient and ecological
characteristics work in tandem to influence quality of care (Donabedian, 1988). The
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literature contains mixed results relating facility size with care quality. Large facilities
receive higher patient volume and therefore are expected to perform better on QIP
criteria. High volume brings down treatment cost. Large organizations receive higher
patient volume which in turn enables them to make more revenues and negotiate on lower
prices. However, Zhang et al.’s study found that the larger facilities performed worse
(Yue Zhang, 2015). QIP may impact small size dialysis facilities adversely (A. W.
Williams, 2015). To the best of our knowledge, no study has determined the association
between number of dialysis stations (facility size) and facility QIP performance scores,
controlling for patient, facility and ecological factors and demand side factor (patient
volume and number of treatments). Small facilities are expected to perform poorly and
become liable to QIP penalties, closure and consolidation after the bundled payment.
However, empirical evidence of association between facility size and QIP scores are
missing. Further, QIP criteria are generally critiqued for their narrow clinical focus,
however, no study has yet determined the association between facility QIP score and
patient survival. Therefore, the proposed research addresses two main questions, as
follows.

1.8

RESEARCH QUESTIONS
1) Is facility size associated with the performance of the freestanding dialysis
facilities as measured by QIP scores?
Hypothesis: Net of other factors, larger facilities have better performance scores
than smaller facilities
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2) Is freestanding dialysis facility performance as measured by QIP scores associated
with the survival of the ESRD patients on dialysis?
Hypothesis: Net of other factors, patient survival are positively associated with
QIP performance scores.

9

CHAPTER II: BACKGROUND
2.1

ESRD: A COSTLY AND FATAL DISEASE
ESRD is the principal sequel of chronic kidney disease (CKD) (Couser, Remuzzi,

Mendis, & Tonelli, 2011). CKD results in the inability of kidneys to fully excrete the
body waste. Kidneys are made up of millions of nephrons – filtering units that excrete
body waste and play a role in mineral and water homeostasis (J. E. Hall, 2015). A normal
kidney has a GFR of 125 ml/min/1.73 m2 (Levey et al., 2011). In CKD nephrons die,
reducing the kidney filtration rate, also called the glomerular filtration rate (GFR). As it
progresses, more nephrons die causing further reduction in filtration rate. ESRD ensues
when GFR is reduced to 15 ml/min/1.73 m2 (Levey, et al., 2011).
Reduced GFR results in waste build up inside the body causes uremia – a
syndrome is characterized by a buildup of nitrogenous end products of protein and amino
acids (J. E. Hall, 2015). The nitrogenous end products include urea (measures as Blood
Urea Nitrogen) and creatinine. CKD leads to complications including, hypertension;
weak bones; anemia; infections; pericarditis; pulmonary edema; damaged nerves; poor
nutritional status; and cardiac arrest (Centers for Disease Control and Prevention, 2014;
Taal, 2015). Advanced CKD heralds end stage renal disease (ESRD), a chronic and
debilitating condition. The kidneys completely stop excreting waste (Couser, et al.,
2011).
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Currently, about 10% of the U.S. adult population i.e., about 20 million, suffers
from CKD. The country reported 778,810 ESRD cases in 2013 (Centers for Disease
Control and Prevention, 2014; United States Renal Data System, 2015). The reported
rates of ESRD are three times in the U.S. than other Organization for Economic
Cooperation and Development (OECD) countries (Levey & Coresh, 2012; McCullough
et al., 2011). Indeed, the US ranks third after Taiwan and Japan in ESRD prevalence (Jha
et al., 2013; Levey & Coresh, 2012).
The numbers of ESRD patients are expected to grow with an aging population.
Since 2012, ESRD has risen at a rate of 3.5 % annually, adding 21,000 patients per year
(United States Renal Data System, 2015). Medicare expects its enrollees to increase from
50 million currently to nearly 70 million in 2023 (Blumenthal, Stremikis, & Cutler,
2013). The quality and cost of the ESRD Medicare program will face more brunt of
increasing ESRD aging and frail population with the passing time.
ESRD patients have a higher all-cause mortality rate compared to the other
Medicare patient populations, including cancer (United States Renal Data System, 2015).
In 2015, Jiaquan Xu and colleagues reported kidney diseases among the ten most
common causes of mortality in the US (Jiaquan Xu, 2016). The mortality among ESRD
patients show a rising trend - age adjusted death rate increased by 1.5% between 2014
and 2015 (Jiaquan Xu, 2016). About 20% ESRD patients die within a year of dialysis and
35% die within three years of diagnosis (de Jager et al., 2009; Nissenson, 2013).
2.2

HISTORY OF THE MEDICARE ESRD COST SYSTEM
In 1972, ESRD patients became eligible to enroll in the Medicare program,

irrespective of age (Watnick, et al., 2012; A. W. Williams, 2015). The increasing ESRD
11

enrollees and cost of the program has resulted in CMS introducing payment reforms in
1980s and onwards (Watnick, et al., 2012).

2.2.1

Narrow bundled payment
Before 1983, Medicare reimbursed ESRD facilities using a retrospective FFS

payment model, without any payment cap (Chambers, et al., 2013). In 1983, the Social
Security amendment introduced a composite dialysis payment rate of $130 (Iglehart,
2011). The amendment, however, allowed for some items, including drugs, to be billable
outside the bundle. As a result, the providers prescribed costly medications at a higher
rate (Watnick, et al., 2012). ESA is an example of one such costly drug, the use of which
increased exponentially after the QIP.
In 1989, Medicare approved the use of ESA, that is, Epoetin, as a separately
billable drug (Watnick, et al., 2012). Epoetin maintains blood hemoglobin in normal
limits among anemic ESRD patients. Medicare applied a rate of $40 for initial 10,000
units, and the $30 for the units in excess to 10,000 (Watnick, et al., 2012). However, in
1991, Medicare revised the rate to $10 per 1,000 units.
Providers used Epoetin to maximize profits, making it a major revenue source.
Consequently, in 2006, Epoetin constituted a 70% of the total ESRD drug cost, a $2
billion (Watnick, et al., 2012). The overall cost of the program increased tremendously.
In addition to the possible overuse of ESA, the other factors increasing cost included
increasing ESRD prevalence, the number and severity of comorbidities, and changing
technology and treatment modalities (A. W. Williams, 2015).
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2.2.2

Expanded Bundle Payment System
To rein in the escalating cost, Medicare introduced the ESRD Prospective payment

system (PPS) as a part Medicare Improvements for Patients and Providers Act (MIPPA)
in 2011 (Weiner & Watnick, 2010). As an expansion of narrow bundle, the new PPS
system included the separately billable drugs, laboratory tests and other related services
in a fixed payment bundle of $230 per episode of care. CMS adjusted the bundle for
patient age, body size and morbidities (Medicare & Medicaid Services 2010;
Swaminathan, et al., 2012). The majority of the facilities shifted to the new system within
a year of its implementation.

2.3

ADDRESSING QUALITY OF CARE UNDER BUNDLED PAYMENT
The term quality used here and hereafter relates to the QIP scores assigned by

Medicare ESRD QIP. The bundled payment increases the financial risks of the providers.
The providers had to render services within an allocated amount. Research has indicated
potential negative effects of bundled payment including lower service quantity (stinting)
quality (Kristensen & Wish, 2010; Winkelmayer & Chertow, 2011). Providers can cherry
pick healthier patients and refer patients with complications (Chambers, et al., 2013;
Desai, Bolus, et al., 2009).
Stinting results in higher hospitalizations and readmission and thereby a higher cost
(Iglehart, 2011). Due to the inclusion of ESA in the bundle payment, providers could also
turn to blood transfusions to treat anemia among ESRD patients (Iglehart, 2011; A. W.
Williams, 2015). The cost of blood transfusion and hospitalization are paid outside the
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bundle. An unnecessary blood transfusion compromises the immune system and
increases the risk of infections (Winkelmayer & Chertow, 2011).

2.4

QUALITY AND EVOLUTION OF QIP
CMS formally addressed quality in ESRD through the Balanced Budget Act for the

first time in 1997 (Frederick, Maxey, Clauser, & Sugarman, 2002; Watnick, et al., 2012).
The Act mandated facilities to report on quality. However, the assessment prompted no
monetary penalty or incentives (Ramanarayanan & Snyder, 2012). In early 2000, the
severe quality deficiency was identified in the US healthcare system by the Institute of
Medicine (IOM) (Berwick, 2002). In 2001, the CMS launched a dialysis facility compare
data public reporting system. The system tracked the facility performance and allowed
CMS to incentivize conforming facilities (Ramanarayanan and Snyder 2012). The broad
category of quality criteria included anemia control, dialysis adequacy and survival.
Realizing the compromised quality as a potential risk, Medicare introduced QIP, a
pay-for-performance system, a few months after the PPS (Center for Medicare and
Medicaid Services, 2016b); (Berenson, Pronovost, & Krumholz, 2013). The term “Payfor-performance” embodies quality, efficiency and value based purchasing (Eijkenaar,
2013). It creates rewards for providers who meet or exceed quality criteria (James, 2012).
It also penalizes the noncompliance to quality measures (Berenson, et al., 2013).
Medicare ESRD QIP is such an example. Facility quality measures and benchmarks were
developed and publicly reported with a penalty of 0-2% on non-compliance (Berenson, et
al., 2013; Center for Medicare and Medicaid Services, 2016b; Iglehart, 2011).
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2.4.1

QIP performance indicators
Prior research has shown the association of clinical benchmark such as attainment

of target Hgb, hematocrit, URR, albumin, etc. with health outcomes including improved
survival and lesser hospitalization. (Lacson, Wang, Lazarus, & Hakim, 2009; Plantinga et
al., 2007). Among large nonprofit chains, Tentori et al. found achieving clinical goals
(Urea levels, hemodialysis treatments, hemoglobin level, bicarbonate level, albumin
level, phosphorus level, fistulae, and catheters) in the large nonprofit chain was
associated with better patient survival (Tentori et al., 2007).
Since its inception, QIP criteria varied over the years. The following section
presents clinical and reporting measures and target scores used by QIP over the years
(Table 2.1).
Medicare publishes facility quality reports two years after the actual service year
(Center for Medicare and Medicaid Services, 2016b). Thus, services rendered in calendar
year 2010 are reported in 2012. In the current study we used the calendar (service) year
as a reference to payment year. In the calendar year 2010, the three performance
indicators were included; 1) the proportion of patients with hemoglobin (Hgb) >12 mg/dl,
2) Hgb < 10 mg/dl and 3)urea reduction ratio (URR) of ≥ 65% (Centers for Medicare &
Medicaid Services (CMS), 2013). Hgb >10 and Hgb > 12 determine appropriateness of
anemia management, while URR measures dialysis adequacy (Swaminathan, et al.,
2012). All clinical measures are discussed in more detail at the end of this section.
For the calendar year 2011, CMS revised the QIP criteria. It removed the proportion
of patients with Hgb < 10 mg/dl, keeping the other two aforesaid criteria (Centers for
Medicare & Medicaid Services, 2013a). Medicare decided to remove Hgb < 10 mg/dl
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after the Food and Drug Administration (FDA) added a label on ESA indicating a need
for cautious use of the drug (Food and Drugs Administration (FDA), 2011). The FDA
added the label based on clinical trials reporting cardiovascular events, including stroke
and mortality, associated with the drug (Food and Drugs Administration (FDA), 2011;
Manns & Tonelli, 2012). Since the overuse of ESA has serious side effects, therefore,
Medicare decided to exclude Hgb < 10 mg/dl as a QIP criterion.
In the calendar year 2012, CMS again revised the criteria. This time, it included
three clinical measures to determine total performance scores. The clinical indicators
included, the proportion of patients with Hgb > 12 mg/dl and URR ≥ 65% and vascular
access treatment (VAT) (Centers for Medicare & Medicaid Services, 2013b; Fishbane &
Hazzan, 2012). VAT is associated with lower rates of localized infections, thrombosis
and better patient survival (Chand, Teo, Fatica, & Brier, 2008). Further, lower rates of
Hgb > 12 and higher rates of URR > 65% marks better quality (Fishbane & Hazzan,
2012). In 2012, QIP expanded its base by including pediatric, home dialysis and
peritoneal dialysis facilities.
In calendar year 2013, CMS further included six clinical and four reporting
indicators to examine the quality of dialysis facilities. Additionally, in lieu of URR, CMS
introduced three dialysis adequacy measures – percent adult hemodialysis patients with
Kt/V >1.2, percent pediatric hemodialysis patients with Kt/V >1.2 and peritoneal dialysis
patients with Kt/V >1.7 (Centers for Medicare & Medicaid Services 2013). However,
reporting on anemia management was added as a facility reporting measure (Centers for
Medicare & Medicaid Services 2013).
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It also enforced a 2% penalty on a non-conformance (Chambers, et al., 2013; CMS.gov
Centers for Medicare & Medicaid Services ; Iglehart, 2011).
2.4.2

Calculation and use of performance scores
In the calendar year 2010, Medicare compared facility performance in 2010

against its performance in 2007 or national average in 2008, whichever standard yielded a
better score. Medicare assigned a score of 10 on each measure, if a facility met or
exceeded the given standard. However, it deducted 2 points per percentage if facility fell
short of the standard. Given three measures, Hgb < 10g/dL, Hgb > 12 and URR, a facility
could attain a maximum score of 30. While, Medicare assigned a higher weight of 50% to
Hgb < 10g/dL, the other two were given a weight of 25%. In 2010, Medicare required a
facility to score at least 26 to avoid a penalty, a payment reduction of 0.5-2%.
In the calendar year 2011, Medicare compared facility performance in 2011
against its performance in 2007 or the national average in 2009, whichever yielded a
better result. An equal weight was used for both standards, Hgb > 12 and URR. The
calculated scores were multiplied by 1.5 to get performance scores ranging from 0-30.
Facilities were required to score 30 to avoid payment reductions of 0-2%.
In the calendar year 2012, Medicare compared facility performance in 2012
against its national performance rate of mid 2010-2011 (Centers for Medicare &
Medicaid Services, 2012). A performance score was assigned to facilities based on two
clinical criteria (Hgb >12 and URR) and one reporting criteria vascular access type
(fistula versus catheter). The scores ranged from 0-100. Penalties of 0-2% were applied
on a sliding scale for the scores below 53.
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Table 2.1: ESRD quality incentive program (QIP) performance measures summary 2012-15
Clinical indicators

Reporting indicators

PY a 2012
Hgb e > 12 g/dL
Hgb < 10 g/dL
URR f > 65%

PY 2013
Hgb > 12 g/dL,
URR > 65%

None

None
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Performance period

CYb 2010

CY 2011

Performance standards

Lesser of the
performance rate in
CY 2007 OR the
national performance
rate in CY 2008
50% Hgb < 10 g/dL
25% Hgb > 12 g/dL
25% URR > 65%

Lesser of the
performance rate in
CY 2007 OR the
national performance
rate in CY 2009
50% Hgb > 12 g/dL
50% URR > 65%

Weights

PY 2014
• Hgb > 12 g/dL
• URR
• VAT g

PY 2015
Hgb > 12 g/dL
VAT Measure Topic (fistula,
catheter)
Kt/V Dialysis Adequacy
Measure Topic (hemodialysis,
peritoneal dialysis, pediatric
hemodialysis)

• NHSN c
• ICH CAHPS d
• Mineral
Metabolism
CY 2012

• NHSN c
ICH CAHPS
• Mineral Metabolism
• Anemia Management
CY 2013

National
Performance Rate
(July 1, 2010 – June
30, 2011)

National Performance Rate (CY
2011)

Clinical: 90%,
Reporting: 10%
If the facility has
only one type of
measure, that type is
weighted at 100% of
the score.

Clinical: 75%, Reporting: 25%

Total score (min
requirement)
Minimum Data
Requirements

Low volume adjustment

PY a 2012
30 (26)

PY 2013
30(30)

PY 2014
100 (53)

PY 2015
100 (60)

11 cases for each
measure

11 cases for each
measure

Facility needs both (i) 11 cases
for at least one clinical measure
and (ii) to qualify for at least
one reporting measure. Note:
The 11-case minimum now also
applies to reporting measures.

None

None

Facility needs either
(i) 11 cases for at
least one clinical
measure or (ii) to
qualify for at least
one reporting
measure.
None

Applied to clinical measures
with 11 – 25 cases

Source: Centers for Medicare and Medicaid Services, ESRD QIP Summary: Payment years 2012-2016
19

Notes:
a
PY Payment year;
b
CY Calendar year
c
NHSN National Healthcare, Safety Network
d
ICH-CAHPS In-Center Hemodialysis Survey Consumer Assessment of Healthcare Providers and Systems
e
Hgb Hemoglobin
f
URR Urea reduction ratio
g
VAT Vascular Access Treatment

In the calendar year 2013, CMS compared facility performance in 2013 against its
performance National performance rate of CY 2011 (Centers for Medicare & Medicaid
Services 2013). A performance score was estimated based on six clinical measures and
four reporting measures (Table 2.1). A 75% weight was assigned to clinical and 25% to
reporting measures (Center for Medicare and Medicaid Services, 2012b). The scale of 0100 was devised. Medicare required the facility to score at least 60 to avoid penalties.
In addition to the standards and calculation details, Medicare also defined the
facility eligibility for score reporting. Before 2012, the eligible facilities included those
for which each performance measure was reported for at least 11 patients (Centers for
Medicare & Medicaid Services, 2012). In 2012, the eligibility included reporting on 11
patients for at least one clinical indicator and informing on the reporting indicator. In
2013, the total performance scores were reported for facilities that received scores on at
least one clinical and one reporting measure (Centers for Medicare & Medicaid Services
2013).
The section below includes the description and clinical significance of the recent
measures. For the calendar year, 2013 QIP scores are calculated using both clinical and
reporting measures. The clinical measures include, Hgb of >12 mg/dl, Kt/V for adult
hemodialysis, adult peritoneal dialysis patients and pediatric hemodialysis patients, VATCatheter and VAT-AVF (Centers for Medicare & Medicaid Services 2013). While,
reporting measures incorporate, reporting infections to the Centers for Disease Control
and Prevention’s (CDC) National Healthcare, Safety Network (NHSN); conducting
patient surveys on care experience and monitoring patient calcium and phosphorus levels
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(Center for Medicare and Medicaid Services, 2016b). In the calendar year 2013,
Medicare included anemia management as an additional reporting measure.

2.4.3

QIP: The ESRD Clinical Performance Measures (CPM) for calendar year 2013

The clinical rationales behind the current QIP measures are discussed here. This includes
a discussion for the inclusion, and subsequent exclusion, of low hemoglobin values as a
measuring point.
Hemoglobin levels
Anemia, or low hemoglobin levels, is the most common complication kidney
failure (Kazmi et al., 2001). The lack of erythropoietin, a renal hormone that stimulates
bone marrow for RBC production, results in anemia (Bunn, 2013). Uremia, an abnormal
urea level in blood, also contributes towards RBC destruction, production of defective
RBCs and inability of platelets to create clots at bleeding points (Bunn, 2013). These
mechanisms result in either lower RBC count and reduced hematocrit (amount of
hemoglobin in the RBC). Hgb less than 9.0-10 g/dl or hematocrit less than 33% are
associated with higher mortality among ESRD patients (Hanafusa, Nomura, Hasegawa,
& Nangaku, 2014; Hörl, 2013). Treating anemia reduces risk of stroke, cardiovascular
diseases and improve outcomes among patients (Groenveld et al., 2008; Saeed, Kousar,
Qureshi, & Laurence, 2012).
Before the introduction of bundled payment and FDA label, providers treated
anemic patients with Hgb < 10mg/dl with ESA (National Institute of Diabetes and
Digestive and Kidney Disease, 2014a). Although, ESA effectively increases the Hgb
levels, however, the increase in Hgb ≥ 12g/dl is also associated with risk uncontrolled
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hypertension; vascular thrombosis (blood clots); heart attacks; stroke and higher mortality
(Lankhorst & Wish, 2010). The risk of complications increases with the variation in level
of Hgb. Specifically, an increase of 1 g/dl in standard deviation of Hgb among ESRD
patient population is associated with a 33% increase in mortality rates (Yang et al., 2007).
Therefore, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)
disapproves the use of ESA among patients with Hgb > 11.5 mg/dl (National Institute of
Diabetes and Digestive and Kidney Disease, 2014a). The inclusion of the drug in the PPS
bundle and the relabeling by FDA about its use with caution label further restricted the
use of epoetin (Manns & Tonelli, 2012). Consequently, the Medicare excluded Hgb < 10
mg/dl from the QIP list. The clinical measures Hgb >12g/dl and URR were included in
the QIP criteria in the calendar year 2011.

Dialysis Adequacy Measures
QIP used two measures of URR ≥65% and Kt/V ≥1.2 (National Institute of
Diabetes and Digestive and Kidney Disease, 2014b). URR measures a percentage
reduction in blood urea during a single dialysis treatment. URR is measured after every
12-14 dialyses or once a month (National Institute of Diabetes and Digestive and Kidney
Disease, 2014b). A higher URR demonstrate better dialysis effectiveness. Although,
research does not indicate a definitive level of adequate URR, however, URR ≥ 65%
implicates in better survival (Port, Ashby, Dhingra, Roys, & Wolfe, 2002).
In 2013, Medicare replaced URR with Kt/V, which denotes dialyzer clearance of
urea (Centers for Medicare & Medicaid Services 2013). In Kt/V, ‘Kt’ represents dialysis
time and ‘V’ indicates the volume of urea distribution (National Institute of Diabetes and
Digestive and Kidney Disease, 2014b). Kt/V estimates both the urea generated by the
22

body during dialysis and extra urea removed during dialysis along with excess fluid
(National Institute of Diabetes and Digestive and Kidney Disease, 2014b). The
recommended Kt/V normal values for adult and pediatric patient population is ≥ 1.2 and
peritoneal dialysis value of ≥ 1.7 (Centers for Medicare & Medicaid Services 2013). A
Kt/V of ≥ 1.2 corresponds with the URR of about 63% (National Institute of Diabetes and
Digestive and Kidney Disease, 2014b).
Research showed Kt/V ≥ 1.2 relates to lesser dialysis complications and mortality
among ESRD patients (Chandrashekar, Ramakrishnan, & Rangarajan, 2014; Greene et
al., 2005; Maduell et al., 2016). However, a systematic review of 128 articles that
included 44 laboratory outcomes yielded significant but modest effect of dialysis
adequacy on mortality compared to the other laboratory markers such as tumor necrosis
factor (TNF), pre-albumin, and C-reactive protein (CRP) (Desai, Nissenson, et al., 2009).

Vascular access treatment
Vascular access treatment (VAT) implies the site on the body that is used to
remove and return blood during dialysis (National Institute of Diabetes and Digestive and
Kidney Disease, 2014c). A perfectly functioning vascular access plays a critical role in
efficient dialysis (Pantelias, 2012). The term VAT embodies three types of vascular
access, arteriovenous fistula (AVF), an arteriovenous graft (AVG) and central venous
catheter (CVC) (Santoro et al., 2014). Compared to the others, AVF is the safest due to
lesser infections and thrombosis rates (Chand, et al., 2008; Ng et al., 2011; Pisoni et al.,
2009; Ravani et al., 2013). Most providers use a catheter at the onset of dialysis and
thereon shift to AVF (Centers for Medicare & Medicaid Services 2013). In calendar year
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2013, Medicare included both the percentage of patients with catheter use for more than
90 days and AVF as QIP indicators.

2.4.4

QIP: The ESRD reporting measures for the calendar year 2013

Blood stream infections (BSI)
Hemodialysis increases the risk of localized infection at the vascular access site or
widespread BSIs (Patel, Kallen, & Arduino, 2010). NHSN defines BSI as “a positive
blood culture collected from a hemodialysis patient as an outpatient or within 1 calendar
day after a hospital admission”(Centers for Disease Control and Prevention, 2015). In
2014, CMS introduced BSI as a reporting indicator. Facilities reported infection events
on a given protocol to the NHSN, which established an infection surveillance system
(National Healthcare Safety Network, 2015) (Center for Disease Control and Prevention,
2015b; Medicare & Medicaid Services 2012).
The order of access type from lowest to highest risk of infections includes,
arteriovenous fistula (AVF), an arteriovenous graft (AVG) and Cardiovascular catheter
(CVC) (Fysaraki et al., 2013; Patel, et al., 2010). Incidence rates vary from 0.5-27.1/100
patients/month given the type of access used (Klevens et al., 2007). In 2008, CDC
reported 37,000 cases of BSI among hemodialysis patients with CVC access. (National
Healthcare Safety Network, 2015). BSIs result in substantial complications,
hospitalizations and deaths (Li et al., 2009; National Healthcare Safety Network, 2015;
Patel, et al., 2010; United States Renal Data System, 2013)
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In-Center Hemodialysis- Consumer Assessment of Healthcare Providers and Systems
(ICH-CAHPS) survey
CMS designed ICH-CAHPS in support with the AHRQ to capture patient care
experiences (Cavanaugh, 2016; Darby, Crofton, & Clancy, 2006). The survey captures a
patient perspective about nephrologist communication and caring; staff communication
and caring; operations of the dialysis facility; patient knowledge of treatment options;
provider and staff handling of patient problems; and global ratings (Center for Medicare
and Medicaid Services, 2016c). In 2011, the facilities started conducting the surveys,
however, CMS included ICH-CAHPS as a reporting indicator in 2012 (Centers for
Medicare & Medicaid Services, 2013b). CMS publicly reports the survey results and
mandates facilities to conduct patient surveys twice a year. (Center for Medicare and
Medicaid Services, 2012b).
The psychometric studies on ICH-CAHPS have demonstrated excellent reliability
and validity of the survey tool to capture variation in care quality (Weidmer et al., 2014).
Further, better patient care experiences translate into higher treatment adherence, lesser
use of unnecessary care and lower cost of care (Price et al., 2014).
Mineral Metabolism
In ESRD, damage incapacitate kidneys to maintain blood phosphorus and calcium
balance, resulting in deformed bones, vascular problems and seizures (Blaine, Chonchol,
& Levi, 2014; Hruska, Mathew, Lund, Qiu, & Pratt, 2008). In the absence of kidney
functions, dialysis maintains the mineral balance. Therefore, QIP requires facilities to
measure patient serum calcium and phosphorus levels at least once a month (Center for
Medicare and Medicaid Services, 2012b).
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Anemia Management
To further improve the quality of care and containing the cost, CMS included the anemia
management at the facility reporting measure in 2013 (Centers for Medicare & Medicaid
Services 2013).

2.5

CONCERNS ABOUT QIP
Researchers raised concerns about QIP’s lack of focus on patient outcomes such as

patient quality of life and survival (Chambers, et al., 2013; Swaminathan, et al., 2012;
Watnick, et al., 2012) (Kliger, 2015). The program has been criticized for its narrow
focus on easy to capture clinical and reporting criteria (Moss & Davison, 2015;
Nissenson, 2013; Smith & Hayward, 2011). Further, concerns were also raised that
completing and reporting QIP data will come at the expense of provider loss of focus on
patient care (Watnick, et al., 2012). Research indicated the potential of QIP reports to
increase the disparities among ESRD patients, due to not adjusting the scores for patient
demographics and socioeconomic conditions (Casalino et al., 2007; A. W. Williams,
2015).
Despite the concerns, the data indicate QIP succeeded in improving the clinical
benchmarks (Berenson, et al., 2013). Proportion of patients having target Hgb increased
(Fuller, Pisoni, Bieber, Port, & Robinson, 2013; Molony et al., 2016). Data also show a
slight increase in use of peritoneal and home dialysis (Rivara & Mehrotra, 2014). QIP
also marked an increase in AVF use, after its inclusion as a clinical indicator in 2014. The
AVF use increased from 63% in 2010 to 68% in 2013, whereas, catheter use decreased
(Pisoni, Zepel, Port, & Robinson, 2015). However, most patients (80%) still undergo
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catheterization at the onset of hemodialysis (Pisoni, et al., 2015). The main reason for the
increase use of the catheter at the initiation of hemodialysis are financial and regulatory
barrier to the initial placement and revision of AVF fistula (Allon et al., 2011).
In their review of existing literature, Nissenson et al. found specific clinical
measures being weakly correlated with the patient survival (Nissenson, 2013).
Conversely, literature showed improvement in survival and reduction in hospitalization
rate in 2013 (Medicare Payment Advisory Commission (US), 2015; United States Renal
Data System, 2015). Literature also reported the decline in adverse cardiovascular
outcomes, including stroke and acute myocardial infarction in ESRD patients in 2013
(Medicare Payment Advisory Commission (US), 2015). However, a limited research
exists on association between facility QIP scores and patient outcomes.
This shows that individual clinical measure in the absence of pay-forperformance initiative such as QIP influence care outcome differently.
Another concern regarding QIP implementation was an increased risk of
consolidation or closure among smaller and low volume facilities (Slinin & Ishani, 2013;
A. W. Williams, 2015). Initial research after the bundled payment initiative indicated
merging of smaller facilities with the larger chains (Chambers, et al., 2013). Smaller
facilities are more likely to be involved in cherry picking and stinting of required services
due to inability to offset financial risk compared to large dialysis organizations
(Chambers, et al., 2013; Medicare Payment Advisory Commission (US), 2015). This may
impact the quality of care and health outcomes among rural and isolated patients since
most rural facilities are smaller in size compared to urban counterparts (Eisenstein, et al.,
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2008; Medicare Payment Advisory Commission (US), 2015; Yan, Norris, Xin, et al.,
2013).
2.6

THEORETICAL FRAMEWORK FOR ADDRESSING QUALITY
The Donabedian model provides a theoretical foundation for our work

(Donabedian, 1988). The model has been used in prior researches on ESRD care quality
(Argentero, Dell’Olivo, Santa Ferretti, & on Burnout, 2008; Y. N. Hall, Xu, Chertow, &
Himmelfarb, 2014; Himmelfarb, Pereira, Wesson, Smedberg, & Henrich, 2004; Lawson
& Yazdany, 2012). Donabedian linked structures, processes and outcomes in a continuum
to evaluate quality of care (Donabedian, 1988). His model shows structures and processes
are associated patient outcomes and quality of care.
In our research, structures include, organizational, patient and population factors
(see figure 2.1 below). The processes are the activities that help achieve clinical targets
and reporting measure ensured by CMS QIP. The outcomes are further classified into
intermediate and final outcomes. The example of intermediate outcomes includes
hospitalization ratio and transfusion ratio and of the final outcomes includes, survival
rates of patients.
2.6.1

The structure, process and outcome measures
Understanding quality requires a multidimensional paradigm. Here, quality of

care refers to QIP scores. The structures, processes and outcomes work closely in tandem
to affect quality. The section below presents the structure, process and outcome measures
pertinent to our study.

28

Structures
The structure refers to the characteristics of the setting where the healthcare is
provided (Donabedian, 1988). They include administrative processes and physical
characteristics, which support the provision of care (Donabedian, 1988). A few examples
include human resources (the number of qualified health care personnel, and other health
care supporting staff); material resources (money invested and equipment used) and
organizational factors (medical staff and method of reimbursement) (Donabedian, 1988).
Structural characteristics are not necessary, but when present, increase the
likelihood of better outcomes (Hearld, Alexander, Fraser, & Jiang, 2008). These
characteristics impact care processes, which in turn influence healthcare quality. Better
health care quality improves health outcomes. The structural variables in our research
include dialysis facility resources (chain status, ownership, profit /nonprofit, total
stations, night shifts offered); dialysis types offered (in-facility vs home dialysis) and
ecological factors (percent population living below the poverty line; percent uninsured;
the education rate in the county).
Further, our study also classifies some of the patient characteristics affecting process and
outcomes. These characteristics include age; sex; race; comorbidities; the primary cause
of renal failure; insurance; location (rural/urban); distance between patient residence and
facility ZIP codes (Figure 2.1).

Process
Process refers to activities directly related to the provision of health care
(Donabedian, 1988). Healthcare processes involve healthcare providers and support staff.
The activities include patient examination, laboratory and radiological testing and disease
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diagnosis and treatment (Donabedian, 1966). Quality in healthcare process entails
meeting required professional standards.
Process measures have a fundamental role in understanding the variation in the
performance of the organization and health care outcomes. However, a major limitation
in examining the process is that not all processes in an organization can be captured
(Donabedian, 1966). Further, a process measure must also be related to the outcome
under study. Process measures do not ensure the outcomes, but rather increase the
likelihood of them (Donabedian, 1988). Our study includes total performance scores for
the QIP six clinical and four reporting measures as a process indicator and its relationship
with patient survival.
Outcomes
The outcome measures generally include, patient survival or mortality,
morbidities, satisfaction with care, quality of life, the cure of disease (Donabedian, 1966).
The organizational structures and processes influence patient outcomes. Further, patient
factors also underlie in the relationship between healthcare and health outcomes
(Donabedian, 1966). For instance, age, gender, race neighborhood and economic
opportunities can confound the relationship between the healthcare and cancer survival.
Further, outcomes mostly occur late in the continuum of care, making it difficult to link
the processes to the outcome, e.g. survival of cancer patients (Powell, Davies, &
Thomson, 2003). Also, multiple factors contribute towards outcomes, making it difficult
to attribute factors to an outcome (Steinwachs & Hughes, 2008).
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Figure 2.1: Structures, Processes, Outcomes of our study, using the Donabedian framework

The literature emphasizes on using measurable structure, process and outcome
indicators (Donabedian, 1966; Steinwachs & Hughes, 2008). For instance, choosing
survival as an outcome of a disease that is not acutely fatal could make the study
unnecessarily long. However, using death as an outcome of fatal diseases is associated
with less bias (Kobewka et al., 2016). Therefore, researchers have assessed the quality of
ESRD care using mortality as an outcome indicator (Kobewka, et al., 2016).
ESRD patients have exceptionally high mortality rates. About 20% die annually
with a median survival rate of 38 months and five-year survival rate of 33-35%
(Kalantar-Zadeh, Kovesdy, & Norris, 2012). This makes mortality a useful indicator of
the quality of care of ESRD care.
The section below presents the ESRD literature in relation to the patient, facility
and ecological factors associated with the quality of ESRD care and patient outcomes. In
summary, a majority included facility and ecological factors or facility and patient
factors. However, research generally lacks in accounting for all three types of factors,
including, patient, facility and ecological, and even more so after the QIP
implementation. Appendix A shows the summary table of the cited articles.

2.7

FACTORS ASSOCIATED WITH ESRD CARE QUALITY
Freestanding facilities constitute 91% ESRD facilities (Medicare Payment

Advisory Commission (US), 2015). The facility factors that have been studied for
associations with quality of ESRD care include, size, ownership (profit vs. nonprofit) and
chain status (chain vs. independent) (William M McClellan, Soucie, & Flanders, 1998;
William M. McClellan et al., 2009; Yue Zhang, 2015; Yi Zhang, Cotter, & Thamer,
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2011). Mostly, the researchers assessed quality using laboratory indicators, such as URR,
Hgb and AVF and albumin levels. However, we found limited data on the association
between facility factors and QIP performance scores.

2.7.1

Relationship of facility factors to QIP performance measures/scores

Recently, Zhang et al. reported a variation in QIP performance scores associated with
facility and ecological factors (Yue Zhang, 2015). However, the author mentioned not
adjusting for the patient factors as the major limitation. Almachraki and colleagues found
QIP penalties associated with the facility location. For instance, QIP penalized 6.2%
facilities in rural and 4.6% in urban areas (Almachraki et al., 2016). Similarly, facilities
in lower socioeconomic areas received more penalties (Almachraki, et al., 2016).
Adjusting for facility, ecological and patient factors, Tangri and colleagues
reported that facility factors explain 11.5% variation in URR (Tangri, Tighiouart, Meyer,
& Miskulin, 2011). The variation, however, dropped to 6.7% when adjusted for patient
case-mix. The study also found patient gender, body surface area, dialysis access type
and compliance to the treatment associated with variation in URR. In another study, Fink
et al. found that URR varied more by facility factors than individual characteristics,
23.6% vs. 11.3% (Fink, Blahut, Briglia, Gardner, & Light, 2001).
In another study, Tangri et al. reported an association between facility factors and
AVF use (Tangri, Moorthi, Tighiouhart, Meyer, & Miskulin, 2010). The variation in
AVF due to facility factors persisted even after adjusting for the patient demographics
and comorbidities. The authors identified lack of data on surgeon’s availability and
expertise as a major limitation of their study (Tangri, et al., 2010). Patient gender, age,
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comorbidities and place of residence did not play a significant role in the AVF use.
Further, other researchers also indicated a significant role of facility factors in catheter
use, dialysis adequacy and anemia management (Fink, et al., 2001; Fink et al., 2007;
Pisoni, et al., 2009).
For-profit status
For-profit organizations own about 85 % renal dialysis facilities (Medicare
Payment Advisory Commission (US), 2015). The data show a rising trends in for-profit
freestanding dialysis facilities for the past two decades (USRDS 2015). The property
rights theory explains the divergence in behavior between profit and nonprofit
organizations (Valentinov, 2007). For-profit organizations pursuit for more services to
maximize profits to pay dividends to the shareholders (Valentinov, 2007). Compared
with non-profit, for-profit ESRD facilities have fewer personnel per dialysis run and
lower skilled staff (Meyer and Kassirer 2002; (Held, Garcia, Pauly, & Cahn, 1990;
Yoder, Xin, Norris, & Yan, 2013). While for-profit are able to achieve better Hgb and
URR targets than non-profit, however, no significant difference is found in patient
survival in the two types of facilities. In the case of ESRD care, most facilities are forprofit. Further, market pressure on nonprofits, cause them to become efficient as well
(Ozgen 2002).
Studies report a higher proportion of for-profit dialysis facilities achieve clinical
benchmarks, after adjusting for the patient factors or facility and ecological factors
compared to nonprofit facilities (Griffiths et al., 1994; Hirth, Turenne, Wheeler, Ma, &
Messana, 2010; M. R. Saunders & Chin, 2013; Szczech et al., 2006; Yue Zhang, 2015).
For instance, Hirth et al. adjusted the patient case-mix to determine the aforesaid
association, however, Saunders and colleagues and Zhang et al. adjusted for both the
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facility and ecological factors, while Szczech et al. adjusted for patient and facility
factors. Saunders and colleagues reported URR associated with the status, but not the
hemoglobin levels (M. R. Saunders & Chin, 2013; Yue Zhang, 2015). Further, adjusting
for patient and facility factors, Foley et al. indicated that for-profit status implicated in
better URR, hemoglobin levels and lower use of ESA, intravenous iron, and blood
transfusions (Foley et al., 2008).

Chain status
The USRDS defines chain as “…a group of 20 or more freestanding facilities that
have been owned or operated by a corporation for one year or longer and that are located
in more than one state” (United States Renal Data System, 2014). A remarkable growth
has been seen in the chain affiliated freestanding dialysis facilities from 1988 (14%) to
2011 (91%) (United States Renal Data System, 2015).
Two large dialysis organizations account for 70% of all facilities and 75% of
treatment of Medicare patients (Medicare Payment Advisory Commission (US), 2015).
CMS defines the large dialysis organizations (LDOs) as the ones that own 200 or more
facilities. The data show a trend in the consolidation of LDOs. Between 2004-2008, six
LDOs merged into two. Further, research also showed that smaller organizations also
merged with LDOs at a higher rate after the bundle payment and QIP (Medicare Payment
Advisory Commission (US), 2015; The American Society of Nephrology, 2014).
Trend in chain affiliation has increased due to increase in number of dialysis
facilities providing outpatient dialysis as a single product (Pozniak, Hirth, Banaszak‐Holl,
& Wheeler, 2010). Although, financial insolvency is associated with consolidation,
however, it is not the only major reason for dialysis facility chain affiliation (Erickson et
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al., 2016). ESRD facilities with above average profits and quality also merged with
chains (Pozniak, et al., 2010). Consolidation appears to be influenced by the presence of
other ESRD facilities in close proximity (Erickson, et al., 2016; Pozniak, et al., 2010).
In a recent study, Zhang reported chain affiliated facilities demonstrated better
QIP performance scores (Yue Zhang, 2015). While, the literature reports on the
association between chain affiliation and specific clinic measures, however, it remains
scarce in reporting on the association between QIP scores and chain affiliation. For
instance, comparing quality across the large chains vs. independent facilities, Hirth et al.
found that large chains achieved URR targets better than independent facilities (Hirth, et
al., 2010). The same study found no association between chain affiliation and hematocrit
levels. Saunders reported that both URR and hematocrit varied by chain status (M. R.
Saunders & Chin, 2013).
Ozgen et al argued that consolidation of the market has an effect on dialysis
facility care quality (Ozgen & A Ozcan, 2002). They allude that monopolistic behavior of
organization holding a large share of the market impact quality negatively. The authors
utilized Hirschman-Herfindahl index (HHI) to determine market competitiveness (Ozgen
2002; (Erickson, et al., 2016)). The risk of consolidation has further increased for small
facilities since the QIP implementation (Erickson, et al., 2016; Iglehart, 2011).

2.8

FACILITY FACTORS AND PATIENT SURVIVAL

Facility size
While limited research exists on facility size and survival, although research
indicates facility size influences patient outcomes in other settings (Fareed, 2012).
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Review of prior research is complicated by the fact that studies measure size in different
ways. The literature indicates use of the number of stations (Yan, Norris, Xin, et al.,
2013), number of patients treated (Eisenstein, et al., 2008) and number of treatments
rendered (Pozniak, et al., 2010) as measures of facility size. Therefore, reports on the
association between facility size and patient survival has remained vague.
Further, facility size has also shown a recent increase. A Medicare report of 2015
reported a 4% increase in dialysis stations and 2% increase in the number of treatments
between 2013-2014. Similarly, the number of patients treated have shown an annual
increase of 2% since 2009 (Medicare Payment Advisory Commission (US), 2015).
Larger facilities of both profit and nonprofit ownership may be operationally
efficient- a concept of economies of scale (Nissenson & Rettig, 1999; Richards, Shultz, &
Singh, 2009). Yan reported a higher mortality among patients in facilities with 15 dialysis
stations or less. Their analysis adjusted for patients, facility and ecological factors (Yan,
Norris, Xin, et al., 2013). The study also reported that, compared with whites, blacks and
Hispanics demonstrated a higher mortality in the facilities with less than 15 stations (Yan,
Norris, Xin, et al., 2013). The authors asserted that financial constraints cause smaller
facilities to lack the resources needed to treat complicated patients.
Lee and associates classified facility size using number of patients (Lee, Chertow,
& Zenios, 2010). The facilities with 75 or more patients demonstrated 14% higher
hospital length of stay than those with 35 or less patients (Lee, et al., 2010). Further,
patients being treated in facilities with more than 100 patients demonstrated less
compliance or receive shorter treatment than those who visited small size facilities (C.
Obialo, Zager, Myers, & Hunt, 2014). Low compliance and shorter treatments are
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associated with higher mortality (C. I. Obialo, Hunt, Bashir, & Zager, 2012). Einstein
also determined facility size using number of patients (small ≤60, medium 61–120, and
large ≥120). Smaller size facilities were associated with higher long term mortality
among diabetic and non -diabetic patients receiving in-center hemodialysis patients
(Eisenstein, et al., 2008).

Chain affiliation
Comparing data from two large chains, Saunders showed no effect of chain type
on patient mortality (M. R. Saunders & Chin, 2013). Saunders used ESRD facility
reported mortality aggregates. Conversely, comparing chain versus non-chain facilities,
USRDS reported lower mortality among patients treated at a chain affiliated facility,
using 2012-13 data (United States Renal Data System, 2015). The analysis adjusted for
patient age, race, ethnicity, sex, diabetes, duration of ESRD, nursing home status, patient
comorbidities at incidence, body mass index (BMI) at incidence, and population death
rates. However, it did not account for the ecological and facility factors.

Size of the chain and length of ownership
The chain size, in addition to facility size, shows an association with mortality (Yi
Zhang, et al., 2011). Zhang et al. reported that patients at nonprofit small chain affiliated
facilities demonstrate lesser mortality than the for-profit large chain organization. The
facilities associated with for-profit large chains tend to use higher intravenous drugs,
however, do not show improved survival (Yi Zhang, Thamer, Kshirsagar, & Cotter,
2013). Similarly, Van Wyck et al. reported the length of chain ownership among large
chain facilities was associated with improved patient (Van Wyck, Robertson, Nissenson,
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Provenzano, & Kogod, 2010). The study, however, did not compare the large versus
small chains or independent facilities. Further, the study adjusted for the patient factors
only.
For-profit dialysis facility
Dalrymple et al. reported higher overall hospitalizations due to cardiac failure and
vascular access complications among dialysis patients at the for-profit facilities
(Dalrymple et al., 2013). The majority of for-profit dialysis facilities achieved better
clinical benchmark (URR>65%, hematocrit level and albumin level). However, the
studies relating for-profit status with mortality found mixed results. While, most studies
demonstrated higher mortality among for-profits (Devereaux et al., 2002; Garg, Frick,
Diener-West, & Powe, 1999; M. R. Saunders & Chin, 2013; Straube, 2014; Yi Zhang, et
al., 2011), some others found equivocal results (Brooks et al., 2006; Foley, et al., 2008).
Brooks and colleagues demonstrated no association between profit status and patient
survival using instrumental variable analysis, a pseudo-randomized observational study
participants to control for unmeasured bias (Brooks, et al., 2006). Though Foley found a
relationship between for-profit status and the attainment of Hgb, URR>65%, but did not
find with the survival (Foley, et al., 2008). Foley included hospital patients, in addition to
the patients visiting freestanding facilities.
The mixed results of studies examining the survival by profit status facilities
suggest the need for further research. Earlier, research indicates that nonprofits try to
improve their efficiency in the face of market pressure due to the presence of for-profits.
(Garg, et al., 1999; Hirth, 1997). Conversely, for-profit facilities are under pressure due
to competition from non-profit to provide services at a lower cost (Hirth, 1997). Forprofit are more likely to use fewer resources compared to non-profit to maximize the
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profits (Yoder, et al., 2013). Therefore, for-profit facilities have also found to be
associated with lower care quality and poor patient outcomes including higher
comorbidities and mortality (Devereaux, et al., 2002; M. R. Saunders & Chin, 2013; Yi
Zhang, et al., 2011).
2.9

ECOLOGICAL FACTORS AND PATIENT SURVIVAL
Evidence suggests a role of neighborhoods in shaping health care systems and their

quality and patient outcomes (Stafford & Marmot, 2003; Yen, Michael, & Perdue, 2009).
Variation in morbidity, mortality, health care access, risky behavior, income inequality
exists across the US nation (Truman et al., 2011). The ecological factors interacts with
facility structural factors to influence performance and health outcomes (William M.
McClellan, et al., 2009). Dialysis facilities serving poor neighborhoods having more
uninsured, minority, unemployed and less educated population are affected with poor
patient survival and health outcomes (Y. N. Hall, et al., 2014; Kimmel, Fwu, & Eggers,
2013; Patzer & McClellan, 2012). Similarly, facilities in rural and remote areas report
poor performance/quality of care and health outcomes (Almachraki, et al., 2016; Yue
Zhang, 2015).
The sections below review major ecological factors that may be associated with
dialysis quality and patient survival.

2.9.1

Socioeconomic status
Link and Phelan identified socioeconomic status (SES) as a major determinant of

health disparities (Link & Phelan, 1995). SES has been defined as "a broad concept that
refers to the placement of persons, families, households and census tracts or other
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aggregates with respect to the capacity to create or consume goods that are valued in our
society"(Miech & Hauser, 2001). Given a broad definition of SES, prior research has
used patient income, education and occupation to create a composite factor of
socioeconomic status at the individual level without considering the impact of the
socioeconomic status of the neighborhood (Link & Phelan, 1995). However, more recent
research has focused on neighborhood racial composition, level of Rurality and regional
poverty and education levels to determine the impact of SES in relation to incidence and
health outcomes (Y. N. Hall, et al., 2014; Ludwig et al., 2011; Nuru-Jeter & LaVeist,
2011; Plantinga, 2013; Shavers, 2007); (Kimmel, et al., 2013; Patzer & McClellan, 2012;
Rodriguez et al., 2007; M. Saunders, Cagney, Ross, & Alexander, 2010). The section
below presents SES determinants and their association with health outcomes among
dialysis patients.

Regional Poverty
Neighborhood poverty and racial segregation are strong predictors of ESRD
incidence and associated health outcomes and disparities (Hu, Gonsahn, & Nerenz, 2014;
Ludwig, et al., 2011; Stevens et al., 2014; Volkova et al., 2008). In the U.S., about 20%
dialysis facilities are located in poor counties (Almachraki, et al., 2016). ESRD facilities
located in poor urban counties also serve minorities (Y. N. Hall, et al., 2014). Dialysis
patients in poor areas are younger and African Americans (Almachraki, et al., 2016).
The characterization of poverty varies in ESRD literature. The commonly used
criteria include, geospatial concentration of poverty, ZIP code defined areas, and the
areas defined by census tract. Facilities located in poor areas show poor health outcomes,
including patient survival, in both urban and rural areas (Almachraki, et al., 2016;
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Kimmel, et al., 2013; William M McClellan et al., 2010; M. Saunders, et al., 2010).
Whites tend to live in areas with a higher median income (black, $26,742 versus White,
$41,922) (Kimmel, et al., 2013). Living in a higher income area relates to better survival
(M. R. Saunders & Chin, 2013). Further, minority ESRD patients living in segregated
areas are more likely to die early (Kimmel, et al., 2013).

Rurality
Facility location has been reported as associated with health outcomes among
ESRD patients (Maripuri, Arbogast, Ikizler, & Cavanaugh, 2012; O'hare, et al., 2006).
Rural patients face more healthcare access issues than urban. The section below presents
the association between facility rurality and its interaction with structural and patient
factors and health outcomes among dialysis patients.

Rurality and facility volume
About 20% of ESRD facilities are rural (Medicare Payment Advisory
Commission (US), 2015). The low number of rural facilities relates to low rural
population density. Rural facilities face low patient volume and low profit margins
(Medicare Payment Advisory Commission (US), 2015). Further, compared to urban
facilities, rural facilities operate fewer dialysis stations and offer fewer night shifts
(O'hare, et al., 2006; Yoder, et al., 2013). Rural facilities are also smaller in size, cater to
a smaller number of patients, have fewer nursing staff and provide a lower number of
treatments (Medicare Payment Advisory Commission (US), 2015; O'hare, et al., 2006;
Yoder, et al., 2013). These facilities also offer less peritoneal dialysis services and home
hemodialysis training services (O'hare, et al., 2006).
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Due to a low profitability, large chains and for-profit do not prefer to operate in
rural areas. Therefore, most rural facilities are owned by small chain, independent and
nonprofit organization (O'hare, et al., 2006). Rural facilities also face financial constraints
due to low volume of patients and a higher treatment costs (Medicare Payment Advisory
Commission (US), 2015). The remote rural facilities remain at even a higher financial
risk.

Rurality and patient characteristics
Rural patients face access to care challenges, including availability of only incenter hemodialysis; lack of transportation; longer travel distances and commuting time;
geographic isolation; less dietary education, lack of access to a nephrologist and
specialized care; delayed initiation of Pre-ESRD care and lower quality of care (Bennett,
Probst, Vyavaharkar, & Glover, 2012; L. Chan, Hart, & Goodman, 2006; Maripuri,
Ikizler, & Cavanaugh, 2013; Murray, 2008; Nemet & Bailey, 2000; Stephens et al., 2013;
Wang, Lee, Patel, Maciejewski, & Ricketts, 2011).
Moreover, referral hospitals may be out of reach for the patients due to large
travel distance in the rural areas. Rural patients travel 2.5-4 times farther than the urban
patients to access specialized ESRD care (Stephens, et al., 2013). The fewer night shifts,
lesser dialysis stations and consolidation also cause rural patients to travel more distances
(O'hare, et al., 2006). Higher travel distances are associated with missed appointments
and shorter treatment sessions (K. E. Chan, Thadhani, & Maddux, 2014).
These barriers, along with the need for a long-term dialysis, needing about 3-4
sessions of 3-4 hours each per week, hamper rural patients access to care. Frailty among
ESRD patients also aggravates the negative effects of these physical barriers (Jhamb,
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Weisbord, Steel, & Unruh, 2008). Rural residents also tend to be uninsured, live farther
from hospitals and lack transportation (L. Chan, et al., 2006). Therefore, lower adherence
of dialysis is common among rural patients.

Rurality and health outcomes
Research indicated worse outcomes among rural patients undergoing peritoneal
dialysis (Maripuri, et al., 2012). Patients especially, in micropolitan and remote rural
areas experience higher mortality than urban patients. Maripuri et al. suggested that rural
patients opt for peritoneal dialysis as the modality can be administered at home.
(Maripuri, et al., 2012). Maripuri et al adjusted for patients’ characteristics.
Contrary to Manipuri et al., other studies did not find an association between
rurality and patient survival (Ajmal, Bennett, & Probst, 2016; Thompson et al., 2012).
The authors adjusted for patient characteristics including, travel distances. In another
study, Mairpuri et al related patient survival with the pre-ESRD care (Maripuri, et al.,
2013). They noted that rurality did not influence patient survival, keeping pre-ESRD care
and other patient covariates constant. O’Hare and associates explored within rural
variation, after adjusting for patient factor only. They reported a better survival among
rural blacks than rural whites (O'hare, et al., 2006).
Neighborhood segregation and racial composition
Minority serving facilities are larger in size and mostly located in metropolitan
poor counties (Y. N. Hall, et al., 2014). Hall categorized facilities into quintiles with
facilities in 5th quintile serving lower socioeconomic areas. They also provide lesser
home dialysis to the patients and fewer part time staff member as compared to the
facilities providing treatment to the lesser number of minority population (Y. N. Hall, et
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al., 2014). Facilities serving black populations and poor neighborhood lack specialized
care and report lower rates of AVF use (William M McClellan, et al., 2010; Prakash et
al., 2010).
Prior research showed that the racial composition of the neighborhood also
influences the occurrence of ESRD, access to pre-ESRD care, rate of transplantation and
survival (Evans et al., 2011; Kucirka et al., 2011; Nee et al., 2016; M. Saunders, et al.,
2010). Black patients receiving hemodialysis in minority neighborhoods experience more
disparities in health, income and employment, compared with whites (Kimmel, et al.,
2013). Further, black hemodialysis patients living in segregated areas experience higher
mortality (Kimmel, et al., 2013). Facilities serving a predominantly black population
score lower on QIP criteria than those serving largely white populations (Yue Zhang,
2015). Facilities serving minorities in the greater number report worse survival (Y. N.
Hall, et al., 2014; Kalbfleisch et al., 2015; M. R. Saunders & Chin, 2013). The facilities
located in black neighborhoods reported worse survival among black patients, compared
with white patients going to the same facilities. The association sustained even after
controlling for neighborhood poverty (M. R. Saunders & Chin, 2013).
Converse to the above findings, Rodriguez et al. found a black advantage in
survival when race was used to determine at an individual patient level (Rodriguez, et
al., 2007). The authors compared black and white survival among patients living in
predominantly black ZIP codes. After adjusting for the patient and ZIP code
characteristics, they found that blacks were less likely to die, however, the time to
transplant did not differ in the two races. However, the facility aggregated data showed
worse outcomes in facilities located in predominantly black ZIP codes.
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Neighborhood regional education and income level
Research to assess the impact of regional education and income level at the of
quality of dialysis facility remains scarce. Educational attainment and income level
implicate both in healthcare access and health outcomes (Adler & Newman, 2002; Ross
& Mirowsky, 1999). The county morbidities and mortality levels vary by regional income
and education (World Health Organization, 2008). Lower county income is associated
with higher mortality among both black and white population (Kimmel, et al., 2013).
Lower county education and income are also associated with lower rates of pre-ESRD
care and delayed nephrologist referral (Patzer & McClellan, 2012).

Regional ESRD networks
After the inclusion of ESRD as a disease based eligibility for the Medicare in
1972, the Congress realized a need to integrate a broad array of ESRD providers. In 1976,
CMS proposed 32 ESRD networks in the country (Center for Medicare and Medicaid
Services, 2012a). Subsequently, in 1978, Congress created a statutory requirement for the
Network Organization Program in consistency with the criteria defined by the secretary
of the Department of Health and Human Services (Center for Medicare and Medicaid
Services, 2012a). The Network Coordinating Councils (NCC) were formed to coordinate
ESRD care. They linked hospital and dialysis facility representatives with patients,
physicians, dietitians, social workers and other related healthcare professionals. The
focus of ESRD networks was to bring cost effectiveness and accountability; ensure
quality of care and promote kidney transplantation and home dialysis (Center for
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Medicare and Medicaid Services, 2013). Later in 1987, the 32 networks were condensed
into 18 networks. Broadly, the networks were classified by regions - Northeast: 1-5;
South: 6-8 and 13-14; Midwest: 9-12 and West: 15-18.
In 1988, CMS awarded contracts to the 18 networks. Quality assurance remained
a major focus of the network organizations. Facilities submit data to their respective
regional network. The networks conduct quality improvement projects by collecting
information on the measures including the Kt/V, urea reduction ratio, serum albumin, and
hemoglobin. The reports help determine a regional variation in care quality and facility
performance.
Intra and inter network variations exist in AVF use, anemia management and
URR targets (United States Renal Data System, 2015). The networks also vary in ESRD
incidence rates and health outcomes (M. R. Saunders & Chin, 2013). Analyzing the
networks by the regions, South, Midwest, West and Northeast, the same study found
South was more likely to report a worse survival and less likely to attain target
hemoglobin, compared with the Midwest. Conversely, South demonstrated better dialysis
adequacy. Zhang reported worse ESRD care quality in the Northeast (Yue Zhang, 2015).
Szcezec et al. reported a confounding effect of case-mix in association between network
and mortality (Szczech, et al., 2006).

2.10 PATIENT FACTORS AND SURVIVAL
Health outcomes vary by individual age; race; ethnicity; gender; poverty; health
insurance; employment, number and severity of comorbidities (Truman, et al., 2011).
Patient factors relate with the incidence and prevalence of CKD and ESRD and
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associated health outcomes (Centers for Disease Control and Prevention, 2014). In our
study, patient factors are adjusted as covariates. The section below reviews evidence
about the association between individual factors and health outcomes.

Race
Patient level racial disparities pose a major challenge in providing equitable care
in the U.S. Racial disparities are multifaceted. Assari delineated the underlying factors in
the association between patient race and mortality(Assari, 2016). He hypothesized that
racial difference in mortality is basically the function of the interconnection of
multidimensional factors: the proximity factor (behavioral factors), intermediate factor
(chronic medical condition) and distal factors (SES) (Assari, 2016). Community level
vulnerability (residential segregation, poverty) and individual level vulnerability
(individual dialysis dose, treatment frequency, race, income, education) are intertwined to
influence health and health outcomes (Nissenson, 2013).
A clear gradient exists between income and education among minorities versus
whites, and so in the health outcomes (D. R. Williams, Mohammed, Leavell, & Collins,
2010). Minorities are more likely to have CKD associated risk factors (Centers for
Disease Control and Prevention, 2014; Jackson et al., 2013). Minorities experience a
higher prevalence of CKD, its complications and rapid progression to ESRD (Derose et
al., 2013). Further, Minorities including blacks, Hispanics, Native Americans and Asians
develop ESRD at a 1.5-4 times higher rates than whites (Garcia-Garcia & Jha, 2015).
SES interacts with relationship of race and CKD/ESRD (Crews, Charles, Evans,
Zonderman, & Powe, 2010). ESRD, also shows an increasing trend among older age
minority population (United States Renal Data System, 2015).
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Despite the higher incidence of CKD, ESRD and associated risk factors among
minorities (Kochanek, Arias, & Anderson, 2013);(Volkova, et al., 2008), minority ESRD
patients demonstrate better survival than whites (Arce, Goldstein, Mitani, &
Winkelmayer, 2013; Derose, et al., 2013; Yan, Norris, Alison, et al., 2013). The survival
advantage of blacks is called ‘survival paradox’ (Kalantar-Zadeh, et al., 2012; United
States Renal Data System, 2015). While, the mortality among blacks and whites is
comparable at younger at, blacks show better survival than whites at later ages (Kucirka,
et al., 2011; United States Renal Data System, 2014).
Krucika et al provides a possible explanation for the aforesaid paradox. (Kucirka,
et al., 2011). They found an interaction between age and race. While, younger ESRD
black patients had worse survival than the White counterparts, however, the white
advantage reversed among patients older than 50 years (Kucirka, et al., 2011). Zadeh et
al. asserted that lack of insurance, access to care and access to specialized care among
younger black patients result in worse outcomes (Kalantar-Zadeh, et al., 2012). These
factors delay access to pre ESRD care resulting in patients seeing providers with more
advanced disease and complication. However, older blacks and whites have better parity
in health insurance coverage and access to care (Kalantar-Zadeh, et al., 2012). Author
asserted in addition to difficulties in access, younger blacks also mistrust the healthcare
system.
The other researchers have indicated biological phenomenon underlying survival
paradox. Whites possess higher levels of pro inflammatory cytokine interleukin (IL) 6
and C-reactive protein (CRF) (Crews, Sozio, Liu, Coresh, & Powe, 2011; Noori et al.,
2011). The IL6 increases the predisposition to inflammation and mortality (Crews, et al.,
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2011). The survival advantage among older blacks also links with a larger body mass
index (BMI) and high energy fat diet, compare with whites(Ricks et al., 2011). Further, a
higher parathyroid hormone has also been implicated in the survival advantage among
blacks (Noori, et al., 2011). Feroze et al found that family system among blacks relates to
the advantage (Feroze, Martin, Reina-Patton, Kalantar-Zadeh, & Kopple, 2010).

Age and gender
Older males are more likely to develop CKD and faster progression to ESRD than
women (Centers for Disease Control and Prevention, 2014). Older age among ESRD
patients is also associated with higher morbidity. The aging U.S. population, increasing
comorbidities, and longevity have resulted in higher ESRD incidence and prevalence (M.
E. Williams, Sandeep, & Catic, 2012). Further, the risk of mortality also increases with
the comorbidities including, dementia; cancer; congestive heart failure; peripheral
vascular disease and low albumin level are individually associated with mortality in the
initial six months of maintenance dialysis therapy (Bradbury et al., 2007; Cohen,
Ruthazer, Moss, & Germain, 2010).
Villar and colleagues reported age, gender and diabetes associated with the long
term health outcomes among patients on hemodialysis (Villar, Remontet, Labeeuw, &
Ecochard, 2007). The study reported higher four-year mortality rates among women than
men after accounting for patients characteristics and comorbidities (Villar, et al., 2007).
The high mortality of women in ESRD is contrary to the female survival advantage in the
general population.
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Comorbidities/risk factors
Diabetes, cardiovascular disease, obesity and hypertension predispose individual
to CKD (United States Renal Data System, 2015). Further, they are also the common
comorbidities associated with ESRD. Diabetes and Hypertension attribute to more than
two-third ESRD incidence (Centers for Disease Control and Prevention, 2014). Cancers
and cardiovascular diseases (CVD) relate to a higher mortality (United States Renal Data
System, 2015). USRDS indicated CVD as a main cause of mortality among ESRD
patients (United States Renal Data System, 2015).

Mineral metabolism, albumin levels and GFR
In a meta-analysis, Palmer et al found deranged serum phosphate associated with
a higher ESRD mortality (Palmer et al., 2011). Conversely, the analysis reported no
effect of parathyroid hormone and calcium on mortality. The other study reported a
higher mortality among patients with albuminuria and low GFR (Hallan et al., 2012).

Access to pre-ESRD care
Early initiation of Pre-ESRD care is associated with lesser infections,
hospitalization, morbidity and mortality, and higher transplantation rates (Chen et al.,
2010; Gillespie et al., 2015; Maripuri, et al., 2013; Smart & Titus, 2011). Early pre ESRD
care improves patient readiness and smooth transition for dialysis. Receiving ESRD care
is associated with decrease rate of all-cause mortality and increase transplant (Hao et al.,
2015; Maripuri, et al., 2013; William M. McClellan, et al., 2009; Ravani, et al., 2013).
Duration of pre-ESRD care plays an important role in the survival of dialysis patients.
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Pre-ESRD care for more than 12 months is more likely to result in better health outcomes
(Gillespie, et al., 2015).
A better survival among ESRD patients is associated with timely referral to a
nephrologist; initiation of dialysis and dietary education; placement of a permanent
vascular access; and referral for pre-emptive kidney transplantation (Saggi et al., 2012).
However, data indicate low rates of pre-ESRD care (67%) (Hao, et al., 2015) including,
nephrologist care (53.5%), permanent dialysis access at the time of the start of
hemodialysis (17.7%) and dietary education (11.9%) (Gillespie, et al., 2015; Maripuri, et
al., 2013). Even lower proportion of patients (28%) had consistent access to Nephrology
care for 12 months or more (Gillespie, et al., 2015). Further, about 33% of incident cases
of CKD did not receive any nephrology care. Rural and micropolitan population receive
even less dietary and other care(Maripuri, et al., 2013).
Barriers to optimal pre-ESRD care include, older age; low SES; being a minority,
living in black residential, large metropolitan and remote rural areas; lack of education
and insurance and comorbidities (Hao, et al., 2015; William M. McClellan, et al., 2009;
Navaneethan, Aloudat, & Singh, 2008; Prakash, et al., 2010; Yan, Cheung, et al., 2013).
Navaneethan and associates reported lack of communication between primary care
physician and nephrologist as a reason for delayed pre-ESRD care. Linking census data
to the CMS data, McClellan reported an inverse association between county poverty and
AVF use (William M McClellan, et al., 2010).
Among pre-ESRD care factors, only AVF is the part of the QIP criteria. Despite
the initiatives such as “fistula first” and AVF inclusion in QIP, the rates of AVF use
remain low, especially among incident hemodialysis patients. Linking census data to the
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CMS data, McClellan reported an inverse association between county poverty and AVF
(William M McClellan, et al., 2010). Research lacks in probing interaction between
poverty and minority population in relation to the health outcomes among ESRD patients.

Dialysis modality
ESRD patients on dialysis undergo either peritoneal dialysis or hemodialysis.
Most patients undergo hemodialysis, which is mostly administered in facilities (United
States Renal Data System, 2015). Conversely, peritoneal dialysis is usually performed at
home.
Data show mortality rates dropped by 22% among hemodialysis patients and by
34% among peritoneal dialysis (United States Renal Data System, 2015). In 2013, the
adjusted mortality rate among hemodialysis patients was 172/1000 patients/year and
among peritoneal dialysis patients was 152/1000 patients/years. The mortality by dialysis
modality varies with facility location, severity of comorbidities and age. Peritoneal
dialysis is associated with lesser mortality among younger than 65 years nondiabetic
patients with no cardiovascular comorbidities (McDonald, Marshall, Johnson, &
Polkinghorne, 2009; Weinhandl et al., 2010).
Duration of treatment also affects the association of dialysis modality and
outcomes. Mehrotra et al. reported no difference in mortality among patient on
hemodialysis and peritoneal dialysis in the initial phase (Mehrotra, Chiu, Kalantar-Zadeh,
Bargman, & Vonesh, 2011). Conversely, Sinnakirouchenan et al. reported a better
survival among peritoneal than hemodialysis patients, however, the latter survived better
after the initial phase of treatment, with an overall survival advantage of 1.5-2 years
(Sinnakirouchenan & Holley, 2011). However, younger than 65 years, nondiabetic
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peritoneal dialysis patients with no comorbidities at the incidence of ESRD demonstrated
better survival. Type of vascular access interact with dialysis modality to influence
survival. For instance, use of CVC among hemodialysis patients is associated with better
survival in the early treatment period than among peritoneal dialysis patients (Perl et al.,
2011).

Distance from facilities
Given frequent and long term treatment, travel time and distances are particular
issues faced by the ESRD dialysis patients. A typical dialysis patient travels 150-160
times/year to seek treatment. In the U.S., each visit entails an average travel of 7.2 oneway miles (Stephens, et al., 2013). Travel distances vary by region. Rural patients travel
2.5 times farther than urban patients (an average of 15.9 one-way miles versus 6.2 oneway miles) The travel distances are longest in the South central region (9.5 miles oneway) and the shortest in the Northeast region (average of 6.0 miles one-way) in the
country(Stephens, et al., 2013). ESRD patients living in remote areas experience most
access to care challenges, along with higher likelihood of comorbidities and
complications.
The distance adds its toll with a need for frequent travel episodes. Age and frailty
add to the travel stress. Patients living 50 km (about 31 miles) or more from the facility
are assessed less frequently on HbA1c and serum albumin levels and less likely to receive
medications including, Angiotensin-converting enzyme (ACE) inhibitors or receptor
blocker (Rucker et al., 2011). The distances are also associated with delayed pre-ESRD
care-seeking, suboptimal hemoglobin levels, serum calcium and phosphorus level (Chao,
Lai, Huang, Chiang, & Huang, 2015; Thompson et al., 2013).
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The literature also reports an association between travel distances and mortality
(Bello et al., 2012; Rucker, et al., 2011; Thompson, et al., 2012). Using centroid (straight
line distances between center of patient ZIP code and facility ZIP code), Thompson and
colleagues reported a distance of 100 miles or more from facility increase the risk of
mortality among ESRD patients (Thompson, et al., 2012). Conversely shorter travel
distances are associated with higher treatment adherence, better quality of care and
improved survival (Moist et al., 2008).

2.11 LIMITATION OF PUBLISHED LITERATURE
Given QIP recent promulgation, limited evidence exists in association between
facility factors such as facility size and QIP scores and the association between the scores
with patient survival. Further, patients, facility and ecological factors work in tandem to
influence care quality and patient survival, therefore, they need to be adjusted while
determining factors associated with QIP and survival. In a recent study, Zhang et al.
determined association between facility and ecological factors with QIP performance,
however, non-inclusion of aggregated patient characteristics was their major limitation
(Yue Zhang, 2015). Further, Almachraki et al. also did not include aggregated patient
data while demonstrating an association between facility location and QIP scores
(Almachraki, et al., 2016). Therefore, our study adjusted for aggregated patient, facility
and ecological factors to demonstrate the association between facility size and QIP
scores. Moreover, association between QIP scores and patient outcomes including
survival has yet not been studied.
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2.12 HYPOTHESES
1. Net of other factors, free standing dialysis facilities have better performance
scores than smaller facilities
2. Net of other factors, patient survival is associated with QIP performance scores.
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CHAPTER III- METHODS

3.1

RESEARCH QUESTIONS

1) Is facility size, measured as number of dialysis stations at the facility, associated with
the performance of freestanding dialysis facilities as measured by QIP scores?
Hypothesis: Net of other factors, larger facilities have better performance scores than
smaller facilities
2) Is freestanding dialysis facility performance as measured by QIP scores associated
with the survival of the ESRD patients on dialysis?
Hypothesis: Net of other factors, patient survival is positively associated with QIP
performance scores

3.2

STUDY METHODS - QUESTION 1

Before we start describing study 1 methods, it is important to clarify that for Medicare
data, reporting or payment year (PY) lags by two years from the service or calendar year
(CY). For example, services rendered in 2013 are reported in 2015 (Centers for Medicare
& Medicaid Services, 2013a). For AHRF, Census and USRDS data, we take the data
corresponding to the Medicare CY data.
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3.2.1

Study design and unit of analysis
We used a cross-sectional design. All analyses were conducted at the facility level

using CY 2013 data files. The performance scores vary by year, therefore we used the
latest scores for which we could have complete CMS and USRDS data files. The USRDS
individual patient data were aggregated to calculate facility level information for
variables not present in the aggregated files including Medicare, Census or AHRF. Our
aggregated facility indicators included: proportion of patients of age ≥ 65 years,
proportion of African-Americans patients, proportion of patients with two or more
comorbidities, proportion of patients with pre-ESRD care and proportion of patients
jointly covered by Medicare and Medicaid. The details are included in the section
describing variable construction (Section 3.2.5).

3.2.2

Study Sample
We used the most recent Medicare data (CY 2013 or PY 2015) and USRDS 2013

data files. A total of 5517 facilities, yielded from merging the CMS “Quality Incentive
Program” (QIP), “Dialysis Facility Compare” (DFC) and “Dialysis Facility Level
Impact” data files, were included in the analysis.

3.2.3

Data files
The study utilized Medicare and USRDS data including CMS QIP; CMS dialysis

facility compare; CMS facility level impact; United States Renal Data, Core Standard
Analytical ((USRDS-SAF); Census data and Area Health Resource Files (AHRF). As
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indicated earlier, the USRDS patient data were aggregated only for variables not
available in facility level Medicare, Census or AHRF files.
The section below describes the data files and variables included in them. Table
3.1 lists the covariates we included from each file in our study.

Medicare facility files
CMS QUALITY INCENTIVE PROGRAM DATA
The QIP file PY 2015 were used to extract facility QIP performance scores
(outcome) for CY 2013. The variable served as the outcome for study 1 and the key
exposure in the study 2. The QIP file is publicly available at the URL:
https://data.medicare.gov/data/archives/dialysis-facility-compare.

CMS DIALYSIS FACILITY COMPARE DATA
The CMS dialysis facility compare data was used in the calendar year 2013. We
extracted facility structural factors including ownership (profit/non-profit), chain status
and number of stations. The file can be accessed from the URL:
https://data.medicare.gov/data/archives/dialysis-facility-compare.

CMS FACILITY LEVEL IMPACT FILE
The CMS level impact file of the calendar year 2013 was used for the analysis.
The impact data file reports facility location, type (freestanding/hospital based), number
of treatments rendered and volume (low vs. not low). The file is available at the URL:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/EndStage-Renal-Disease-ESRD-Payment-Regulations-and-Notices-Items/CMS-1614-F.html
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UNITED STATES RENAL DATA SYSTEM PATIENT AND FACILITY DATA
United States Renal Data system (USRDS), a national renal data registry, which
collects, analyzes and disseminates findings about the ESRD patients in the U.S (United
States Renal Data System). Funded by the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), USRDS collects patient sociodemographic, morbidity
and mortality; treatments; and dialysis facility level information.
We used the USRDS patient and facility Standard Analytical Files (SAF). The
SAF files include both facility and patient data in separate files. The facility file included
number of treatments, number of patients, number and type of staff (technician and
dietitian) (Table 3.1). The patient file included patient demographics, socioeconomic
status, treatment history, insurance and comorbidities (Table 3.1). Patients data were
aggregated at facility level using facility USRDS identification (PROVUSRD) to report
indicators mentioned in the section 3.2.1 above. We linked USRDS facility and
aggregated patient data with the publicly available CMS dialysis facility files including
DFC, impact and QIP.
AREA HEALTH RESOURCE FILE
Area Health resource files (AHRF) comprised of information about health care
resources and socioeconomic characteristics of the population relevant to health care use.
We used 2013 AHRF file. The data are provided of more than 6000 variables across US
counties. AHRF data are available at https://ahrf.hrsa.gov/download.html. We included
median annual household income, percentage of persons in poverty, proportion of blacks
and Hispanic per county and unemployment rate among 16 plus individual, using the
county FIPS.
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3.2.4

List of variables

Dependent variable
We included QIP performance scores, CY 2013, as the study 1 outcome
Independent variable
Main exposure
The number of dialysis stations per facility was our main exposure.
Covariates
The study adjusted for patient, facility and ecological characteristics at an
aggregated level. Please see the table 3.1 for details of source file and variable names and
types.

3.2.5

Variable construction

Dependent variables
Of the 5517 facilities included in CMS QIP, DFC and impact files, in CY 2013,
we noted missing QIP scores for 305 (5.5%). Among the 5,212 facilities for which the
QIP scores were reported, 269 facilities scored less than 60 (failed). CMS did not report
QIP scores for facilities rendering less than 11 treatments (Centers for Medicare &
Medicaid Services, 2012).

Independent variables
Main exposure
The number of dialysis stations per facility was our main exposure.
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Facility level variables
ESRD Network
We consolidated the 18 ESRD networks into four regions including Midwest,
Northeast, South and West. Further, prior research has also consolidated networks into
regions (M. R. Saunders & Chin, 2013).

Estimation of rurality
The facility level rurality was determined using Urban Influence Codes (UIC).
The UIC codes are available at the URL:
https://www.ers.usda.gov/data-products/urban-influence-codes.aspx. UIC categorizes
3,143 counties, county equivalent and the independent cities of United States into 12
distinct groups (United States Department of Agriculture Economic Research Service:
Economic Research Service, 2013). The division is based on population size and
commuting data from population data from the 2010 Census of Population and
commuting data from the 2006-2010 American Community Survey (ACS). UICs of 1
and 2 levels of rurality was classified as “Urban” while all other UICs as rural. Analysis
across levels of rurality used three groups: “micropolitan rural” (UICs 3 5 and 8) “small
adjacent rural” (UICs 4 6 and 7) and “remote rural” (UICs 9 10 11 and 12).
Market competition
Market competition was determined using Hirschman-Herfindahl index (HHI)
(Hyman & Kovacic, 2004). The index utilizes market share of each organization in the
larger pool of similar organization. The market share of each organization was then
squared to determine HHI and summed across the organization in a market, which ranges
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from 0-1. A higher score demonstrates less competition or monopoly (Hyman & Kovacic,
2004).
We calculated the market share of each dialysis facility using the proportion of
total dialysis treatments produced by a facility to the total number of dialysis treatments
rendered by all other freestanding, in each county.

USRDS patient data-aggregated at the facility level
Age and gender
Gender and age of patients was aggregated as per facility proportion of male
patients and per facility average age of the patients, respectively. We calculated age by
using data of birth and date of death and December 31, 2013 for patient who remained
alive until the end of December, 2013.

Racial composition
We adjusted for per facility proportions of non-Hispanic black patients and
proportion of Hispanic patients.

Average distance covered by the patient at the facility
We also adjusted for the per facility average distance covered by the patients in
2013. We calculated centroid distances between patient and facility ZIP Code using
ZIPDIST SAS macro (SAS support, 2014). Further, the average distance of patients from
respective facilities was calculated.
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Proportion of patients with more than 2 comorbidities and health insurance
We calculated per facility proportion of patients jointly covered by Medicaid,
uninsured and with two or more comorbidities as separate variables.

3.2.6

Data Management

3.2.7

Data merging
The data merging was a three-step process. First, we merged the Medicare facility

files containing facility level data, including QIP, DFC and facility level impact, using
Medicare facility unique identification, called “PROVIDER_ID”. Second, USRDS
facility and patient aggregated data was merged with the Medicare using USRDS
crosswalk file, which provided both USRDS facility identification (PROVUSRD) and
Medicare facility identification (PROVHCFA). Finally, AHRF files were merged using
the county FIPS as a unique identifier, the final merged file included 5,193 facilities.

3.2.8

Analytical Approach
We used SAS version 9.4 for analysis. We conducted descriptive analysis,

calculating frequencies for categorical and mean and standard deviations for continuous
variables. Bivariate analysis compared the facility size and QIP score categories on the
covariates (table 3.1). We used Chi-square test to determine the association between
performance categories and categorical variables and ANOVA for the continuous
variables. Generalized linear model was conducted to determine the association between
facility size and performance, adjusting other covariates.
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3.3
3.3.1

STUDY METHODS - QUESTION 2
Study design and unit of analysis
The study utilized a retrospective cohort study. All analyses were conducted at the

patient level. The USRDS patient data and facility data were used. Further, facility and
ecological correlates were merged to each patient information using Medicare, and
AHRF data.

3.3.2

Study population
Our study population included all adult (age ≥18 years) incident patients between

January 1, 2013 — December 31, 2013 (n=96,102). We included incident patients from
January 1, 2013- December 31, 2013. We followed patients who survived the first 90
days from (April 1, 2013-March 31, 2014) to determine one year survival and its
association with QIP scores, adjusting for the covariates. Patients were followed up until
death or until the end of follow-up (March 31, 2014) and censored if patients received a
kidney transplant after 90 days of dialysis. Research indicates transplant patients having
better survival than dialysis patients (Levey & Coresh, 2012). Transplant ends exposure
to dialysis.

3.3.3

Data files

Patient data
The USRDS patient data from were used to extract patient information.
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Facility data
For facility data, CMS QIP, DFC and facility level impact files were used (see
details in the section 3.2.3 above). Further, the USRDS facility level data were used for
variables not included in the CMS data.

3.3.4

Variables

Dependent variable
Time to death is our outcome variable.
Most dialysis patients (60%) aged younger than 65 years (K. E. Chan et al.,
2011). It takes 90 days for Medicare to enroll younger ESRD patients. Further, dialysis
patients demonstrate significantly higher mortality in the first 90 days (Bradbury, et al.,
2007; K. E. Chan, et al., 2011). We applied the 90-day rule because USRDS recommends
beginning outcome analysis after 90 days of the first ESRD service, partly because of
delay in enrollment of new patients with Medicare and partly to stabilize patients on a
suitable dialysis modality (United states renal Data System, 2015).
We calculated the one-year mortality from 91-455 days (from April 1, 2013 —
March 31, 2014), and its association with QIP scores, adjusting for the covariates. We
used the data for the aforesaid years, since the most recent USRDS and CMS data were
available for these years at the time of the study.
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Independent variables
Main exposure
QIP scores
We used the QIP scores for the year 2013. Further, we excluded the patient
records for which the respective facility QIP scores are missing.
As noted above, among 5212 facilities, for which the QIP scores were reported,
269 (4.9%) facilities failed to achieve a target score of 60.

Covariates
The study adjusted for patient, facility and ecological characteristics. Please see
the table 3.1 for details of source file and variable names and types.

Variable Construction
Age
Patient age was included using age at incidence.

Race and Ethnicity
The variable race was constructed using two separate variables, race and
ethnicity. The new variables included four categories: White non-Hispanic, Black nonHispanic, Hispanic only and others non-Hispanic.
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Patient Insurance
The USRDS captures the public and private insurance status as separate binary
variables. We included three distinct categories including Medicaid insured, private
insured and uninsured in our analysis.

Estimation of centroid for distance
Straight line distances (centroids) were calculated between facilities zip codes and
patients’ zip codes. For centroid calculations, we used the “SAS ZIP Code file of January
2015” provided by SAS (SAS support., 2015). The longitude and latitude of each of the
respective patient and facility zip codes were extracted and processed using the SAS
“ZIPCITYDISTANCE” macro to calculate the centroids. The distances were categorized
based on the lower quartile median and upper quartile.
Comorbidities
We de-concatenated the variable “comorbids” in the USRDS patient file to
calculate the count of comorbidities as a covariate to adjust for severity of comorbidities.
Primary cause of ESRD
We included most common causes of ESRD namely, diabetes, hypertension,
glomerulonephritis as distinct categories. Further, we made separate categories for other
causes and unknown cause.

Pre ESRD care
We included four discrete components of pre-ESRD care, including Epoetin use,
nephrologist care, the presence of mature AVF/AVG and diet care as distinct variables.
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Data merging
We included information on 96,102 incident cases of patients who received care
from freestanding dialysis facilities between January 1 and December 31, 2013. We
excluded patients who died in the first 90 days (n=5,205); who received transplants in the
initiation of treatment (n=36) and who were lost to follow up (n=334) yielded 90,527
records.
We then merged Medicare facility data with USRDS patient data. Then, the
Medicare QIP, DFC and impact files were merged (5,212 free standing dialysis facility).
Finally, AHRF data were merged with the Medicare facility data, using the county FIPS.
We merged 2013 USRDS “Patient” and “Medical Evidence” files, using
USRDS_ID as the unique patient identifier. The USRDS “Treatment History” file
contained the unique identification number for both the patient (USRDS_ID) and facility
(PROVUSRD). We merged treatment history file in the next step. Finally, the “Facility
File” was merged, using the provider identification number, to include the facility ZIP
codes. We used the USRDS crosswalk file to merge Medicare data with the USRDS data,
using Medicare facility identification as a unique identifier (PROVHCFA). Merging
Medicare and USRDS data yielded 85,187 records.

3.3.5

Statistical Analysis
Descriptive analysis was conducted to present the characteristics of the dialysis

facility, ecological and patient characteristics. Bivariate analysis was run using time to
death as an outcome and binary performance scores variable (achieved and not achieved)
as exposure. Kaplan Meier estimates were used to determine the survival probabilities.
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The Log Rank test was used to determine the suitability of using the Cox Proportional
hazards model.
We used the Cox Proportional hazards model to estimate the association between
facility performance scores and with time to death, after adjusting for patient, facility and
ecological factors (Table 3.1). Each covariate was assessed using “Assess” function to
determine whether the covariate is time dependent. Two sided tests were used at a level
of significance of 5%.
We conducted a multilevel modeling to demonstrate distinct effects of the patient,
facility and ecological factors. In the model 1, we adjusted for patient factors, including,
demographic and socioeconomic characteristics; comorbidities; primary cause of renal
disease, severity of comorbidities and pre-ESRD care. In the model 2, we added facility
structural factors, including for-profit status, chain ownership, number of treatments and
number of stations. Finally, in the model 3, we adjusted additionally for area rurality;
ESRD network regions (Northeast, South, Midwest, and West); and socioeconomic and
demographic characteristics of the patients’ county, including, percentage of black and
Hispanic population; median household income, percentage of persons in poverty and
unemployment rate in 16 plus.
3.4

INSTITUTIONAL REVIEW BOARD

We sought an exemption from full ethical review from the institutional review board of
the University of South Carolina for the use of secondary USRDS and Medicare data for
our analysis.
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Table 3.1: List of covariates and data sources
File

Variable name

Variable

Variable
type

Facility factors
CMS QIP data file

QIPs scores

QIP scores

Numeric

Dialysis Facility

Profit/nonprofit *

OWNTYPE

Categorical

Dialysis Facility

Part of chain, chain owned

CHAINYN

Categorical

Compare

(Y/N) *

Dialysis Facility

Late shift (Y/N) *

SHIFT

Categorical

Total stations # *

TOTSTAS

Numeric

Dialysis Facility

In-center hemodialysis

HD

Categorical

Compare

(Y/N) *

Dialysis Facility

In-center peritoneal dialysis

PD

Categorical

Compare

(Y/N) *

Dialysis Facility

Home hemodialysis *

HOMEHD

Categorical

CMS facility level

Size of the facilities (<4000

Size

Numeric

Impact

treatments, 4000-10000,

Low volume

Categorical

Compare

Compare
Dialysis Facility
Compare

Compare

>10,000) ††
CMS facility level

Low volume††

Impact
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File

Variable name

Variable

Variable
type

Dialysis treatments ††

Dialysis treatments

Numeric

USRDS (facility

Total number of patients per

END_TOT

Numeric

file)

facility †

USRDS (facility

Patient to full time staff

Estimated using

Numeric

file)

ratio†

END_TOT and # of

CMS facility level
Impact

full time staff (RN,
SW, D, APN)
USRDS (facility

Number of outpatient

file)

treatments†

USRDS (facility
file)

TRSI_TRT

Numeric

Number of nurses,

HAPNFT, HDIETFT,

Numeric

technician and dietitians †

HLPNFT, HPCTFT,
HRNFT, HSWFT

Patient factors
Gender †

SEX

Categorical

Race †

RACE, HISPANIC

Categorical

USRDS (Patient

Date of Birth (to calculate

BORN

Categorical

file)

age) †

USRDS (Patient

Age at incidence

Inc_age

Numeric

USRDS (Patient
file)
USRDS (Patient
file)

file)
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File

Variable name

Variable

Variable
type

USRDS (Patient

Date of Death† (to calculate

file)

time to death)

USRDS (Patient

DIED

Date

Primary Cause of death†

CAUSEPRIM

Categorical

Date of first dialysis†

FIRSTDIAL

Date

data)
USRDS (Patient
data)
USRDS (Patient

Date of First ESRD Service† FIRST_SE

data)

(to determine the time to

Date

death)
USRDS (Patient

Proportion of patients with

data)

co-morbidities†

USRDS (Patient

Proportion of patients with

data)

primary cause of renal

COMORBID

Categorical

PDIS

Categorical

Categorical

failure†
USRDS (Patient

Proportion of patients who

DIETCARERANGE,

data)

received early nephrology

EPORANGE,

care†

NEPHCARERANGE,
AVF/AVGMATURIN
G

USRDS (Patient

Serum Hemoglobin level

data)

(g/dl) †
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HEGLB

Numeric

File

Variable name

Variable

Variable
type

USRDS (Patient

Insurance type†

NOCOV, MDCD,

data)

Categorical

MDCR,
MEDCOV_GROUP,
MEDCOV_Others

Tobacco use†

SMOKE

Categorical

Employed/not employed†

EMPCUR

Categorical

USRDS (Medical

Body Mass Index -

BMI

Categorical

evidence file)

Calculated†

Numeric

USRDS (Patient
data)
USRDS (Patient
data)

Ecological factors
USRDS - Patient

Distance between patient

Centroid distances

&

ZIP codes & facility ZIP

were calculated

Facility data

codes†

between ZIP codes

AHRF

Rurality using UIC of the

Estimated using AHRF

facility

files

Minorities living in ZIP

Hispanic (f1392013,

code of the facility †††

f1392113)

AHRF

Numeric

Numeric

Black (f1397913,
f1398013)
AHRF

Proportion of people in
poverty
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f1332113

Numeric

File

Variable name

Variable

Variable
type

AHRF

Unemployment rate §

f0679513

Numeric

AHRF

Median household income

f1322613

Numeric

DFC

ESRD networks*

Network

Numeric

USRDS (facility

Facility state†

PHYSTATE

Nominal

Facility county†

PHYCOUNTY

Nominal

data)
USRDS (facility
data)
Data sources
* Dialysis Facility Compare (DFC)
† United States Renal Data Systems (USRDS
†† CMS Facility Level Impact File

§ Areas Health Resource File (AHRF)
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CHAPTER IV- MANUSCRIPT ONE: Association of facility size and
Medicare ESRD Quality incentives program’s performance scores1

1

Ajmal F., Probst J.C., Brooks J.M., Hardin J.W., & Qureshi Z. Association of facility
size and Medicare ESRD Quality incentives program’s performance scores. To be
submitted to American Journal of Kidney Disease and Kidney International
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4.1

ABSTRACT

Background
End stage renal disease (ESRD) requires long term and costly care. As such,
Medicare has worked on strategies to bring efficiency in ESRD care since the inclusion
of the disease as the first disease- based eligibility in the program in 1972. In 2011,
Medicare launched an expanded bundled payment reform with the Quality Incentive
Program (QIP). This reform was devised to control for the possible fall in quality and
quantity of care after the bundled payment.
The QIP rates facilities using clinical and reporting indicators, and penalizes
underperforming facilities by 0-2% of total payments. Small dialysis facilities are
expected to receive such penalties due to poor performance. Further, small facilities are
more likely to be rural, low volume and low profit margin and are, therefore, expected to
receive more penalties due to poor performance. The current study investigates the
association between facility size and QIP scores.

Methods
We used the Medicare dialysis facility compare file; Medicare facility level
impact file; Medicare Quality Incentive programs file; United State Renal Data System
facility and patient data (aggregated by a facility) and Area health resource (AHRF) file.
We restricted data files to service year 2013, the most recent data available. The facility
size was classified based on number of dialysis stations into small (≤10), medium (11-25)
and large (>25) sizes. A generalized linear model for which inference was based on a
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5% level of significance to determine an association between facility size and QIP scores,
after adjusting for other potential covariates.

Results
The medium and large sized facilities scored higher compared to small facilities.
We found significantly higher QIP scores among facilities not offering peritoneal
dialysis, located in the South, affiliated with a chain, except chain 3, reporting higher
number of dialysis hours per session and higher number of patients who had access to
pre-ESRD care. Further, a higher proportion of Hispanics in the facility and facility
neighborhood was associated with higher QIP scores. Conversely, a higher proportion of
black population in the facility or neighborhood was associated with lower QIP scores.
Finally, facilities where patients travelled longer distances to access care were associated
with lower QIP scores.

Conclusions
We found an association between facility size and QIP scores. The QIP scores
also varied by characteristics of the patient population and neighborhood population. We
recommend more research in the area to advocate for inclusion of the facility size, patient
population and neighborhood population characteristics as factors adjusting the QIP
scores.
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4.2

BACKGROUND
End stage renal disease (ESRD) patients constitute less than 1% Medicare

population but consumes 7% of its cost (Ojo, 2014; The American Society of
Nephrology, 2014).Medicare ESRD care cost is high as the majority of patients remain
on dialysis due to non-availability of kidney donors and renal tissue mismatch (Levey &
Coresh, 2012). Patients on dialysis require long term and frequent treatment (National
Kidney and Urologic Diseases Information Clearinghouse, 2013). Medicare, being
cognizant of the rising cost trend, has proposed payment reforms since 1983. Despite
Medicare’s continued efforts, ESRD costs have been escalating each year (United States
Renal Data System, 2015) .
In 2011, Medicare launched a new payment reform called ESRD expanded
bundled payment (Chambers, et al., 2013; Iglehart, 2011).The reform proposed a fixed
payment per dialysis of $ 230 including laboratory services and medications, previously
paid by fee-for-service methods (Chambers, et al., 2013). Considering a potential drop in
quantity and quality of services after the fixed payments, Medicare introduced the quality
incentive program (QIP) few months after the reform to monitor service quality (Iglehart,
2011; Watnick, et al., 2012). QIP penalizes facilities for not achieving the target
performance scores by 0-2% of the payments. In 2012, Medicare rebased the bundle,
reducing per dialysis payment further by $30 (Wish, et al., 2014).
The reduction in payments was expected to adversely affect small facilities
(Chambers, et al., 2013; Watnick, et al., 2012). Since such facilities are mostly located in
rural and remote areas and run on a low volume and low profit margins (Medicare
Payment Advisory Commission (US), 2015; Wish, et al., 2014). Lower facility revenues

79

are associated with poor service quality. Thus, small facilities are more vulnerable to QIP
penalties (Chambers, et al., 2013; Slinin & Ishani, 2013; Watnick, et al., 2012) . Research
indicates facilities operating on lower profit margins demonstrate poor patient outcomes
(Ly, et al., 2011). Prior research indicates facilities located in rural and low
socioeconomic areas demonstrating poor facility performance and health outcomes
(Almachraki, et al., 2016; Kimmel, et al., 2013; M. R. Saunders & Chin, 2013).
Research remains scarce in studies relating facility size with QIP scores. In a
singular study, Zhang reported that a higher number of dialysis stations associated with
poor QIP scores (Yue Zhang, 2015). However, the authors noted not including patient
factors as their major limitations. Patient demographic and socioeconomic factors and
health status are associated with quality of health care (Chao, et al., 2015; Kovesdy et al.,
2013; Rucker, et al., 2011; M. R. Saunders & Chin, 2013; Tangri, et al., 2010; Tangri, et
al., 2011). Medicare adjusts for patient factors while assigning facility QIP scores.
Therefore, adjusting for patient covariates is important while determining the association
between facility factors and QIP scores. In the current study, we determined the
association between freestanding dialysis facility size and QIP scores after adjusting for
facility-level aggregate of patient data and facility and ecological characteristics.

4.3

METHODS

Study population and Data files’ sources
We used a cross sectional design, including Medicare facility data, United States
Renal Disease Data System (USRDS) facility level and patient data, and Area Health
Resource File (AHRF) for the year 2013. Since our unit of analysis was freestanding
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dialysis facility, we aggregated USRDS patient data by facility. Medicare reports facility
dialysis data two years from the service year (Centers for Medicare & Medicaid Services,
2013a). For instance, services rendered in 2013 are reported in 2015(Centers for
Medicare & Medicaid Services, 2013a). Medicare calls service year as the calendar year
(CY) and reporting year as the payment year (PY) (Centers for Medicare & Medicaid
Services, 2013a).
The Medicare datasets included in our study and their respective URL include
Quality Incentive Program (QIP), [Available at
URL:https://data.medicare.gov/data/archives/dialysis-facility-compare; Dialysis Compare
Facility File (DFC) [Available at URL: https://data.medicare.gov/data/archives/dialysisfacility-compare; CMS facility level impact [Available at URL:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/EndStage-Renal-Disease-ESRD-Payment-Regulations-and-Notices-Items/CMS-1614F.html]. The AHRF file was available at https://ahrf.hrsa.gov/topics/ahrf.aspx
We extracted QIP performance scores from the Medicare QIP data file CY2013
(corresponding to PY 2015). The Medicare DFC file provided information about chain
type, profit status, late shift, offer home hemodialysis, peritoneal dialysis and
Hemodialysis. The Medicare impact file included the variables, hospital affiliation,
number of dialysis treatment and low volume status.
USRDS facility data included information about number of staff (full time
dietitians, technicians, registered nurse, practical nurse and social workers), number of
patients and ESRD network. The Centers for Medicare and Medicaid Services
consolidated ESRD providers into 18 regional networks including – Northeast 1-5; South
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6-8 and 13,14; Midwest 9-12 and West 15-18 (Center for Medicare and Medicaid
Services, 2012a). We aggregated patient level USRDS data for each facility. The
variables include patient population mean age; proportion of males; proportion of
Hispanics; proportion of black patients; proportion of uninsured patients; proportion of
patients with Medicaid only; proportion of patients having access to early nephrology
care and proportion of smokers; proportion of patients with two or more comorbidities
and mean of two laboratory indicators Glomerular Filtration Rate (GFR) and Hemoglobin
(Hgb) levels at dialysis initiation.

Variables
Dependent and primary explanatory variable
We included dialysis facility performance scores as the outcome and facility size
as the independent variable. We treated performance scores as a continuous variable. In
2013, Medicare calculated the QIP score using six clinical and four reporting criteria. A
75% weightage was assigned to clinical criteria and 25% to reporting criteria, with a
maximum score of 100. Medicare designated a cut-off of 60 for facilities to avoid a
penalty. The clinical criteria included the proportions of patients with Hemoglobin (Hgb)
> 12g/dl; Arteriovenous fistula (AVF); central venous catheter (CVC) and adult and
pediatric hemodialysis patients and peritoneal dialysis patients with a Kt/V of >1.2,
where “K” stands for dialyzer clearance, “t” stands for time and “V” stands for volume of
water in patient’s body (National Institute of Diabetes and Digestive and Kidney Disease,
2014b). The reporting measures include reporting on anemia management, mineral
metabolism, and on two surveys including In-Center Hemodialysis Survey Consumer

82

Assessment of Healthcare Providers and Systems (ICH CAHPS) survey and National
Healthcare, Safety Network (NHSN).
Our main explanatory variable was facility size. Facility size was determined
using a variable number of dialysis stations per facility. We determined the distribution of
QIP scores and total stations using normal plot (Appendix B). To determine whether to
treat facility size as a continuous variable, we plotted a scatter graph between QIP scores
and number of dialysis stations and included squared and cubic terms of stations in the
model. The scatter plot showed a non-linear relationship (Appendix C). Further, the
linear (stations; p-value <.0001), squared (stations2; p-value <.0001) and cubic (stations3;
p-value <.0001) terms were also significantly associated with the QIP scores, showing a
non-linear relationship between QIP scores and stations. Therefore, we categorized
dialysis stations using Yoder et al.’s criteria, small (≤10 stations), medium (11-25
stations) and large (>25 stations) (Yoder, et al., 2013).
Facility level covariates
Membership in a chain of dialysis facilities was identified with five different
options. For the three largest chains, we assigned each chain a number (1 – 3); all
facilities affiliated with the smaller or regional chains were consolidated into a single
category (chain 4). Remaining facilities, not in a chain, were grouped together. Chain 1
and 3 are two distinct large for-profit chains.
We calculated the number of patients per dialysis station per facility. Moreover,
using Yoder et al method, we categorized mean number of patients per station into a
binary variable using average patients per dialysis station in all facilities (Yoder, et al.,
2013). First, we calculated the average of mean number of patients per station per facility
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(5.4 patients per station). We summed the facility staff including registered fulltime
nurse, technicians, nursing practitioner, dietitian and social worker and calculated total
staff per facility. Further, we also calculated the total staff per 100 patients.
The other covariates included whether a facility offers hemodialysis, home
hemodialysis, peritoneal dialysis and late shift. We also included facility for-profit and
low volume status; number of dialysis treatments; number of dialysis hours per session
and number of dialysis sessions per week per patients.

Facility-level aggregate of patient data
To calculate travel distances, first, we calculated centroid (straight line) distances
between patient and facility ZIP Codes. The patient and facility zip codes were extracted
from the USRDS’ Patient file and facility file, respectively. The “SAS zip code file of
January 2015” file, was used to extract longitude and latitude of patient and facility ZIP
Codes (SAS support, 2014; SAS support., 2015). We used the SAS “zipcitydistance”
macro (SAS support, 2014) to calculate straight line distances between patient and
facility ZIP codes (Bliss, Katz, Wright, & Losina, 2012). Second, we calculated a median
travel distance of all patients in each facility. Finally, the facilities were categorized into
quartiles based on mean distance, <5.4; ≥5.4-<8.5; ≥8.5-<13.9 and ≥13.9 miles.
We deconcatenated the variable ‘comorbid’ that included the information about
multiple comorbidities for each patient. We then summed up the valid counts across the
deconcatenated variables for each patient to determine the number of comorbidities. The
mean comorbidities per patient was 2. We calculated the proportion of patients with two
or more comorbidities per facility. Further, we also aggregated patient characteristics
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including gender (Male); race (Hispanic and black); obesity; insurance (Medicaid and
uninsured); access to a nephrologist; catheter use; comorbidities (>2 comorbidities) and
smoking.
Ecological covariates
Using AHRF data, we included the proportion of Hispanic and of black residents,
unemployment rate among 16 or more, median household income and percent of persons
in poverty in the county facilities was located. Proportions of Hispanic and black
residents were estimated by dividing the Hispanic population and black population by
total population per county.
Based on the criteria devised by the United States Department of Agriculture
Economic Research Services, we categorized facility rurality into three groups using
Urban Influence Codes (UIC): “Urban” (UIC 1, 2), “micropolitan rural” (UICs 3, 5 and
8), and all other rural (UICs 4, 6, 7, 9, 10, 11 and 12) (United States Department of
Agriculture Economic Research Service: Economic Research Service, 2013). Because of
the smaller counts of remote rural facilities (n=112), we merged remote rural and small
adjacent rural facilities into a single category. ESRD networks were consolidated into
four regions including South, Midwest, Northeast and West.
We included Hirschman-Herfindahl Index (HHI) as an indicator of market
competition. The HHI was calculated in three steps. First, we calculated proportion of
treatments produced by a facility, also called facility’s market share, by dividing
treatments rendered by a facility with the total treatments rendered by all facilities in the
county (Held & Pauly, 1983). Second, we squared the market share. Finally, we summed
the squared market share of all facilities in a county to get county level HHI.
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Figure 4.1: Data sources and merging

Data Management
Data merging
We merged the Medicare files including DFC, QIP and impact, using Medicare
identification number, “PROVIDER_ID”, as a unique identifier. The merged data
included 5,517 records. Excluding records with missing QIP scores (n=305) yielded
5,212 records. Medicare does not report scores for facilities rendering fewer than 11
cases for each QIP measure (Centers for Medicare & Medicaid Services, 2012) . We then
merged USRDS facility and patient data aggregated by facility using the USRDS
crosswalk file. Finally, AHRF files were merged using the county FIPS as a unique
identifier. The final merged file included 5,193 facilities.
Analytical Approach
We calculated mean and standard deviation (SD) and median and interquartile
range (IQR) for continuous variables and proportions for categorical variables. We also
checked the distribution of covariates across categories of facility size using Chi-Square
for categorical variables and t-test or ANOVA for continuous variables. Multivariable
linear regression was done using Generalized Linear Modeling approach to test the
association between performance scores (outcome) and facility size (independent), after
adjusting for the covariates, at alpha=0.05. We also tested the known interactions.
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4.4

RESULTS

Characteristics of free standing dialysis facilities
Table 4.1 and 4.2 presents the distribution of facility factors. Most dialysis
facilities included 10-25 station (77.1%). Further, mean stations per facility were 18.9
(SD; 7.8); mean hours per dialysis session were 3.8 (SD;0.3); mean patients per facility
were 5.4 (SD; 4.2), and mean staff per 100 patients were 14.3 (SD; 11.8) (Table 4.1). We
found an overall mean QIP score of 81.3 (SD; 12.4).
Most facilities were chain affiliated (90.6%) and for-profit (92.2%) (Table 4.2).
All facilities offered in-center hemodialysis, while 49.1% and 27.5%, respectively offered
peritoneal and home hemodialysis (Table 4.2). Most facilities were located in South
(44.6%) and metropolitan areas (81.6%) and did not offer a night shift (80.9%). About
5% facilities operated on a low volume.
Table 4.3 presents the distribution of patients and ecological factors. Mean age of
the patient population was 62.6 years (±3.9). The median travel distance was 9.3 miles
(IQR, 10.4). Further, about 68% patients reported more than two comorbidities and 27.7
% were obese (Table 4.3). Average proportion of Hispanic and black patients were higher
in the counties where large facilities were located.
Factors associated with facility size
Most covariates varied by facility size (Table 4.2). The small facilities were also
more likely to be rural (42.8%), not chain affiliated (18.1%) and low volume (23.2%).
Conversely, no large facility operated on a low volume. Large facilities were more likely
to offer home hemodialysis (40.3%) and night shift (32.4%). Further, large facilities also
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reported lesser number of staff per 100 patients (Mean, 12.1; SD, 10.4) (Table 4.1) and a
higher number of patients (>5.4) per station (Mean, 66.9%) (Table 4.2).
Table 4.3 compares patient covariates by facility size. All the patient
characteristics varied by facility size, except hemoglobin level at the initiation of dialysis.
The large facilities included a higher proportion of black (42%) and Hispanic (20.8%)
patients. Conversely, the median travel distance was the highest among small
(Mean:17.7; SD: 22.0) followed by medium (Mean:12.1; SD: 29.9) and large (Mean:9.5;
SD: 12.2) facilities.
The analysis of ecological factors (Table 4.3) showed large facilities were located
in counties that included a higher proportion of Hispanics (20.3 % vs. 11.7% in small),
black population (21% vs. 12.3% in small) and persons living in poverty (19.1 % vs.
16.3% in small). Further, median household income was lower in large facility counties
while unemployment was higher in larger facility (8.4 vs. 7.5 in small) counties.
Unadjusted analysis: factors associated with performance scores
Table 4.4 presents unadjusted associations between QIP score and categorical
facility covariates. Performance scores did not vary across facility size (p-value, 0.1124;
Table 4.4); however, performance did vary across multiple characteristics that are
associated with size. Chain affiliation was associated with better performance scores (pvalue, <.0001). Facilities not offering peritoneal dialysis (p-value, 0.0007) or home
hemodialysis (p-value, <.0001) demonstrated higher scores. For-profit (p-value, 0.0288),
rural facilities (p-value, 0.0188) and facilities located in the West (p-value, 0.0024)
performed better.
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Table 4.5 presents bivariate analysis between QIP score as the outcome and
continuous facility covariates. Conversely, hours per dialysis session (p-value, 0.0024)
and staff per 100 patients (p-value, 0.0044) were associated with lower performance
scores (Table 4.5).
Table 4.6 presents bivariate analysis of aggregated patients and ecological factors
and QIP scores (Table 4.6). We noted facility with a higher proportion of Hispanics per
facility (β, 0.04; SE, 0.01; p-value, <0.001) and patients with access to pre ESRD
nephrology care (β, 0.05; SE, 0.01; p-value, <0.001) were positively associated with the
performance score. Competition index was also associated with better performance
scores (β, 1.47; SE, 0.47; p-value, 0.0018) (Table4.6).
However, a higher proportion of black patients (β, -0.04; SE, 0.01; p-value,
<0.001) and patients mean glomerular filtration rate (GFR) (β, -0.44; SE, 0.10; p-value,
<0.001), with ≥ 2 comorbidities (β, -0.03; SE, 0.01; p-value, 0.0106) and with catheter as
vascular access modality (β, -0.07; SE, 0.01; p-value, <0.001) were negatively associated
with performance scores (Table 4.6). Further, the comparison of quartiles of median
patient distance from facility with QIP scores indicated a significant negative association
(p-value, .0003), with scores generally decreasing with longer travel distances.
Among ecological factors (Table 4.6), county level Hispanic population (β, 0.04;
SE, 0.01; p-value, <0.001) was positively associated with the performance scores, while
Black population (β, -0.06; SE, 0.01; p-value, <0.001) and unemployment rate (β, -0.17;
SE, 0.08; p-value, 0.0344) were negatively associated.
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Multivariable Analysis
Medium (β, 3.67; SE, 1.06, p-value 0.0005) and large facilities (β, 2.81; SE, 1.23;
p-value, 0.0219) demonstrated better scores than small facilities (Table 4.7). Facilities
affiliated with Chain 1, a large for-profit chain (β, 10.46; SE, 0.73; p-value, <.0001);
Chain 2, a large and not for-profit (β, 4.22; SE, 1.46; p-value, 0.0038), other chains (β,
2.98; SE, 0.76; p-value, <.0001), not offering peritoneal dialysis (β, 1.98; SE, 0.46; pvalue, <.0001); located in South (β, 1.66; SE, 0.73; p-value, 0.0234) were positively
associated with performance scores. The average hours per dialysis session (β, 2.39; SE,
.79; p-value, 0.0026) were also positively associated with performance scores.
Among the patient characteristics aggregated by facility, patient traveling distance
of more than 8.5 to <13.9 miles (β, -1.88; SE, 0.55; p-value, <0.0006) and ≥13.9 miles (β,
-1.64; SE, 0.66; p-value, 0.0068); proportion of blacks (β, -0.05; SE, 0.02; p-value,
0.0016) and proportion of catheter as vascular access at the initiation of dialysis (β, -0.11;
SE, .02; p-value, <.0001) were associated with a decline in performance scores. However,
proportion of Hispanic patients (β, 0.10; SE, 0.02; p-value, <.0001) and proportion of
patients with nephrology care in pre-ESRD period (β, 0.08 SE, 0.01; p <.0001) were
associated with an increase in performance scores. The interaction between size and
profit status was insignificant (p= 0.1000).

Sensitivity analysis
We replicated Zhang’s model using the linear and squared term for the stations
(Appendix D). We noted that the squared term was significant and negative. The
significant squared term demonstrated that the relationship between QIP scores and
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stations was non-linear. The negative estimate for the squared term showed that increase
in stations resulted in decline in QIP scores. Using the model below, we found an
inflection point, i.e. QIP scores demonstrated a decrease at 32 stations or more. This is
aligned with Zhang’s findings that smaller facilities performed better.
76.93

0.194 ∗ x

2∗

0.003

Where,
Y = QIP scores; x = Number of stations
On differentiating in terms of x, that is, total stations, we got an inflection point at about
32 stations,
0

0.194

2 ∗ 0.003 ∗

→ 32.33

Further, we also added the patient, facility and ecological factors incrementally to
determine the change in the model with the addition of each level of factors (Appendix
E). The R2 for the model with facility factors only was 15.7%. Meaning, facility factors
explained 15.7% variation in the QIP scores. Adding ecological factors increased the R2
to 17% and patient factors increased it to 25.1%. Therefore, our final model explained
25.1% of variation in the QIP score.

4.5

DISCUSSION

We determined the association between QIP scores and the size of the
freestanding dialysis facility, measured as number of dialysis stations, after adjusting for
facility-level aggregates of patient data and facility and ecological characteristics. We
found an association between QIP scores and facility size. In fully adjusted analysis,
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medium sized facilities scored highest on QIP criteria, followed by large compared to
small facilities.
Our findings differ from prior research findings which reports that small facilities
perform better than the medium and large dialysis facilities (Yue Zhang, 2015). Notably,
our methods also differ from the work done by Zhang. First, while Zhang used dialysis
stations as continuous, however, we found the relationship between QIP and stations nonlinear, therefore, we categorize them using Yoder’s criteria. Second, Zhang used
Medicare DFC data, which do not allow delineation of facility type i.e. freestanding and
hospital based. We restricted our analysis to freestanding facilities. Third, the QIP
assessment criteria also change between 2012 (Zhang’s data) and 2013 (our data). Fourth,
we adjusted for patient factors which was noted as a major limitation in Zhang’s article.
Therefore, our results cannot be compared with Zhang’s data.
While studies exist on determining facility and ecological factors associated with
specific clinical indicators including hemoglobin level, Kt/V, urea reduction ration
(URR), vascular access and albumin level and profit and chain affiliation (Hirth, et al.,
2010; M. R. Saunders & Chin, 2013; Szczech, et al., 2006), there is a dearth of studies
reporting factors associated with QIP scores, especially the association between size,
profit status and chain affiliation and QIP scores. Our study expands on prior research by
relating profit and chain status with QIP scores after adjusting for facility-level
aggregates of patient data. Generally, for-profit organizations maximize profits to gain
dividends for their shareholders (Held, et al., 1990; Yoder, et al., 2013). Prior research
also indicates for-profit facilities being associated with a better URR (Hirth, et al., 2010;
M. R. Saunders & Chin, 2013; Szczech, et al., 2006) (Van Wyck, et al., 2010) and
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hemoglobin level (Foley, et al., 2008; Szczech, et al., 2006). Therefore, we expected forprofit facilities to provide better quality and demonstrate higher QIP scores. However, we
noted no association between profit status and QIP scores.
Comparing chain affiliated facilities with non-chain facilities, we noted that while
one large for-profit chain facility scored better on QIP criteria, the other did not. Saunders
also reported variation in dialysis adequacy and hemoglobin levels among facilities
associated with different chains (M. R. Saunders & Chin, 2013). Zhang et al. reported
that all chain facilities performed better than non-chain facilities (Yue Zhang, 2015).
Evaluating specific clinical outcomes against chain status, Hirth et al. reported large
chains showing better URR, but not hematocrit (Hirth, et al., 2010). We recommend more
research on the processes of care delivery associated with variation in the performance of
chain affiliated facilities.
Notably, our study is the first to adjust for facility-level aggregate of patient
factors. The finding demonstrating that higher patient travel distance to access dialysis
treatments was associated with lower QIP scores is novel. Prior studies have shown that
patients living in remote areas are less likely to achieve specific clinical measures (Chao,
et al., 2015; Rucker, et al., 2011). However, rurality was not associated with the QIP
scores. The changes in reimbursement are expected to negatively affect the performance
of rural and small size facilities. This underscores the importance of considering patient
travel distance as distinct covariates of care quality.
Our study had several limitations. First and foremost, we could not determine
causal associations due to the cross-sectional study design. Second, we did not adjust for
dialysis processes including dialysis dose, dialyzer reuse, and access to a nephrologist
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during dialysis and staff hours per patient. These factors can affect dialysis adequacy and
cause blood stream infections. Third, we did not ascertain the referrals of rural patients to
the urban facility due to complications. Fourth, we did not have information about
severity of comorbidities. USRDS reported comorbidities as binary variables (yes/no) for
incident cases. Fifth, we had no information about facility transitions that patient had
during dialysis treatment. Sixth, we could not determine the validity of self-reported
factors including smoking status.
That said, however, our study adds significantly to the current literature. This is
the first study that included patient factors aggregated at the facility level. These factors
constitute important demand side covariates of quality of care. The study adds to the
recent work conducted by Zhang et al. relating facility size with QIP scores by using the
recent data.

4.6

CONCLUSIONS
We demonstrated an association between facility size and QIP size after adjusting

for facility characteristics, facility-level aggregates of patient data and ecological factors.
Medium and large sized dialysis facilities performed better than small facilities. Other
than size, a higher proportion of black population in the facility was associated with
lower QIP scores, even after adjusting for the county poverty, unemployment and
household median income. Conversely, a higher Hispanic population in the facility was
associated with a better QIP scores. Unfortunately, the data did not allow us to determine
the factors associated with better QIP scores among facilities with more Hispanics than
facilities with more black population. The examples of such factors include type of
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housing, lifestyle factors including diet and exercise. Further, although the USRDS
reports history of smoking and alcohol use once at the time of initiation of dialysis.
However, the data do not report on the duration and quantity of smoking during dialysis.
Similarly, finding that facilities showing higher patient travel distances were
associated with lower QIP scores needs consideration. More research in the area will
better guide Medicare in including patient characteristics, distance from the facility and
facility size as adjustment factors in calculating QIP scores.
Table 4.1: Facility characteristics by facility size, calendar year 2013
Dialysis stations
All

QIP
scores
Stations

5193
Mean
(SD)
81.3
(12.4)
18.9
(7.8)
7645.4
(4752.0)

Large size
(>25 stations)
737
Mean
SD

Medium size
(11-25 stations)
4003
Mean
SD

Small size
(≤ 10 stations)
453
Mean
SD

80.5

11.4

81.5

12.0

81.0

17.5

Pvalue*
0.1124

32.8

7.2

17.7

4.2

7.9

2.5

<.0001

13926. 6167.6 6924.9 3473.1 3794.4 2623.
Dialysis
5
8
treatmen
ts per
facility
14.3
12.1
10.4
14.2
11.3
18.6
16.6
Total
(11.8)
staff/ 100
patients†
3.8
3.8
0.3
3.8
0.3
3.7
0.3
Hours
(0.27)
per
dialysis
session
3.0
3.0
0.1
3.0
0.1
3.1
0.5
Dialysis
(0.2)
session
per week
per
patient
*ANOVA at α = 0.05
†Total staff/ 100 patients = Sum of registered nurses, technicians, licensed
practitioner nurses, social workers, dietitians)/100 patients
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<.0001

<.0001
<.0001

<.0001

Table 4.2: Facility characteristics by dialysis facility size, calendar year 2013
All
facilities

Chain Affiliation
Chain 1 (Large for-profit)
Chain 2 (Large not-forprofit)
Chain 3 (Large for-profit
Chain 4 (Other chains)
No chain
Offers Hemodialysis
Yes
Offers Home hemodialysis
No
Offers Peritoneal dialysis
No
Offers late shift
No
Own type
Non-Profit
Profit
Low volume facility
No
Rural
Micropolitan rural
Small adjacent/remote rural
Urban
Number of patients per station
<=5.4
>5.4
Location of facility in regional
ESRD network
Midwest
Northeast

Large Medium Small P-value*
size
Size
size
(> 25
(11-25
(≤ 10
stations) stations) stations)

n=5193
%

n=737
%

n=4003
%

n= 453
%

33.7
4.0

27.5
4.5

33.8
3.9

42.2
3.5

32.4
20.6
9.4

36.9
22.0
9.1

32.7
21.1
8.4

21.9
14.4
18.1

100.0

100.0

100.0

100.0

N/A†

72.5

59.7

74.6

74.4

<.0001

50.9

34.7

52.5

62.7

<.0001

80.9

67.6

82.4

89.0

<.0001

7.8
92.2

10.6
89.4

7.2
92.8

8.8
91.2

0.0054

94.9

100.0

96.0

76.8

<.0001

11.5
7.0
81.6

6.7
1.6
91.7

11.3
6.2
82.5

20.8
22.1
57.2

<.0001

50.1
49.9

33.1
66.9

51.8
48.2

62.0
38.0

<.0001

23.7
13.7

14.3
15.2

23.8
13.9

38.2
9.3

<.0001
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<.0001

All
facilities

South
West
*Chi Square at α = 0.05
† Not applicable

44.6
18.0

Large Medium Small P-value*
size
Size
size
(> 25
(11-25
(≤ 10
stations) stations) stations)
51.7
18.9
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44.4
17.9

34.7
17.9

Table 4.3: Distribution of aggregated patient and ecological characteristics, by facility size, calendar year 2013
All facilities
Average SD
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Patients characteristics
Distance travel by patients
(median)
Age of patients per facility
Proportion of male per facility
Proportion of Blacks per facility
Proportion of Hispanic per facility
Proportion of patients with >2
morbidities
Proportion of patient with catheter
at the initiation
Proportion of obese patients
Proportion of patients on Medicaid
Proportion of uninsured patient †
Proportion of patients with preESRD care (Nephrology care)
Proportion of smokers
GFR
Hemoglobin
Ecological characteristics
Proportion of Hispanic /county
Proportion of black /county

9.3 (10.4)
62.6
56.6
33.6
17.1
67.5

(3.9)
(7.7)
(27.7)
(21.8)
(14.1)

Large size
(>25 stations)
Average SD

Medium Size
(11-25 stations)
Average SD

9.5

(12.2)

12.1

(29.9)

60.9
55.8
42.02
20.8
62.2

(3.4)
(5.1)
(28.6)
(26.6)
(13.5)

62.8
56.7
32.6
16.5
67.9

(3.7)
(7.4)
(27.2)
(20.7)
(13.7)

Small size
(≤ 10 stations)
Average
SD
17.7
64.4
57.4
28.1
14.6
72.8

pvalue*

(22.0)

<.0001

(5.1)
(12.1)
(26.3)
(19.4)
(16.)

<.0001
0.0024
<.0001
<.0001
<.0001

63.7 (15.9)

55.7 (15.3)

64.9 (15.)

67.2 (20.3)

<.0001

27.7
13.7
10.2
51.8

27
15.1
12.1
46.5

27.7
13.7
9.9
52.0

28.2
12.3
9.4
58.9

0.003
<.0001
<.0001
<.0001

(6.5)
(8.6)
(7.6)
(18.3)

(4.5)
(8.9)
(8.9)
(17.1)

(6.5)
(8.5)
(7.4)
(17.7)

(9.2)
(8.3)
(6.9)
(22.4)

7 (5.5)
9.3 (1.7)
10.1 (2.5)

6.1 (4.6)
8.4 (1.3)
10.0 (1)

6.9 (5.4)
9.3 (1.6)
10.1 (2.6)

9.3 (7.3)
10.0 (2.)
10.1 (2.7)

<.0001
<.0001
0.2609

16.2 17.4
15.9 15.4

20.3 19.6
21.0 16.9

18.3 18.3
17.3 15.5

11.7 13.9
12.3 14.2

<.0001
<.0001

Unemployment Rate, 16+
Median Household Income
Percent Persons in Poverty
Competition index
*ANOVA at α = 0.05
† uninsured at the time of filling
2728 form

7.7 2.2
51557.0 13483.8
17.1 5.8
0.34 (0.34)

8.4 2.3
49596.1 11995.9
19.1 5.7
0.25 (0.25)

7.8 2.1
51836.9 13255.1
17.4 5.7
0.33 (0.33)

7.5 2.2
51452.9 1412
8.0
16.3 5.9
0.55 (0.39)

<.0001
0.0011
<.0001
<.0001
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Table 4.4: Facility characteristics associated with QIP scores, calendar year 2013
Dialysis facility size
N
Mean
SD
Large size (>25 stations)
737
80.5
11.4
Medium size (11-25 stations)
4003
81.5
12.0
Small size (≤ 10 stations)
453
81.0
17.5
Chain type
Chain 1 (Large for-profit)
1748
87.5
9.8
Chain 2 (Large not-for-profit)
205
81.5
11.6
Chain 3 (Large for-profit)
1681
76.3
11.4
Chain 4 (Other chains)
1072
81.0
11.8
No chain
487
76.8
16.1
Offers Home hemodialysis
No
3765
81.8
12.2
yes
1428
79.9
13.1
Offers Peritoneal dialysis
No
2641
81.9
12.3
yes
2552
80.7
12.7
Offers late shift
No
4199
81.2
12.7
yes
994
82.0
11.5
Own type
Non-Profit
407
80.0
12.9
Profit
4786
81.4
12.4
Low volume facility
No
264
82.2
14.7
Yes
4929
81.3
12.4
Rural
Micropolitan
595
82.4
11.9
Small adjacent/remote rural
361
82.6
13.5
Urban
4237
81.1
12.5
State
Midwest
1232
80.6
13.3
Northeast
710
81.2
12.3
South
2316
81.2
12.0
West
935
82.6
12.6
Number of patients per station
<=5.4
2598
81.1
13.0
>5.4
2595
81.5
11.9
Significant p-values are bolded
*t-test at 0.05 level of significance; † ANOVA at 0.05 level of significance
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p-value
0.1124†

<.0001†

<.0001*

0.0007*

0.0746*

0.0288*

0.2101*

0.0068†

0.0024*

0.3089*

Table 4.5: Facility characteristics associated with QIP scores, calendar year 2013

Dialysis treatments per facility

Β0

Β1

80.8

Total staff/ 100 patients
81.9
Hours per dialysis session
91.8
Dialysis session per week per patient 79.9
Significant p-values are bolded
*Simple linear regression
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p-value

0.00

Β
(SE)
0.00

-0.04
-2.77
0.49

0.02
0.63
1.11

0.0044
<.0001
0.6575

0.0453

Table 4.6: Bivariate association between facility-level aggregates of patient and
ecological factors and QIP scores, calendar year 2013
Β0

Β1

Patient characteristics
Distance from the facility
>=13.9 miles
81.5
>=8.5- < 13.9 miles
80.6
>=5.4- < 8.5 miles
81.7
<5.4 miles
82.3
Age of patients per facility
86.2
-0.08
Proportion of male per facility
78.0
0.06
proportion of blacks per facility
82.4
-0.04
proportion of Hispanic per facility
80.7
0.04
Proportion of patients with >2 morbidities
83.4
-0.03
Proportion of patient with catheter at initiation 85.7
-0.07
Proportion of obese patients
80.3
0.04
Proportion of patients on Medicaid
81.2
0.01
Proportion of uninsured patient
81.4
0.01
Proportion of patient with Nephrology care
78.8
0.05
Proportion of smokers
81.7
-0.04
Average GFR of patients/ facility
85.3
-0.44
Average Hemoglobin of patients/ facility
79.9
0.14
Ecological characteristics
Proportion of Hispanic /county
80.7
0.04
Proportion of blacks /county
82.4
-0.06
Unemployment Rate, 16+
82.6
-0.17
Median Household Income
80.6
0.00
Percent Persons in Poverty
82.2
-0.05
Competition index
81.0
1.47
*Simple linear regression; † ANOVA at 0.05 level of significance
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Β (SE)

p-value*

13.7
12.7
11.9
11.5
0.04
0.02
0.01
0.01
0.01
0.01
0.03
0.02
0.02
0.01
0.03
0.10
0.07

0.0003†

0.01
0.01
0.08
0.00
0.03
0.47

<.0001
<.0001
0.0344
0.2587
0.1237
0.0018

0.0788
0.0092
<.0001
<.0001
0.0106
<.0001
0.1589
0.6116
0.6277
<.0001
0.2486
<.0001
0.051

Table 4.7: Adjusted analysis for association between facility size and performance scores,
calendar year 2013
Parameter

Estimate Standard p-value
Error

Intercept
Facility factors
Dialysis facility size (ref: small)
Large
Medium
Chain Type (ref: No chain affiliation)
Chain 1: Large for-profit chain†

72.92

9.61

95%
Confidence
Limits
<.0001 54.08 91.76

2.81
3.67

1.23
1.06

0.0219
0.0005

0.41
1.60

10.46

0.73

<.0001

9.03 11.88

Chain 2: Large not for-profit chain
Chain 3: Large for-profit chain†
Chain 4: Other Chains
HOME Hemodialysis (ref: Yes)
No
Peritoneal Dialysis (ref: Yes)
No
SHIFT (ref: Yes)
No
Own type (ref: Profit)
Non-Profit
Low volume facilities (ref: Yes)
Yes
Region (ref: West)
Midwest
Northeast
South
Patients per station (ref: >5.4/stations)
<=5.4/station
Dialysis treatments
Total staff per 100 patients
Average hours per session
Average dialysis treatment session per
week per patient
Patient factors
Distance travelled by patients (ref=
<5.4 miles)
>=13.9 miles

4.22
-1.40
2.98

1.46
0.76
0.76

0.0038
0.0634
<.0001

1.36
-2.88
1.49

7.08
0.08
4.48

0.72

0.49

0.1456

-0.25

1.69

1.98

0.46

<.0001

1.09

2.88

-0.77

0.47

0.1029

-1.69

0.15

-1.71

0.96

0.0742

-3.58

0.17

2.80

1.46

0.0555

-0.07

5.66

0.11
1.10
1.66

0.71
0.77
0.73

0.8724
0.1504
0.0234

-1.27
-0.40
0.22

1.50
2.60
3.09

-0.46
0.00
0.04
2.39
-0.08

0.49
0.00
0.03
0.79
1.79

0.3532
0.7809
0.2347
0.0026
0.9656

-1.42
0.00
-0.03
0.84
-3.58

0.51
0.00
0.11
3.95
3.42

-1.64

0.60

0.0068

-2.82

-0.45
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5.21
5.74

>=8.5- < 13.9 miles
>=5.4- < 8.5
Age of patients per facility
Proportion of male per facility
Proportion of Black patients per facility
Proportion of Hispanic patients per
facility
>= 2 comorbidities
Proportion of catheter at initiation of
dialysis treatment
proportion of obese/facility
Medicaid insured /facility
Uninsured /facility
Pre-ESRD Nephrology care by facility
Tobacco users per facility
Average GFR per facility
Average Hemoglobin per facility
Ecological factors
Rural (ref: Urban)
Small adjacent /remote rural
Micropolitan
Proportion of Hispanics population in
county
Proportion of Blacks population in
county
Proportion of Unemployment Rate, 16+
Median Household Income
Proportion Persons in Poverty
Competition index
*Proc GLM at α= 0.05
† refers two distinct large for-profit chains
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-1.88
-0.33
-0.05
0.05
-0.05
0.10

0.55
0.53
0.09
0.03
0.02
0.02

0.0006
0.5272
0.5968
0.1678
0.0016
<.0001

-2.96
-1.36
-0.21
-0.02
-0.08
0.06

-0.80
0.70
0.12
0.11
-0.02
0.14

0.01
-0.11

0.02
0.02

0.5354
<.0001

-0.03
-0.14

0.06
-0.07

0.03
0.04
0.03
0.08
-0.01
-0.70
0.09

0.04
0.03
0.03
0.01
0.05
0.17
0.08

0.3993
0.2498
0.3726
<.0001
0.8141
0.3833
0.2633

-0.04
-0.02
-0.04
0.06
-0.11
-1.03
-0.07

0.11
0.09
0.10
0.11
0.09
0.37
0.25

2.28
1.51
-0.02

1.27
0.83
0.03

0.0722
0.0685
0.3611

-0.21
-0.12
-0.07

4.77
3.14
0.03

0.02

0.03

0.4184

-0.03

0.08

0.00
-0.14
-0.01
1.46

0.00
0.08
0.12
0.91

0.535
0.0863
0.9018
0.1111

0.00
-0.29
-0.24
-0.34

0.00
0.02
0.21
3.25
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5.1

ABSTRACT

Introduction
Medicare included end-stage renal disease (ESRD) as the first disease-based
eligibility in 1972. Since then, Medicare has worked to bring efficiency into ESRD care.
In its latest initiative, Medicare launched a bundled payment reform along with a quality
incentive program (QIP) to address ESRD care cost and quality. The bundle payment
component included a fixed payment of $230 per dialysis treatment and QIP was
implemented to evaluate facilities using clinical and reporting measures.
QIP scores have been criticized for the inclusion of easy to measure clinical
criteria with a concern that there is a limited association between the measures and
patient outcomes. However, no study has empirically tested the association between QIP
scores and patient outcomes, including patient survival.

Methods
We used a retrospective cohort design. The data files included Medicare dialysis
facility compare; Medicare facility level impact; Medicare Quality Incentive program;
United State Renal Data System (USRDS) facility and patient data and Area health
resource file (AHRF). We restricted data files to service year 2013, the most recent
USRDS data available at the time of study. All the incident ESRD patients from January,
2013 to December, 2013, who survived for the first 90 days after the first ESRD service,
were included (n=117,129). Linking patient data with USRDS and Medicare free
standing dialysis facility data yielded information on 89,540 patients and 5,194 facilities.
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We categorized QIP scores into 9 based on smoothing splines with optimal
degrees of freedom. We used a multivariable Cox proportional hazard model at the 5%
level of significance to assess whether there was an association between facility QIP
scores and 1-year survival.

Results
Overall, 11.8% of patients died within one year of follow up (after excluding
deaths of the first 90 days of first ESRD service). The unadjusted mortality rates by QIP
categories were given by [0,60) (15.6%); [60,65) (12.5%); [65,70) (11.9%); [70,75)
(12.5%); [75,80) (11.5%); [80,85) (11.9%); [85,90) (11.3%); [90,95) (11.1%); and
[95,100] (11.1%).
We found an association between QIP scores and one year patient survival after
adjusting for other covariates. Patients receiving treatment from facilities scoring < 60
showed a higher mortality, compared with patients receiving treatment from facilities
scoring ≥ 95.

Conclusions
Contrary to the concerns that QIP criteria include easy to measure clinical criteria,
we found an association between QIP scores and 1-year patient survival. Notably,
Medicare also uses a cutoff QIP score of 60 to classify underperforming facilities and
apply 0-2% penalties. We recommend more studies to confirm our results.
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5.2

BACKGROUND
End stage renal disease (ESRD) is a chronic, irreversible and costly disease

requiring renal transplant or frequent dialysis for survival (Centers for Disease Control
and Prevention, 2014; Levey & Coresh, 2012). Most ESRD patients remain on dialysis
due to lack of donors and mismatch of renal tissue (National Kidney and Urologic
Diseases Information Clearinghouse, 2013). Considering the high cost of care, Medicare
included ESRD as the first disease based edibility in 1972 (A. W. Williams, 2015). The
program’s ESRD population grew from 10,000 in 1972 to 399,455 in 2014 (United States
Renal Data System, 2014). The cost also showed a continuing rising trend over the last
four decades (United States Renal Data System, 2015). Medicare continued to
promulgate reforms to bring efficiency in ESRD care.
In its most recent reform in 2011, Medicare proposed an ‘expanded bundle
payment program’(Iglehart, 2011). Given that fixed payments could potentially result in
lower quality of services, Medicare implemented a quality incentive program (QIP) as
part of bundle payment reform (Watnick, et al., 2012; A. W. Williams, 2015). Failing to
meet or exceed QIP criteria reduces reimbursements by 0-2% for facilities (Fishbane &
Hazzan, 2012). These criteria have varied over time, with the inclusion of additional
measures each year (Center for Medicare and Medicaid Services, 2016b).
In 2013, QIP scores were defined using six clinical and four reporting measures
to define a facility score between 0-100 (Centers for Medicare & Medicaid Services
2013). The clinical measures included hemoglobin (Hgb) > 12; urea clearance adequacy
for adult and pediatric hemodialysis (Kt/V >1.2 and Kt/V >1.7, respectively) and adult
peritoneal dialysis (Kt/V >1.2); catheter use, and the presence of an arteriovenous fistula
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(AVF) (Centers for Medicare & Medicaid Services 2013). Reporting measures included
reporting on anemia management, mineral metabolism, blood stream infections and
patient satisfaction (Centers for Medicare & Medicaid Services, 2012).
Since the QIP was implemented without a prior pilot study, the impact of the
program on health outcomes such as survival is still unknown (Vandecasteele & Tamura,
2014; A. W. Williams, 2015). The QIP is criticized for including easy to measure narrow
clinical criteria, with a limited focus on patient health outcomes (Chambers, et al., 2013;
Moss & Davison, 2015; Nissenson, 2013). The literature has used survival/ mortality as
the most common outcome among dialysis patients (Brooks, et al., 2006; Foley,
Gilbertson, Murray, & Collins, 2011; Perl, et al., 2011; Thompson, et al., 2012; Yan,
Norris, Xin, et al., 2013). However, to the best of our knowledge, no study has yet
empirically investigated an association between QIP scores and patient survival. The
mortality among ESRD incident patients is considerably higher in the first year of
dialysis (Collins, Foley, Gilbertson, & Chen, 2009). Therefore, in the current study, we
determined an association between QIP scores and one year mortality.
5.3

METHODS

Study design, study population
We used retrospective cohort design. We included ESRD incident cases of age 18
and over from January 2013 to December 2013 (n=117,129). We tracked 1-year patient
mortality from April 1, 2013 to March 31, 2014. We used USRDS 2013-14 data as these
were the latest data for which Medicare facility data were available at the time of study.
Medicare reports data two years after the service year or calendar year (CY) (Centers for
Medicare & Medicaid Services 2013). For instance, services rendered in CY 2013 are
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reported in 2015, called payment year (PY). Therefore, we used Medicare publicly
available data reported in 2015 for our study. Medicare data included dialysis facility
compare (DFC), facility level impact and Quality improvement program (QIP) of the CY
2013.
The publicly available datasets and their URLs include, QIP: [Available at
URL:https://data.medicare.gov/data/archives/dialysis-facility-compare], DFC: [Available
at URL: https://data.medicare.gov/data/archives/dialysis-facility-compare]; facility level
impact: [Available at URL: https://www.cms.gov/Medicare/Medicare-Fee-for-ServicePayment/ESRDpayment/End-Stage-Renal-Disease-ESRD-Payment-Regulations-andNotices-Items/CMS-1614-F.html]. The AHRF file was accessed from, [Available at
URL: https://datawarehouse.hrsa.gov/topics/ahrf.aspx].

Data merging
We included information on 96,102 incident cases of patients who received care
from freestanding dialysis facilities between January 1 and December 31, 2013.
Excluding patients who died in the first 90 days (n=5,205); who received transplant in the
initiation of treatment (n=36) and who were lost to follow up (n=334) yielded 90,527
records.
We then merged Medicare facility data with USRDS patient data. Merging
Medicare QIP, DFC and impact files yielded 5,212 facility records. We merged AHRF
data with Medicare facility data using county Federal Information Processing Standards
(FIPS). We used the USRDS crosswalk file to merge Medicare data with the USRDS
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data, using Medicare facility identification as a unique identifier (PROVHCFA). Merging
Medicare and USRDS data yielded 85,187 records. Excluding cases with missing
information on any of the variables of interest yielded 84,493 incident patients.
Comparison of included versus excluded cases
Comparing included and excluded records by patient demographic and health factors
revealed no difference: gender (p-value, 0.836); ethnicity (p-value, 0.789), age (p-value,
0.053); primary disease causing ESRD (p-value, 0.483); and transplants (p-value, 0.345).

Variables
Dependent and primary explanatory variable
Outcome: Patient survival
We followed only incident cases for patients who had survived the initial 90 days
after the first ESRD service (n=84,493). We applied the 90-day rule because USRDS
recommends beginning outcome analysis after 90 days of the first ESRD service, partly
because of delay in enrollment of new patients with Medicare and partly to stabilize
patients on a suitable dialysis modality (United states renal Data System, 2015) . The
one-year follow up started from April 1, 2013, the date when the first case was expected
to complete a 90-day survival, and ended on March 31, 2014.

Time to death and censoring
We created a binary variable called status – indicating death as ‘event’ and survival till
end of the study or transplantation after 90 days of dialysis initiation as ‘censored’. We
calculated follow-up time by subtracting the date of death or the date of transplantation
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Figure 5.1: Data sources and merging

from date of first service. For patients who did not die or undergo transplantation, time
until March 31, 2014 was included as the follow-up period.

Independent variable: Facility QIP scores
We included 2013 facility QIP scores, ranging from 0-100, as the independent
variable. We tested the linearity between time to death and QIP scores by adding squared
and cubic terms for the QIP scores in separate bivariate models. We found both the
squared (p-value <.0001) and cubic terms (p-value <.0001) significantly associated with
the patient survival. Therefore, we classified QIP scores into 9 categories based on
smoothing splines using optimal degrees of freedom (Therneau & Grambsch, 2013).

Covariates
Patient characteristics
Patient characteristics included age; race; ethnicity; sex; insurance; body mass
index (BMI); current employment; smoking status, primary dialysis modality, number of
comorbidities including history of diabetes, hypertension, atherosclerotic heart disease
(ASHD), Cerebrovascular attack (CVA), peripheral vascular disease (PVD); pre-ESRD
care including nephrologist care, use of Epoetin, dietary care, mature arteriovenous
fistula or arteriovenous graft.
Age was calculated at the time of treatment initiation. We consolidated race and
ethnicity to include white-non-Hispanic, black-non-Hispanic, Hispanic only and others
categories. We included three binary (yes/no) variables for insurance status at the time of
initiation of ESRD service: Medicaid, private and no insurance.
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We calculated the number of patient comorbidities and categorized the variable
into four categories, “One or less”, “two”, “three” and “four or more”. We included six
distinct binary variables for comorbidities including diabetes, hypertension,
atherosclerotic heart disease (AHSD), peripheral vascular disease (PVD), cerebrovascular
attack (CVD), and no comorbidity.
The primary cause of ESRD was classified into four categories: diabetes,
hypertension, glomerulonephritis and other. We also included four components of preESRD care, including Epoetin, nephrologist care, the presence of mature AVF/AVG and
diet care as distinct variables. BMI was categorized using the Center For Disease Control
(CDC) criteria into four categories underweight (<18.5); normal (≥ 18.5-<25);
overweight (≥ 25-<30) and obese (≥30) (Center for disease control and Prevention,
2015a).
To calculate centroid (straight line) distances between travel points, first, we
calculated centroid (straight line) distances between patient and facility ZIP Codes. The
SAS ZIP Code file of January 2015 was used to extract longitude and latitude of patient
and facility ZIP Codes (SAS support, 2014; SAS support., 2015). We used the SAS
“zipcitydistance” macro (SAS support, 2014) to calculate straight line distances between
patient and facility ZIP codes (Bliss, et al., 2012). The continuous distances were then
grouped into quartiles - <1.9; ≥1.9-<6.9; ≥6.9-<15.0 and ≥15.0 miles.

Facility level covariates
Facility covariates included chain affiliation; for-profit and low volume status;
number of dialysis treatments; number of registered nurses, number of dialysis hours per
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session; number of dialysis sessions per week per patients and services such as home
hemodialysis; peritoneal dialysis; and late shift.
Membership in a chain of dialysis facilities was identified with five different
options. For the three largest chains, we assigned each chain a number (1 – 3); all
facilities affiliated with the smaller or regional chains were consolidated into a single
category (chain 4). Remaining facilities, not in a chain, were grouped together.

Ecological covariates
Ecological covariates were measured at the county level. We included the
proportions of the population represented by Hispanics and black residents and people in
poverty; unemployment rate among age 16 years or more and median household income
in the county.
We classified rurality into four groups using Urban Influence Codes (UIC): “Urban”
(UIC 1, 2), “Micropolitan rural” (UICs 3, 5 and 8), and “small adjacent rural” (UICs 4 6
and 7) and “remote rural” (UICs 9 10 11 and 12). (United States Department of
Agriculture Economic Research Service: Economic Research Service, 2013). We also
included facility ESRD regional networks in our analysis and merged them into facilities
located in South, West, Midwest and Northeast.
Analysis
We used SAS version 9.4 (SAS Institute, Cary, NC) and R software version 3.4.0
for analysis. We also checked the distribution of covariates across categories of
performance scores using Chi-Square for categorical variables and ANOVA for
continuous variables.
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Bivariate analysis was conducted using time to death as an outcome and
performance scores as the predictor. One-year survival probabilities were calculated
using the Kaplan–Meier method. The Log Rank test was used to assess equality of
survival across QIP categories.
A multivariable Cox regression model was estimated to assess the association of
mortality and performance scores using performance score [95,100] as a reference
category. Confidence intervals (CI) and p-values were calculated for each covariate. We
performed an analysis that sequentially adjusted for three sets of variables for all incident
hemodialysis patients. All analyses were conducted at the 5% level of significance.

5.4

RESULTS

Overall study population, facilities and county characteristics
The data included 89,514 incident ESRD cases between January, 2013 and December,
2013, of patients who survived the initial 90 days after receiving their first ESRD service,
remained on dialysis and did not receive transplants before death or until the end of
follow up period (March 31, 2014).
Patient characteristics
The mean age of the patients at the time of treatment initiation was 63.8 (±14.5)
years (Table 5.1). Most patients were male (57.2%), white Non-Hispanic (52.3%),
unemployed (29.3%) or retired (61.6%) and obese (40.5%). Hypertension (58.6%) was
the most common comorbidity and diabetes (47.6%) was the most common cause of
ESRD, followed by hypertension (31.6%). About 7% patients were uninsured and 9%
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were employed. The most common vascular access at dialysis initiation was central
venous catheter (CVC) (73.8%).
Patient’ facility characteristics
Table 5.2 presents Patients’ facility characteristics. Most patients were served by
medium (10-25 stations) (71.9%); large chains — Chain 1 (32.9%), Chain 3 (32.0%); forprofit facility (92.4%) and the facilities providing >10,000 treatments (61.8%) (Table
5.2). All patients had access to hemodialysis. Additionally, about 57% had access to
facilities providing peritoneal dialysis, 33% to facilities conducting home hemodialysis
and 24.6% to the facilities offering late night shifts.
Patients’ county Characteristics
Table 5-3 presents patients’ county characteristics. Most patients lived in urban
areas (86.9%) and South (41.3%) (Table 5.3). The average proportions of black and
Hispanic residents in patients’ counties were 15.6 (SD=14.8) and 18.3 (SD=18.3),
respectively. The average unemployment rate was 7.9 (SD=2.3)

Unadjusted analysis: Comparison of patient, facility and county characteristics by QIP
scores
Comparison of Patient factors by QIP scores
We found a significant association between all patient characteristics and QIP
scores, except BMI, smoking status, and history of hypertension (Table 5.1). Facilities
reporting ≥ 90 total scores were more likely to treat Hispanics (17.1%), retired (62%),
diabetic (59.3%) and hypertensive (88.3%) patients and patients who saw a nephrologist
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(62.5%) as part of pre-ESRD care. Facilities scoring <73 were more likely to have a
higher proportion of non-Hispanic black patients (28.7%), with ≥4 comorbidities
(35.3%), catheter at initiation of dialysis (73.8%) and absence of a pre-ESRD mature
arteriovenous fistula or graft (63.0%).
Comparison of patients’ facility factors by QIP scores
Most patients (27.9%) visited facilities with ≥90 QIP score (Table 5.2). Our
bivariate analysis showed a significant association between facility characteristics and
QIP scores. A total of 27.9% patient visited facilities scoring ≥ 90. Patients served by
facilities scoring ≥90 were more likely to visit facilities affiliated with chain 1 (59.5%),
for-profit facilities (93.8%), late shift (26.2%) and low volume facilities (2.5%), while
facilities scoring ≥73-<83 were more likely to have 10-25 stations and provided >10,000
treatments (Table 5.1) Conversely, facilities scoring <73 were more likely to be affiliated
with chain 3 (another large for-profit), offer PD (60.3%), home hemodialysis (38.7%).
Comparison of patients’ county factors by QIP scores
All patient county factors were associated with QIP scores in our bivariate
analysis. Patients being treated at the facility scoring <73 were in counties with a higher
proportion of residents who were black (16.9%), unemployed (8.1%), and persons in
poverty (17.4%). Conversely, facilities scoring >90 were in the counties with a higher
proportion of Hispanic residents (20.2%). Among the facilities scoring ≥73- <83, most
were in South (43.3%).

Unadjusted hazard ratio of one-year mortality by patients, facility and county factors
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Table 5.4 presents the bivariate relationships between patient characteristics and
one-year mortality. Briefly, all patient characteristics except the distance between patient
and facility ZIP Codes were associated with mortality (Table 5.4). Age was associated
with increased risk of mortality (HR: 1.04; 95% CI: 1.04- 1.05). Further, unemployed
(HR: 2.34; 95% CI: 2.07- 2.64]), retired (HR: 4.22; 95% CI: 3.76- 4.73) and underweight
(HR: 1.35; 95% CI: 1.24- 1.47]) demonstrated a higher risk of mortality. Patients covered
by Medicaid at the initiation of treatment (Medicaid covered vs. no Medicaid (HR: 1.08;
95% CI: 1.03- 1.13), private insurance (private insurance vs. No private insurance (HR:
1.67; 95% CI: 1.59- 1.75) and no coverage (No coverage vs. any coverage (No coverage
vs. any coverage — HR: 3.07; 95% CI: 2.71- 3.47) showed a higher risk of mortality.
We also found pre-ESRD care, including nephrologist care (HR: 0.70; 95% CI:
0.67- 0.72), dietary care (HR 0.80; 95% CI: 0.73- 0.87), mature AVF/AVG (HR 0.67:
95% CI: 0.63- 0.70) and Epoetin use (HR 0.88: 95% CI; 0.83- 0.94] to be associated with
lower mortality risk. Compared with non-Hispanic White patients, we found a lower risk
Black non-Hispanic (HR: 0.55; 95% CI: 0.52- 0.58), Hispanic (HR: 0.52; 95% CI: 0.490.55) and other races (HR: 0.48; 95% CI: 1.04- 1.05). Lower mortality risk was found
among obese (HR 0.84 [95% CI 0.80- 0.88]) and overweight (HR 0.68 [95% CI 0.650.72]) patients, compared with underweight. Catheter use at the initiation of therapy was
(HR 2.27 [95% CI 2.12- 2.42]) associated with higher risk.
Table 5.5 presents an unadjusted hazard ratio for one-year mortality associated
with facility characteristics. We found a lower mortality risk among patients visiting
medium (HR: 0.65; 95% CI: 0.59- 0.71) and large size facilities (HR: 0.76; 95% CI: 0.700.82), compared with small facilities (Table 5.5). Similarly, a higher mortality risk was
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found among patients visiting facilities providing <4000 treatments (HR: 1.13; 95% CI
1.05- 1.21), and 4000-9999 treatments (HR: 1.15; 95% CI: 1.10- 1.20) and low volume
facilities (HR 1.19; 95% CI: 1.04- 1.35). Mortality risk was lower among chain affiliated
facilities (Chain 1 (HR: 0.87; 95% CI: 0.81- 0.93), Chain 2 (HR: 0.81; 95% CI: 0.710.92), Chain 3; (HR: 0.81; 95%: CI 0.75- 0.86) and Chain 4 (HR: 0.91; 95% CI: 0.840.94), compared with non-chain affiliated facilities. Mortality risk was also lower among
patients visiting facilities offering a higher number of hemodialysis sessions per patient
per week (HR 0.87 [95% CI 0.84- 0.90]).
We found a lower risk of mortality among patients living in South (HR: 0.85;
95% CI: 0.80- 0.89) and West (HR: 0.74; 95% CI: 0.69- 0.79) (Table 5.6). The risk of
mortality was higher among patients living in micropolitan rural (HR 1.11 [95% CI 1.041.19]), compared with Urban patients.

Examining QIP scores: unadjusted and fully adjusted results
Table 5.7 presents unadjusted hazard ratios of one-year mortality rate by QIP scores.
Overall, 11.8% patients died within one year of follow up (after excluding deaths of the
first 90 days of first ESRD service). The unadjusted mortality rate by QIP is shown in the
table 5.7.
The hazard ratio varied by QIP score. Mortality was markedly higher among
patients visiting facilities scoring < 60 (HR: 1.44; 95% CI: 1.31- 1.58) and scoring and
>=70- <75 (HR: 1.12; 95% CI: 1.03- 1.22), when compared to mortality at facilities with
the highest QIP scores. Notably, patients visiting facilities scoring >=60- <65, >=65- <70
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and 75 or more demonstrated no difference compared with those scoring ≥95 (referent
category).
We used incremental modelling approach, first adjusting for patient and then for
facility and finally for ecological factors. In the model adjusted for patient, facility and
ecological covariates (Table 5.8; model 1-c), we found a higher mortality rate among
patients visiting facilities scoring a QIP score of < 60 (HR: 1.21; 95% CI: 1.09- 1.34),
compared with facilities scoring ≥95 (Table 5.7). We found interaction between rurality
and race and rurality and distance insignificant. The association of other covariates from
the final adjusted model (model 1-c) is presented in the supplemental table (Appendix F).
5.5

DISCUSSION
We determined the association between dialysis facility performance scores and

patient survival among incident patients who had survived for the first 90 days after the
first ESRD treatment. Patients visiting facilities scoring <60 on QIP criteria demonstrated
a higher risk of mortality than the reference group, i.e., patients visiting facilities scoring
≥95. We found no difference in mortality among patients visiting facilities scoring more
than 60 and reference group. To the best of our knowledge, we are first to demonstrate an
association between QIP scores and patient survival. Notably, Medicare uses a QIP score
of <60 to apply payment penalties of 0-2% of facilities.
Notwithstanding that no prior study has determined an association between
facility QIP scores and patient survival, the literature reports an association of survival
and specific QIP measures, including hemoglobin >12 and vascular access treatment
(AVF) and patient survival (Chand, et al., 2008; Lankhorst & Wish, 2010; National
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Institute of Diabetes and Digestive and Kidney Disease, 2014a; Ravani, et al., 2013). For
instance, normal levels and lower variation of hemoglobin are associated with fewer
complications and better survival. One g/dl increase in standard deviation of hemoglobin
was associated with a 33% increase in mortality (Yang, et al., 2007). Similarly, higher
use of AVF and lower use of catheter are associated with lower blood stream infections
and better patient survival (Chand, et al., 2008; Perl, et al., 2011; Santoro, et al., 2014).
Conversely, studies have also shown that normal levels of URR and Kt/V are not or
modestly associated with patient survival (Desai, Nissenson, et al., 2009; Moss &
Davison, 2015).
The patient survival among facilities scoring ≥60 was not different from the
survival in facilities scoring ≥ 95. Research has demonstrated a strong association
between some of the factors not included in the QIP criteria and patient survival. For
instance, inflammatory and nutritional biomarkers such as tumor necrosis factor (TNF),
C-reactive protein (CRP) and pre-albumin are found strongly associated with survival of
hemodialysis patients (Desai, Nissenson, et al., 2009). The inclusion of these biomarker
might increase the discriminatory effect of QIP scores on patient survival. We
recommend future studies on associations between these factors and patient survival.
In their review, Nissenson et al., and Moss et al., proposed including patient
prognosis and preferences in ESRD QIP to effectively improve quality and health
outcomes among patients (Moss & Davison, 2015; Nissenson, 2013). Medicare has
recently revised QIP criteria to include facility reported standardized readmission ratio as
a clinical criterion in 2017 (Center for Medicare and Medicaid Services, 2016a). The
ratio measures unplanned patient readmission to the hospital after adjusting patient risk
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factors (The University of Michigan Kidney Epidemiology and Cost Center, 2016). This
shows Medicare’s shift in focus from clinical-centric to patient-centric criteria. The
facility reported patient survival rate can also be considered as a QIP criterion.
This study has several limitations. The data only included the information on the
facility from where patients received the first service, therefore, we could not adjust our
analysis for number of transitions if patient visited multiple facilities during dialysis
treatments. Similarly, we could not adjust our analysis for transitions in treatment
modality, if there were any. Further, our data did not include information about a few
potential covariates of patient survival, including dialysis dose and its variation, dialyzer
reuse and availability of on-site nephrologist.
Despite these limitations, we are first to report association between QIP scores
and one year patient survival, using national data. Further, our analysis accounted for
multilevel covariates including the patient, facility and ecological factors.

5.6

CONCLUSIONS
We found facilities scoring <60 on QIP criteria associated with higher one year

patient mortality. Medicare defines such facilities as “failed facilities” and reduces their
reimbursements by 0-2%. However, patient survival in facilities scoring more than 60
was not different from patient survival in facilities scoring ≥95. We recommend research
on possibility of inclusion of more patient centric measures such as facility reported
patient survival in QIP criteria.
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Table 5.1: Patient characteristics by QIP scores in calendar year (CY), 2013
Characteristics

QIP
Scores
ref= <73
n 89,519
21031
%
100
23.5

Patients gender
Male
Age at incidence
mean (SD)
Race
White NonHispanic
Black NonHispanic
Hispanic only
Others
Body Mass Index
Underweight
(<18.5)
Normal (≥ 18.5<25)
Overweight (≥ 25<30)
Obese (≥30)
Insurance
Medicaid
Private insurance
No insurance
Employed
Not employed
Employed
Retired
Vascular access
AVF/AVG
Catheter
Others
Distance
<1.9 miles
≥1.9- <6.9 miles
≥6.9- <15.0 miles

All

QIP
Scores
≥73-<83
20,887
23.3

QIP
Scores ≥
83-<90
22,621
25.3

QIP
Scores
≥ 90
24,980
27.9

P-value

57.2
63.8
(14.5)

56.8
64.2
(14.5)

57.5
63.7
(14.6)

57.3
63.6
(14.5)

57.3
63.8
(14.3)

<.0001*
<.0001†

52.3

52.4

54.0

50.4

52.4

<.0001*

27.2

28.7

28.1

28.0

24.5

15.4
5.1

15.1
3.7

13.0
4.9

16.1
5.5

17.1
6.1

3.9

4.0

4.0

4.1

3.7

27.8

27.2

27.7

28.0

28.1

27.8

27.7

27.4

27.9

28.0

40.5

41.1

40.9

40.0

40.3

26.4
18.0
6.8

25.9
83.0
6.6

25.4
82.1
6.7

27.6
81.7
7.3

26.7
81.4
6.8

<.0001*
<.0001*
0.0125

29.3
9.1
61.6

29.7
8.6
61.7

29.2
9.3
61.5

29.7
9.3
61.1

28.7
9.4
62.0

0.0084*

18.2
73.8
8.0

16.0
76.7
7.3

18.8
73.2
8.0

18.6
73.2
8.2

19.3
72.4
8.3

<.0001*

25.0
25.0
25.0

22.4
24.3
26.2

24.9
24.6
25.2

25.9
26.0
24.5

26.5
25.0
24.3

<.0001*

125

0.0837*

Characteristics

All

≥15.0 miles
Primary disease
causing ESRD
Diabetes
Hypertension
Glomerulonephritis
Others
Number of
Comorbidities
≤1
2
3
≥4
Comorbidities
Diabetes
Atherosclerotic
heart disease
(ASHD)
Congestive heart
failure (CHF)
Chronic obstructive
pulmonary disease
(COPD)
Hypertension
(HTN)
Cerebrovascular
accident (CVA)
Peripheral vascular
disease (PVD)
None
Current smoker)
Pre-ESRD care
Epoetin
Yes
No
Not reported
Dietary care
Yes
No

25.0

QIP
Scores
ref= <73
27.1

QIP
Scores
≥73-<83
25.3

QIP
Scores ≥
83-<90
23.6

QIP
Scores
≥ 90
24.3

47.6
31.6
6.7
14.2

46.5
33.3
6.1
14.1

47.1
31.9
6.8
14.3

47.2
32.0
7.0
13.8

49.2
29.4
6.9
14.6

<.0001*

20.8
25.8
20.7
32.8

19.8
24.9
20.0
35.3

20.6
26.0
20.8
32.6

21.8
26.1
21.1
31.0

20.6
26.2
20.8
32.4

<.0001*

58.6
16.2

58.7
16.6

57.6
16.6

58.3
15.3

59.6
16.3

0.0003*
0.0004*

30.3

31.6

30.3

29.9

29.5

<.0001*

9.8

10.5

10.1

9.0

9.7

<.0001*

88.0

87.8

88.0

87.8

88.3

0.1904*

8.9

9.4

9.3

8.6

8.5

0.0005*

11.8

12.8

12.0

11.3

11.1

<.0001*

1.9
6.4

1.8
6.6

1.9
6.7

2.0
6.1

1.8
6.4

0.1049*
0.0853*

14.6
56.0
29.4

12.8
54.7
32.5

15.2
56.2
28.6

14.3
56.4
29.3

15.7
56.8
27.5

<.0001*

6.3
70.3

5.7
68.4

6.4
70.5

5.9
71.1

7.0
71.0

<.0001*
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Characteristics

All

Not reported
23.4
Presence of mature
AVF/AVG
Yes
19.0
No
57.8
Not reported
23.2
Nephrologist care
Yes
60.3
No
26.2
Not reported
13.6
Notes:
*Chi-Square at Alpha 5%
† ANOVA at Alpha 5%
n=89,519

QIP
Scores
ref= <73
25.9

QIP
Scores
≥73-<83
23.1

QIP
Scores ≥
83-<90
23.0

QIP
Scores
≥ 90
22.0

16.6
63.0
20.3

18.8
57.6
23.6

19.3
57.1
23.6

20.8
54.3
24.9

<.0001*

56.1
27.6
16.34

61.0
25.8
13.2

61.0
26.2
12.9

62.5
25.4
12.2

<.0001*
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Table 5.2: Patient’s facility characteristics by QIP scores, 2013
All

n
%
Size (stations)
Large (> 25)
Medium (11-25)
Small (≤11)
Chain type
Chain 1: Large
for-profit
Chain 2: Large
not for-profit
Chain 3: Large
for-profit
Chain 4: Others
No chains
Dialysis
treatment
<4000
4000-9999
>=10000
For-Profit
Offers Peritoneal
dialysis
Offers home
hemodialysis
Offers night shift
Low volume
Hemodialysis
hours per
session, (mean
(±SD)
Hemodialysis
session per week,
mean (±SD)
Patient Care
Technicians
mean, (±SD)

QIP
Scores
≥73-<83

QIP
Scores ≥
83-<90

89519
100

QIP
Scores
ref=
<73
21031
23.5

20887
23.3

22621
25.3

23.0
71.9
5.1

24.3
68.3
7.4

22.0
74.9
3.1

25.6
71.0
3.4

20.4 <.0001*
73.3
6.4

32.9

8.4

20.7

37.4

59.6 <.0001*

3.2

2.8

4.0

3.4

2.6

32.0

49.4

42.1

28.8

11.9

21.7
10.3

22.9
16.6

22.9
10.4

22.3
8.2

19.2
6.7

9.2
29.1
61.8
92.4
57.2

12.4
29.0
58.6
92.2
60.3

9.4
32.3
58.3
90.8
58.3

6.5
27.5
66.1
92.4
56.4

8.7 <.0001*
27.9
63.4
93.8 <.0001*
54.4 <.0001*

33.1

38.7

33.7

32.2

28.9 <.0001*

24.6
1.9
3.8 (0.5)

22.5
1.7
3.9
(0.5)

24.6
2.0
3.8 (0.5)

24.8
1.4
3.8 (0.5)

26.2 <.0001*
2.5 <.0001*
3.8 (0.5) <.0001†

3.0 (0.2)

3.0
(0.2)

3.0 (0.2)

3.0 (0.2)

3.0 (0.2) 0.0376†

7.7 (5.1)

7.4
(5.2)

7.4 (5.1)

8.1 (5)

7.7 (5.2) <.0001†

128

QIP
Scores
≥ 90
24980
27.9

p-value

All

n

89519
5.6 (4.2)

QIP
Scores
ref=
<73
21031
6.1
(5.6)

QIP
Scores
≥73-<83

QIP
Scores ≥
83-<90

20887
5.6 (4.0)

22621
5.5 (3.4)

Registered
Nurses,
mean(±SD)
Notes: *Chi-Square at Alpha 5%; † ANOVA at Alpha 5%
n=89,519

QIP
Scores
≥ 90
24980 p-value
5.2 (3.5) <.0001†

Table 5.3: Patient’s county characteristics by facility QIP scores, 2013
All
n
%
Regions
Midwest
Northeast
South
West
Rurality
Micropolitan
Remote
Small adjacent
Urban
Proportion of
black, Mean
(±SD)
Proportion of
Hispanics,
Mean (±SD)
Unemployment
Rate, 16+,
Mean (±SD)
Percent
Persons in
Poverty 2013,
Mean (±SD)

89519
100

QIP
Scores
ref= <73
21031
23.5

QIP
Scores
≥73-<83
20887
23.3

QIP
Scores ≥
83-<90
22621
25.3

QIP
Scores
≥ 90
24980
27.9

21.4
16.7
41.3
20.6

26.6
17.3
38.9
17.2

21.8
17.6
43.3
17.3

18.2
16.1
43.0
22.8

19.7
16.0
39.9
24.4

<.0001*

9.4
1.2
2.6
86.9
15.5
(14.8)

7.3
1.0
1.9
89.7
16.9
(14.3)

9.6
1.1
2.9
86.5
16.5
(15.4)

9.6
1.1
2.1
87.2
15.9
(15.5)

10.7
1.6
3.3
84.5
13.4
(13.5)

<.0001*

18.3
(18.4)

17.2
(17.3)

15.9
(17.0)

19.2
(19.2)

20.2
(19.5)

<.0001†

7.9 (2.3)

8.06(2.2)

7.9 (2.2)

7.9 (2.1)

7.8 (2.4)

<.0001†

17.2 (5.7)

17.4(5.4)

17.2 (5.8) 17.3 (5.8) 16.9 (5.6) <.0001†
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p-value

<.0001†

All

QIP
QIP
QIP
QIP
Scores
Scores
Scores ≥
Scores
ref= <73 ≥73-<83
83-<90
≥ 90
n
89519
21031
20887
22621
24980
p-value
%
100
23.5
23.3
25.3
27.9
52077.9
51458.2
51773.6
52415.7
52525.3 <.0001†
Median
(13359.6) (12494.7) (13432.9) (13665.9) (13670.0)
Household
Income, Mean
(±SD)
Notes:
*Chi-Square at Alpha 5%
† ANOVA at Alpha 5%
n=89,519
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Table 5.4: Unadjusted hazards ratio of 1-year mortality by Patients characteristics, 2013
Patient
Characteristics
Sex (Ref = Female)
Male
Age at incidence
Race (Ref = NonHispanic White)
Black Non-Hispanic
Hispanic only
Others
Medicaid (Ref= No)
Private insurance
(Ref= No)
No insurance (Ref=
No)
Employment status
(Ref= Employed)
Unemployed
Retired
Body Mass Index
(Ref= Normal)
Overweight
Obese
Underweight
Vascular access
treatment at initiation
of service (Ref=
AVF/AVG)
Catheters
Others
Distance (Ref= <1.9
miles)
≥1.9- <6.9 miles
≥6.9- <15.0 miles
≥15.0 miles
Primary disease
causing ESRD (Ref=
Others)
Diabetes

Parameter
Estimate

SE

ChiSquare

pvalue

Hazard
Ratio

95% Cis

0.00
0.04

0.02
0.01
0.9344
0.00 2679.02 <.0001

1.00
1.04

0.96 1.04
1.04 1.05

-0.60
-0.66
-0.73
0.07

0.03
0.03
0.06
0.02

551.87
402.87
170.89
9.83

<.0001
<.0001
<.0001
0.0017

0.55
0.52
0.48
1.08

0.52
0.49
0.43
1.03

0.51

0.03

419.36

<.0001

1.67

1.59 1.75

1.12

0.06

313.60

<.0001

3.07

2.71 3.47

0.85
1.44

0.06
0.06

189.92
599.68

<.0001
<.0001

2.34
4.22

2.07 2.64
3.76 4.73

-0.18
-0.38
0.30

0.03
0.02
0.04

47.16
240.10
44.64

<.0001
<.0001
<.0001

0.68
0.84
1.35

0.65 0.72
0.80 0.88
1.24 1.47

0.82
-0.10

0.03
0.06

609.75
2.81

<.0001
0.0936

2.27
0.91

2.12 2.42
0.81 1.02

0.01
0.03
0.12

0.03
0.03
0.03

0.06
1.28
18.53

0.8146
0.258
<.0001

1.01
1.03
1.13

0.95 1.07
0.98 1.09
1.07 1.19

-0.49

0.03

314.92

<.0001

0.62

0.58 0.65
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0.58
0.55
0.54
1.13

Patient
Characteristics
Hypertension
Glomerulonephritis
Severity of
comorbidities (Ref= 01 comorbidities)
2 comorbidities
3 comorbidities
≥4 comorbidities
Comorbidities
Diabetes (Ref=No)
Atherosclerotic
heart disease
(ASHD) (Ref= No)
Congestive heart
failure (CHF) (Ref=
No)
Chronic obstructive
pulmonary disease
(COPD) (Ref= No)
Hypertension (Ref=
No)
Cerebrovascular
accident (CVA)
(Ref= No)
Peripheral vascular
disease (PVD) (Ref=
No)
None (Ref= No)
Current smoker (Ref=
No)
Pre ESRD care
Nephrologist care
(Ref= No)
Yes
Not reported
Presence of mature
AVF/AVG (Ref=
No)
Yes
Not reported

Parameter
Estimate

SE

ChiSquare

pvalue

Hazard
Ratio

95% Cis

-0.34
-0.84

0.03
0.05

138.77
256.51

<.0001
<.0001

0.71
0.43

0.67 0.75
0.39 0.48

0.17
0.41

0.04
0.04

22.57
132.76

<.0001
<.0001

1.18
1.51

1.10 1.27
1.40 1.61

0.92

0.03

890.36

<.0001

2.52

2.37 2.68

-0.07
0.44

0.02
0.02

12.26
331.99

0.0005
<.0001

0.93
1.55

0.90 0.97
1.48 1.63

0.62

0.02

929.35

<.0001

1.85

1.78 1.93

0.61

0.03

479.75

<.0001

1.84

1.74 1.94

-0.40

0.03

210.76

<.0001

0.67

0.64 0.71

0.32

0.03

101.37

<.0001

1.37

1.29 1.46

0.44

0.03

262.62

<.0001

1.55

1.47 1.64

0.49
-0.02

0.09
0.04

28.56
0.31

<.0001
0.5771

1.64
0.98

1.37 1.97
0.90 1.06

-0.34
0.08

0.02
0.03

217.63
7.30

<.0001
0.0069

0.72
1.09

0.68 0.75
1.02 1.15

-0.40
-1.00

0.03 222.88 <.0001
0.03 1008.23 <.0001

0.67
0.37

0.63 0.70
0.35 0.39
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Patient
Characteristics
Received Epoetin
(Ref= No)
Yes
Not reported
Dietary care (Ref=
No)
Yes
Not reported
Notes:
Sample n=84,493

Parameter
Estimate

SE

ChiSquare

pvalue

Hazard
Ratio

95% Cis

-0.13
0.12

0.03
0.02

16.75
27.80

<.0001
<.0001

0.88
1.13

0.83 0.94
1.08 1.18

-0.23
0.07

0.05
0.02

25.15
8.97

<.0001
0.0027

0.80
1.07

0.73 0.87
1.03 1.12
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Table 5.5: Unadjusted Hazard Ratios of 1-year mortality by facility characteristics, 2013
Facility characteristics
Facility size (ref=<11
stations)
Medium (11-25 stations
Large (>25 stations)
Chain affiliation (ref= No
chains)
Chain 1: Large forprofit
Chain 2: Large not forprofit
Chain 3: Large forprofit
Chain 4: Others
Number of treatment
(ref= ≥ 10,000)
<4000 treatments
4000-9999 treatments
For-profit (ref= No)
Offers peritoneal dialysis
(ref= No)
Offers home Hemodialysis
(ref= No)
Offers late shift (ref= No)
Low volume facility (ref=
No)
Hemodialysis hours per
session
Hemodialysis session per
week
Patient care technicians
Registered nurses
n=84,493

Parameter
Estimate

SE

ChiSquare

-0.43
-0.28

0.05
0.04

92.10
46.59

<.0001 0.65 0.59 0.71
<.0001 0.76 0.70 0.82

-0.15

0.03

18.06

<.0001 0.87 0.81 0.93

-0.22

0.07

10.79

0.001

-0.22

0.03

38.41

<.0001 0.81 0.75 0.86

-0.09

0.04

6.76

0.0093 0.91 0.85 0.98

0.12
0.14
0.07
-0.01

0.03
0.02
0.04
0.02

12.08
38.14
2.91
0.45

0.0005
<.0001
0.0883
0.504

-0.02

0.02

0.58

0.4481 0.98 0.94 1.03

-0.04

0.02

2.73

0.0983 0.96 0.92 1.01

0.17

0.07

6.30

0.0121 1.19 1.04 1.35

-0.13

0.02

38.48

<.0001 0.88 0.84 0.92

-0.15

0.06

6.55

0.0105 0.86 0.77 0.97

-0.02
0.00

0.00
0.00

76.50
1.10

<.0001 0.98 0.98 0.99
0.2953 1.00 0.99 1.00
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pvalue

HR

95% CI

0.81 0.71 0.92

1.13
1.15
1.07
0.99

1.05
1.10
0.99
0.95

1.21
1.20
1.15
1.03

Table 5.6: Unadjusted Hazard Ratios of 1-year mortality of patient’s county
characteristics, 2013
Ecological Characteristics
Regions (ref= Northeast)
Midwest
South
West
Rurality (ref= Urban)
Micropolitan rural
Remote rural
Small adjacent rural
Proportion of Hispanic
Proportion of black
Unemployment rate
among 16+
Proportion of persons in
poverty
Median household income

Parameter
Estimate

SE

ChiSquare

pvalue

HR

-0.04
-0.17
-0.31

0.03
0.03
0.03

1.80
36.62
85.32

0.1793 0.96 0.90 1.02
<.0001 0.85 0.80 0.89
<.0001 0.74 0.69 0.79

0.10
0.03
0.07
0.00
0.00
0.00

0.03
0.09
0.06
0.00
0.00
0.00

9.85
0.08
1.42
58.43
39.74
0.79

0.0017
0.7822
0.2326
<.0001
<.0001
0.3733

0.01

0.00

47.69

<.0001 0.99 0.98 0.99

0.00

0.00

2.09

0.1483 1.00 1.00 1.00

1.11
1.03
1.08
1.00
1.00
1.00

95% CI

1.04
0.86
0.95
0.99
0.99
0.99

1.19
1.23
1.21
1.00
1.00
1.01

Table 5.7: Unadjusted 1-year mortality and unadjusted Hazard ratio, 2013 incident
patients
Unadjusted Parameter
Mortality
(%)
QIP score
(ref= ≥95)
< 60
≥60- <65
≥65- <70
≥70- <75
≥75- <80
≥80 - <85
≥85- <90
≥90- <95
≥ 95

15.6
12.5
11.9
12.5
11.5
11.9
11.3
11.1
11.1

0.36
0.10
0.06
0.12
0.02
0.05
0.01
-0.02
*

SE

ChiSquare

pvalue

HR

95%
confidence

0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.04
*

59.50
3.35
1.79
7.17
0.34
1.95
0.04
0.28
*

<.0001
0.0673
0.1811
0.0074
0.5582
0.1631
0.8432
0.5957
*

1.44
1.10
1.06
1.12
1.02
1.06
1.01
0.98
*

1.31
0.99
0.97
1.03
0.95
0.98
0.94
0.91
*
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1.58
1.22
1.16
1.22
1.11
1.14
1.09
1.06
*

Table 5.8: Adjusted Hazard Ratios of 1-year mortality in 2013
Paramet
er
Score (Ref= ≥95)
< 60
≥60- <65
≥65- <70
≥70- <75
≥75- <80
≥80 - <85
≥85- <90
≥90- <95

0.18
-0.01
0.02
0.06
0.03
0.02
0.02
-0.01

Score (ref= ≥95)
< 60
0.19
≥60- <65
0.01
≥65- <70
0.05
≥70- <75
0.08
≥75- <80
0.04
≥80 - <85
0.04
≥85- <90
0.04
≥90- <95
-0.01

SE

Chip-value
Square
Model 1a*

HR

95% confidence

0.05
14.36 0.0002
0.05
0.02 0.9007
0.05
0.18 0.6683
0.04
2.15 0.1425
0.04
0.38 0.5375
0.04
0.25 0.6198
0.04
0.20 0.6548
0.04
0.09 0.7592
Adjusted model 1b†

1.20
0.99
1.02
1.07
1.03
1.02
1.02
0.99

1.09
0.90
0.93
0.98
0.95
0.94
0.94
0.92

1.31
1.10
1.12
1.16
1.11
1.10
1.10
1.07

0.05
13.94 0.0002
0.06
0.04 0.8473
0.05
0.94 0.3332
0.05
3.19 0.0742
0.04
0.78 0.3784
0.04
0.84 0.3605
0.04
1.03 0.3106
0.04
0.10 0.7545
Adjusted Model 1c‡

1.21
1.01
1.05
1.09
1.04
1.04
1.04
0.99

1.10
0.91
0.95
0.99
0.95
0.96
0.96
0.91

1.34
1.13
1.16
1.19
1.13
1.13
1.12
1.07

Score (ref= ≥95)
< 60
0.19
0.05
13.36 0.0003
1.21
1.09
1.34
≥60- <65
-0.02
0.06
0.09 0.7588
0.98
0.88
1.10
≥65- <70
0.06
0.05
1.61 0.2044
1.07
0.97
1.18
≥70- <75
0.09
0.05
3.33
0.068
1.09
0.99
1.20
≥75- <80
0.03
0.04
0.51 0.4743
1.03
0.95
1.13
≥80 - <85
0.04
0.04
0.76 0.3843
1.04
0.96
1.13
≥85- <90
0.04
0.04
0.98 0.3222
1.04
0.96
1.12
≥90- <95
-0.02
0.04
0.16
0.689
0.98
0.91
1.07
Notes:
* Adjusted for patient factors including patients race, age, sex, insurance status,
currently employed, smoker, primary disease causing renal failure, severity of
comorbidities, comorbidities (diabetes, Hypertension, peripheral vascular disease,
congestive heart disease, chronic obstructive pulmonary disease, cerebrovascular
accident, None), presence of catheter at the time of treatment initiation, pre-ESRD care
(nephrologist care, dietary care, Epoetin, presence of mature AVF/AVG)
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† Model 1b: Adjusted for covariates in model 1a and facility factors including chain
affiliation, size, dialysis treatment, low volume, for-profit, offer Peritoneal dialysis,
offer home hemodialysis, offer late night shift, presence of registered nurse, dialysis
session per week per patient, dialysis hours per session
‡ Adjusted for covariates in model 1a and 1b and county factors including proportion
of Hispanic per county, proportion of black per county, proportion of persons in
poverty, unemployment rate in 16+, medical household income, rurality and regions

137

CHAPTER VI- CONCLUSIONS
The CMS has been working on bending the continuing rise in the Medicare cost
curve. In pursuit of that, it focuses on areas of high cost and inefficiency. The ESRD care
is one such area. ESRD is a costly disease. Medicare included the disease as the first
disease based eligibility in 1972, which enabled the program to enroll ESRD patients
irrespective of their age. ESRD care uses disproportionate Medicare funds, that is,
although the ESRD population comprises about 1% of the Medicare patients, it uses 7%
of the program funds. Considering the high and constantly increasing cost of ESRD care,
Medicare introduced an ESRD bundled payment reform and the associated Quality
Incentive Program (QIP) in 2011. QIP rates facilities on clinical and reporting criteria. It
sets a target score for the facilities for them to avoid financial penalties of 0-2%.
The reform can impact small facilities adversely (Iglehart, 2011; A. W. Williams,
2015). Such facilities are mostly rural, low volume and low profit margin. The
combinations of these factors and the bundled reform can make small and rural facilities
more vulnerable to closure or consolidation. The closure or consolidation of small
facilities will result in ESRD patients traveling longer distances to access dialysis. ESRD
patients are frail and need timely and recurrent dialyses. Therefore, closure of nearby
facilities can impact the patients seriously. The patient, facility and ecological factors
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associated with small facilities can be different from that in medium and large facilities.
Therefore, in our study 1, we determined the association between the factors and QIP
scores, adjusting for the patient, facility and ecological factors.
After including three clinical indicators at the time of inception of QIP, Medicare
has increased the number of indicators over the years (Centers for Medicare & Medicaid
Services, 2012). The program, however, is critiqued for including easy to measure
clinical and reporting indicators (Moss & Davison, 2015; Nissenson, 2013). The patient
outcomes are missing among QIP criteria. The association of QIP scores with survival is
still an unanswered question. Therefore, in our study 2, we also attempted to determine
the association between patient survival and QIP scores.
The majority (91%) dialysis facilities are freestanding in the U.S (Medicare
Payment Advisory Commission (US), 2015). Therefore, we focused on freestanding
dialysis facilities in the current research. We investigated the association between
freestanding dialysis facility size and QIP scores as its first study and association between
QIP scores and patient survival as the second. The study used Medicare DFC, QIP and
impact files and USRDS and AHRF data for the year 2013. To the best of our knowledge,
we are first to report the association between facility size, QIP scores and patient survival
after adjusting for the facility, patient and ecological factors.
We found an association between facility size and QIP scores. We determined the
facility size using a supply side indicator, number of dialysis stations. We noted that the
medium (11-25 stations) and large facilities (>25 stations) achieved a higher QIP score,
compared with small facilities. Further, facility aggregated patient factors were also
significantly associated with the QIP scores. For instance, facilities where patients
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travelled more distances to access care were associated with lower QIP scores. Therefore,
such facilities are more at risk of receiving QIP penalties and closure. The closure of such
facilities will result in patients using alternate facilities and traveling longer distances.
Further, we found black and Hispanic populations in the ESRD facilities
implicated difference in QIP scores. For instance, while a higher black population in the
facility was associated with lower QIP scores, a higher Hispanic population was
associated with higher QIP scores. The finding warrants more research into further
explore these findings.
In our study 2, which focused on determining association between QIP scores and
1-year patient survival, we included incident ESRD cases from Jan-Dec 2013, who
survived the first 90 days after the first ESRD service. We noted that the facilities
receiving <60 on QIP criteria demonstrated a lower patient survival than those achieving
95 or more scores.
We found that patient mortality varied by the facility QIP scores. Although, the
QIP has been critiqued for using easy to measure clinical indicators, however, the
association between QIP scores and patient mortality shows that the composite score
(QIP score) comprising of clinical and reporting measures (QIP criteria) have relevance
to the patient survival. However, we did not find any difference in 1-year patient survival
in facilities scoring more than a score of 60 (the target QIP score), compare with those
scoring 95 or more. Notably, we found that facility scoring the Medicare recommended
target QIP score of 60 and more did not show a statistically different 1-year mortality.
However, we do not know the reason behind this indifferent association between the QIP
scores of 60 and more and 1-year mortality. We recommend further research on this and
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to determine the association between QIP scores and other patient outcomes including
hospitalization and readmissions.
In the current ESRD care landscape, the bundled payment reform, QIP and further
payment rebasing have broad based implications for ESRD care providers. The penalties
have both financial and organizational implications. Therefore, considering both clinical
and contextual factors in assigning the QIP scores is important. For instance, adjusting
for the population racial mix at the facility might provide more appropriate QIP scores.
Further, the mean travel distances of patients from the facility can also influence the
quality of care in a facility. Patients traveling longer distances may skip dialysis treatment
schedules and therefore show more complications (deranged clinical/laboratory
indicators) due to non-compliance to treatment. While we did not find association with
rurality however, with closure and consolidation, rural patients will be more adversely
affected in the future. We also found patient distances associated with a higher 1-year
mortality among ESRD patients in our study 2.
The Medicare currently does not adjust facility scoring for QIP score calculation
except for not giving scores to the facilities with fewer than 11 in-center dialysis patients
during the performance period (Centers for Medicare & Medicaid Services 2013). QIP
scores have high implications on the facility with penalties being applied. We explored
associations of higher number of covariates with the QIP scores, including the facility
size. Facility size was also found associated with one year of survival in the current and
previous research. The earlier research mostly used demand side facility size factors
including number of treatments and number of patients. We found the supply side size
factor, that is, number of dialysis stations associated with QIP scores. Further, research

141

can highlight if these factors need to be adjusted to appropriately rate facilities on QIP
criteria.
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catheter

Year

Yanhon
g Li,
2009

20042005

Dayana
Fram,
2014

2010 2013

Unit of
Design
data type
Main
Outcome
analysis
exposure
3359
The
Primary data
Blood
Mortality,
patients
randomized,
stream and hospitalization
placebonon blood
controlled,
stream
doubleinfection
blind, phase
3 clinical
trial was
conducted at
164 sites

168

Author

32
patients in
Group 1
and 61 in
Group 2.

Nested
case–control

Primary data

BSI

Study Findings

Approximately one in 12
patients receiving dialysis
via arteriovenous fistula or
synthetic or heterologous
tissue graft developed S.
aureus infection during a 1yr period. All-cause
mortality at 12 weeks was
20.2% for patients
hospitalized with S. aureus
bacteremia and 15.7% for
patients with other types of
S. aureus infection. Patients
with either type of infection
were hospitalized 11 to 12 d
and incurred inpatient costs
of approximately $20,000
during the 12 weeks after
hospitalization with S. aureus
infection.
Mortality,
Patients with BSI caused by
hospitalization Staphylococcus aureus had
an 8.67 times higher chance
of progressing to death or
hospitalization, multiresistant
organism are more likely to
increase early mortality and
hospitalization

Author
Priti R.
Patel,
2013

Eduard
o
Lacson,
2009

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
Jan-DEC Patients
Quality
Primary data
CDC
BSI and
2009
from 17
improvemen
sponsored
access related
outpatient t project.
project to
BSI
hemodialy
decrease
sis
BSI
facilities
Jan-DEC
2006

169

1,085
Fresenius
Medical
Care,
providing
care to
atleast 25
patients

Prospective Primary data
observationa
l study.

Study Findings

Pooled mean BSI and accessrelated BSI rates decreased
to d 0.89 and 0.42 events per
100 patient-months during
the intervention period,
respectively from 1.09 and
0.73 events per 100 patientmonth
Achieveme Mortality and Achieving more than 5 goals
nt of each
hospitalization averaged 3.5 fewer hospital
goal for
days/patient-year and 20%
equilibrated
lower standardized mortality
Kt/V,
ratios. The incremental
missed HD
number of goals met al.so
treatments,
was associated with
hemoglobin
improvement in facility
level,
mortality (P 0.001) and
bicarbonate
hospital days (P 0.001)
level,
albumin
level,
phosphorus
level,
fistulae,
and HD
catheters

Author

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
28,135
crosssecondary
County
prevalence
patients
sectional
analysis of data
poverty
and incidence
treated by study
collected by the
where
of AVF use
1127
U.S. ESRD
centers are
hemodialy
Network
located
sis centers
Program

William
M.
McClell
an, 2010

20032006

Robert
N Foley,
2008

198-2003 205076
patients

Retrospectiv
e cohort

Medicare data
system

Profits vs
nonprofit
facilities

mortality rates

Study Findings
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County poverty inversely
associated with incident and
baseline prevalence of AVF
use (P for trend 0.001),
substantial increases in
prevalent AVF rates among
treatment centers did not
associate with county
poverty
Dialysis at for-profit
facilities was associated with
higher urea reduction ratios,
hemoglobin levels, Epoetin
doses,
and use of intravenous iron,
and less use of blood
transfusions and lower
proportions of patients on the
transplant waiting-list.
Patients dialyzed at for-profit
and at not-for-profit facilities
had similar mortality risks
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Author

Year

John M.
Brooks,
2005

1996–
1999

David
Van
Wyck,
2010

20052007

Unit of
Design
data type
Main
Outcome
analysis
exposure
Patients
Observation Patient and
Profit status patient’s
al risk
provider-level
of the
survival
adjustment
retrospective
dialysis
and
data
facility
instrumental
variable
methods
Prevalent Prospective Primary data
long-term observationa from DaVita Inc.
hemodialy l study.
database
sis
patients
from 606
before and
504
facilities
during
2005-07

Existing
facilities
(until
December
2004)
compared
to newly
enrolled
facilities in
DaVita
2005-07)

Survival,
anemia
management
and dialysis
adequacy

Study Findings
Using only the variation in
initial dialysis center profit
status that was related to the
relative proximity of forprofit and nonprofit dialysis
centers to the patient, no
relationship between dialysis
center profit status and
patient survival was found
Length of ownership is
associated with the better
clinical outcomes. existing
compared with newly
acquired DaVita facilities
showed optimum anemia
management and dialysis
adequacy however, the there
was no difference in
mortality after two years

Author

Year

172

Unit of
Design
data type
Main
Outcome
analysis
exposure
Retrospectiv Data were
Attainment Survival
Frances 198-2004 13,792
Patients
e analysis
obtained from
of optimum
ca
DCI’s
Dialysis
Tentori,
proprietary
dosage
2007
computerized
(single-pool
medical
Kt/V),
information
hematocrit,
system
serum
(DARWIN)
albumin,
calcium,
phosphorus
,
parathyroid
hormone
Initiated 204463
Retrospectiv U.S. Renal Data Rural All-cause
Saugar
patients
e Cohort
System SAF files urban
mortality and
Maripur dialysis
in 2006 Study
residence
kidney
i, 2012
2007
transplantatio
n

Study Findings
Values within guidelines for
single-pool Kt/V, hematocrit,
Serum albumin, calcium,
phosphorus, and parathyroid
hormone were associated
with decreased mortality.
The largest survival benefit
was found for serum
albumin.

Early mortality or long-term
hemodialysis (HD) mortality
did not significantly differ by
geographic residence.
micropolitan and rural PD
patients had higher risk for
long-term mortality than
urban PD patients, kidney
transplantation was more
likely in micropolitan and
rural HD patients

Author

Year

AM
O’Hare,
2006

19952002

Stephan
ie
Thomps
on, 2012

19952007

Unit of
Design
data type
Main
Outcome
analysis
exposure
552 279
Retrospectiv U.S. Renal Data degree of
Annualized
patients
e Cohort
System SAF files rurality
mortality and
Study
transplant
rates
726,347
adults
initiating
chronic
hemodialy
sis

Retrospectiv
e Cohort
Study

U.S. Renal Data rural/urban
System SAF files and remote
dwelling

Survival

Study Findings
Survival among rural
dwellers was better than rural
patients among black
population, however, rural
patients were less likely to
receive renal transplant
Remote dwelling (>100
miles) rather rural dwelling
is associated with increased
risk of mortality
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Author
Fadi
Almach
raki,
2016

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
performa Dialysis
Descriptive DFC, QIP data
SES of
Performance
nce year facilities
study
counties
penalties
2011
6506

Study Findings
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Dialysis clinic performance
penalties did vary by SES,
poorer outcomes observed
for clinic locations with
lower SES. By
poverty category,
approximately 5% of dialysis
clinics received QIP
penalties (low poverty, 4.8%;
average poverty, 4.3%; high
poverty, 4.5%). By clinic
setting (ie, rural/urban
status), 4.7% of all clinics
received penalties. Of
dialysis clinics in rural
counties, 6.2% received a
QIP penalty, whereas only
4.6% of clinics in urban
counties received penalties
for poor quality.

Author

Unit of
Design
data type
Main
Outcome
analysis
exposure
started
589,036
Retrospectiv USRDS, 2000
Income
Survival
Paul L.
e Cohort
U.S. Census
distribution
Kimmel, hemodial patients
ysis from
Study
data,
al
2013
2000
inequality,
through
residential
2008
segregation
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William
M.
McClell
an, 2010

Year

June 1,
2005 and
May 31,
2006

28,135
patients
treated by
1127
centers at
16 states

crosssectional
study

USRDS, 2000
U.S. Census
data,

Geographic
al poverty
at county
level

use of AVF

Study Findings
Residence in areas with
higher median household
income was associated with
improved survival. Among
whites, income inequality
was associated with
mortality, among blacks
exclusively, residence in
highly segregated areas was
associated with increased
mortality
County poverty inversely
associated with incident
AVF use. substantial
increases in prevalent AVF
rates among treatment
centers did not associate with
county poverty

Year

Hua
Hao,
2015

20072010

Tanya
S.
Johns,
2014

20062009

Unit of
Design
data type
Main
Outcome
analysis
exposure
patients
observationa USRDS, DFC
Geographic Use of AVF
from 5387 l cohort
and SES
and mortality
facilities
study
factors
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Author

11027
patients

Retrospectiv
e Cohort
Study

USRDS, 2000
U.S. Census
data,

Neighborho Mortality
od SES and
racial
difference

Study Findings
67% patients using AVF
with the wide range of 399%. Dialysis facilities with
the lowest rates of pre-ESRD
care were more likely to be
located in urban counties
with high African-American
populations and low
educational attainment. A
10% higher proportion of
patients receiving pre-ESRD
care was associated with
1.3% lower patient mortality
as reflected by facility-level
mortality.
Among patients living in low
SES, black young patients
were at higher risk of
mortality than white patients.
The difference in mortality
between black and white
were attenuated in high SES.

Author

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
399 424
Retrospectiv U.S. Renal Data Urban
Patient level:
Rudolph Patients
who
patients,
e cohort
System SAF
residential
Mortality and
A.
study for
files, (CMS)
segregation time to
Rodrigu initiated dialysis
patients’
Dialysis Facility
transplantatio
ez, 2007 dialysis1 facilities
995-2002 in
sample,
Compare
n; facility
operation cross
database
level: (anemia
in
sectional
management,
December study for the
dialysis
2004 (n=
facilities
adequacy, and
3244)
facility-level
mortality
rates).

Study Findings
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Mortality rates were higher
among white patients but not
among black patients living
in areas with a higher
percentage of
black residents. Time to
transplantation was longer
among both black and white
patients in areas with higher
percentage of black
residents. Dialysis facilities
located in areas with a higher
percentage of black residents
were more likely to have
higher-than expected
mortality rates and were less
likely to meet performance
targets.

Author
Stephen
F.
Derose,
2013
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Andy I.
Choi,
2010

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
2003–
Adult
Retrospectiv Secondary data
Race/ethnic ESRD
2009
members
e cohort
of members of
ity
(dialysis,
of Kaiser
Kaiser
transplantatio
Permanent
Permanente
n); mortality
e Southern
Southern
California
California, an
(526,498
integrated health
whites,
system
350,919
Hispanics,
136,923
blacks,
and
105,476
Asians)
2001 to
201, 5891 Retrospectiv Secondary data
white/black ESRD risk,
2005
veterans
e cohort
of VA
differences mortality

Study Findings
Blacks had more extreme
rates of e GFR decline,
Hispanics, and Asians. Black
were at the highest risk of
projected kidney failure
followed by Hispanic and
Asian as compared to the
Whites. Mortality among
those with projected kidney
failure was highest in whites.

Rates of end-stage renal
disease among black patients
exceeded those among white
patients at all levels of
baseline eGFR. Equal or
higher rates of death among
black persons at all levels of
eGFR. No difference in
mortality between whites and
black at eGFR <15
ml/min/1.75m2 while
mortality was higher among
black as compared to white
at eGFR 45-59

Author
Cristina
M.
Arce,
2013

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
1997615,618
retrospective Secondary data: Hispanic
All-cause and
2005
white
cohort
USRDS
ethnicity
cause-specific
(initiated patients
study.
(vs nonmortality
dialysis)
Hispanic
whites),
year of endstage renal
disease
incidence,
age
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Guofen
Yan,
2013

1995 and
2009

1,282,201
incident
dialysis
patients

retrospective Secondary data:
cohort
USRDS
study.

Race/ethnic
ity

mortality

Study Findings
Hispanics initiating dialysis
therapy experienced lower
mortality than non-Hispanic
whites, but age modified this
association. Mortality in
Hispanics was 33%, lower at
ages 18-39 years and 40-59
years, 19% and 6% lower at
ages 60-79 and 6% at age 80
years, respectively.
Differential access to kidney
transplantation was
responsible for much of the
apparent survival benefit
noted in younger Hispanics
The mortality risk was
lowest in Hispanics,
intermediate in non-Hispanic
blacks, and highest in nonHispanic whites for all age
groups except 18- to 30years group (black adjusted
mortality rates were higher
than white NH)

Author

Year

Lauren
M.
Kucirka
, 2011

19952009

2004Csaba
2006
P.
Kovesdy
, 2013

Unit of
Design
data type
Main
Outcome
analysis
exposure
1 330 007 observationa Secondary data: Race/ethnic mortality
incident
l cohort
USRDS
ity/age
patients
study
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518,406
white and
52,402
black
male US
veterans
nondialysis
dependent
CKD
stages 3–
5.

Historical
cohort.

Secondary data:
VA-Medicare
data merge
project

Black race

CKD stagespecific allcause
mortality

Study Findings
overall Black patients have
higher mortality than white.
Black were at lesser risk of
mortality at age more than 50
years while at higher risk at
age lesser than 50 years
The survival advantage for
blacks was attenuated after
adjustment for age (HR,
1.14; 95% CI, 1.12–1.16),
but was even magnified after
full multivariable adjustment
(HR, 0.72; 95% CI, 0.70–
0.73; p<0.001).

Author

Unit of
Design
data type
Main
Outcome
analysis
exposure
Patients
Patients
Retrospectiv Secondary data: US
Rate of preSaugar
204463
e cohort
USRDS
micropolita ESRD care,
Maripur who
initiated
study
n and rural mortality and
i, 2013
dialysis
dialysis
rate of
in 2006
patients
transplantatio
and 2007
n
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SzuChia
Chen,
2010

Year

19972006

192
hemodialy
sis patient

Retrospectiv
e cohort
study

Secondary data

Early
nephrology
referral vs
late referral

survival

Study Findings
No significant geographic
differences in attainment of
early nephrology care or
permanent dialysis access.
Both micropolitan and rural
patients received less dietary
education. Receiving care
reduced all-cause mortality
and increased the likelihood
of transplantation to a similar
degree regardless of
geographic residence.
ER is significantly associated
with prolonged survival after
exclusion of lead-time bias

Author

Year

Brenda 2006 2010.
W.
Gillespie
, 2015

Unit of
Design
data type
Main
Outcome
analysis
exposure
443 761
Retrospectiv Secondary data: longer pre
Survival
incident
e cohort
USRDS
ESRD
ESRD
study
nephrology
patients
care
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Takeshi 19962001,
Hasega
wa, 2009 20022004

8500
incident
HD
patients

Prospective
data
collection in
phase I & II

Dialysis
Outcomes and
Practice Patterns
Study (DOPPS)

early and
frequent
prenephrology
visit (PNV)

mortality in
the first year

Study Findings
Predictors of >12 months of
nephrology care included
having health insurance,
white race, younger age,
diabetes, hypertension and
US region. Longer preESRD nephrology care was
associated with lower firstyear mortality, higher
albumin and hemoglobin,
choice of peritoneal dialysis
and native fistula and
discussion of transplantation
options. Living in a state
with a 10% higher proportion
of patients receiving >12
months of pre-ESRD care
was associated with a 9.3%
lower relative mortality rate
PNV was associated with
significantly lower risk for
death at patient and facility
level.

Author

Year
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Unit of
Design
data type
Main
Outcome
analysis
exposure
1996 to
n
Prospective Dialysis
One-way
mortality,
Louise
2001,
20,994).
observationa Outcomes and
travel time withdrawal
M.
2002l cohort
Practice Patterns to
from dialysis
Moist,
2004
Study (DOPPS)
hemodialys therapy,
2008
is treatment hospitalization
, and
transplantatio
n
2005We
Retrospectiv Alberta Kidney
Residence
Markers of
Aminu
identified e cohort
Disease Network location (0– quality health
K. Bello, 2006
31 337
study
and the
50, 50.1–
care, mortality
2012
individual
provincial health 100, 100.1–
s with
ministry [Alberta 200 and
diabetes
Health and
>200 km)
and eGFR
Wellness
from
15–59
(AHW)]
nephrologis
mL/min/1.
t
73 m2

Study Findings
Longer travel time was
associated with greater
adjusted relative risk (RR) of
death. No association with
other outcomes

The hazard ratio of all-cause
mortality and hospitalization
increased with increasing
distance among patient with
CKD stage 3 and 4 living at
more than 50 km. remote
dwellers were less likely to
visit a nephrologist, less
likely to have hemoglobin
A1c and urinary albumin
measured within 1 year of
the index eGFR, and less
likely to receive an
angiotensin converting
enzyme
inhibitor, angiotensin
receptor blocker or statin

Author
Diana
Rucker,
2011

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
Jan
31,452
Retrospectiv Alberta Kidney
Residence
All-cause
2005outpatient e cohort
Disease Network location (0– mortality,
Dec2005 s
study
and the
50, 50.1–
dates of
provincial health 100, 100.1– hospitalization
ministry [Alberta 200 and
, and the date
Health and
>200 km)
of
Wellness
from
first renal
(AHW)]
nephrologis replacement
t
therapy for
people who
developed
ESRD

Study Findings
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Remote dwellers were less
likely to visit a nephrologist
or a multidisciplinary CKD
clinic within 18 months of
the index measurement of the
eGFR, receive an angiotensin
converting enzyme inhibitor
or receptor blocker in the
setting of
diabetes or proteinuria.
remote dwellers with
diabetes were significantly
less likely to have
hemoglobin A1c evaluated
within 1 year of the index
eGFR measurement, to have
urinary albumin assessed
biannually. Remote-dwelling
participants were
also significantly more likely
to die or be hospitalized
during follow-up than those
living closer

Author

Year

Unit of
Design
data type
Main
Outcome
analysis
exposure
Not
46
Prospective Data from the
rural and
anemia
Chiamentione chronic,
observationa hospital located
remote
Ter
stable
l cohort
in the rural
dwelling
CHAO, d
elderly
outskirts of New
2014
hemodialy
Taipei City
sis
in Taiwan
patients
4802
Retrospectiv DOPPS
patient
Mortality in
Brian D. 1996incident
e cohort
characterist the first year
Bradbur 2004
patients
study
ics
y, 2007

Study Findings
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travel distance between the
patient’s residence and the
dialysis unit led to an
incremental elevation of risk
of
anemia in chronic
hemodialysis patients
Mortality risk was higher in
initial 120 day after HD
initiation. 20% of all deaths
in the first 120 d occurred
subsequent to withdrawal
from dialysis. Older age,
catheter vascular access,
albumin <3.5, phosphorus
<3.5, cancer, and congestive
heart failure all were
associated with elevated
mortality. Pre-ESRD
nephrology care was
associated with a
significantly lower risk for
death before 120 d. Older
age, catheter vascular access,
albumin <3.5, phosphorus
<3.5, cancer, and congestive
heart failure all were
associated with elevated
mortality.

Author

Year

Dinanda 19942007
J. de
Jager,
2009

Pisoni
RL,
2015

Aug
2010Aug
2013
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Unit of
Design
data type
Main
Outcome
analysis
exposure
123 407
Retrospectiv European Renal cardiovascu Mortality
e cohort
Association–
lar and nonstudy
European
cardiac
Dialysis and
causes
Transplant
Association
registry
Patients
Prospective The Dialysis
Country,
Vascular
(n=3,442) observationa Outcomes and
patient
access use,
l cohort
Practice Patterns demographi pre–end-stage
study
Study(DOPPS)
cs, time
renal disease
Practice Monitor period.
access timing
of first
nephrologist
care and
arteriovenous
access
placement,
patient selfreported
vascular
access
preferences

Study Findings
Patients starting dialysis
have a generally increased
risk of death that is not
specifically caused by excess
cardiovascular mortality
Arteriovenous fistula (AVF)
use increased, Catheter use
decreased since the
introduction of PPS. AVF
use at dialysis therapy
initiation remains low. AVF
use was 2 folds higher in
blacks

Author

Year

John
Kalbflei
sch

2007–
2010

Unit of
Design
data type
Main
Outcome
analysis
exposure
5920
Prospective
CMS ESRD
Facilities
Standardized
dialysis
observationa data, Social
with more
mortality ratio
facilities
l cohort
Security Death
black
(SMR)
during
study
Master File
population
calendar
treated
year 2010

Study Findings
facilities with higher
proportions of black patients
had poorer survival
outcomes among black and
non-black patients; facilities
with the highest percentage
of black patients (top 10%)
had mortality rates
approximately 6% worse
than expected
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APPENDIX B: DISTRIBUTION OF DIALYSIS STATIONS AND QIP
SCORES AND ASSOCIATION BETWEEN THE STATIONS AND QIP
Study 1: descriptive Statistics total stations
The UNIVARIATE Procedure
Variable: TOTSTATS (TOTSTATS)
Moments
5193 Sum Weights

5193

Mean

18.9472468 Sum Observations

98412

Std Deviation

7.78185075 Variance

60.5572012

Skewness

1.31178711 Kurtosis

4.31143661

N

2179110 Corrected SS

Uncorrected SS

314473.546

Coeff Variation 41.0711426 Std Error Mean

0.10797717

Basic Statistical Measures
Location
Mean

Variability

18.94725 Std Deviation

7.78185

Median 18.00000 Variance
Mode

60.55720

12.00000 Range

80.00000

Interquartile Range 11.00000
Tests for Location: Mu0=0
Test

Statistic

Student's t

t

Sign

M

Signed Rank S

p Value

175.4746 Pr > |t|

<.0001

2592 Pr >= |M| <.0001
6719760 Pr >= |S| <.0001

Tests for Normality
Test

Statistic

p Value

Kolmogorov-Smirnov D 0.096781 Pr > D <0.0100
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Cramer-von Mises W-Sq 11.59547 Pr > W-Sq <0.0050
Anderson-Darling A-Sq 72.40248 Pr > A-Sq <0.0050

Study 1: descriptive statistics QIP scores
The UNIVARIATE Procedure
Variable: QIP (Quality Incentive Program)
Moments
N

5193 Sum Weights

Mean

81.3045822 Sum Observations

Std Deviation

12.4789841 Variance
189

5193
422296
155.725044

Moments
-0.9495545 Kurtosis

Skewness

1.57754604

35143280 Corrected SS

Uncorrected SS

808680.151

Coeff Variation 15.3484388 Std Error Mean

0.1731523

Basic Statistical Measures
Location
Mean

Variability

81.30458 Std Deviation

12.47898

Median 83.00000 Variance
Mode

155.72504

88.00000 Range

89.00000

Interquartile Range

17.00000

Tests for Location: Mu0=0
Test

Statistic

p Value

469.5553 Pr > |t|

Student's t

t

Sign

M

<.0001

2597 Pr >= |M| <.0001
6745708 Pr >= |S| <.0001

Signed Rank S

Tests for Normality
Test

Statistic

Kolmogorov-Smirnov D

p Value

0.103515 Pr > D

<0.0100

Cramer-von Mises

W-Sq 8.791008 Pr > W-Sq <0.0050

Anderson-Darling

A-Sq 53.74832 Pr > A-Sq <0.0050
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APPENDIX C: SCATTER PLOT SHOWING RELATIONSHIP
BETWEEN DIALYSIS STATIONS AND QIP SCORES
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APPENDIX D: ZHANG'S MODEL USING DIALYSIS STATIONS AS A
SQUARED TERM
Parameter

Estimate

Standard error Pr > |t|

Intercept
Stations
Stations*stations
chain 1
chain 2
chain 3
No chain
For-profit
Rural
Midwest
Northeast
South
Persons in poverty
Black population in county
Length of certification
R-square= 16.04%

76.926
0.194
-0.003
6.562
1.308
-4.798
-3.961
1.495
1.762
-0.897
1.234
0.690
0.003
-0.069
0.067

1.264
0.066
0.001
0.464
1.196
0.469
0.635
0.922
0.468
0.528
0.609
0.512
0.034
0.013
0.018
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<.0001
0.003
0.006
<.0001
0.274
<.0001
<.0001
0.105
2E-04
0.09
0.043
0.178
0.936
<.0001
2E-04

APPENDIX E: SUMMARY OF INCREMENTAL MODEL PREDICTING
PERFORMANCE SCORES
Estimate

Standard
Error

p-value

Model A
Dialysis facility size (ref: small)
Large
-0.44
0.85
0.6022
Medium
0.82
0.63
0.1942
Model B
Dialysis facility size (ref: small)
Large
1.08
0.87
0.2107
Medium
1.67
0.64
0.0093
Model C
Dialysis facility size (ref: small)
Large
2.81
1.23
0.0219
Medium
3.67
1.06
0.0005
Model A: adjusted for facility factors including chain type, home hemodialysis,
peritoneal dialysis, for-profit status, shift, low volume, regional networks, patients per
station, staff per 100 patients, dialysis treatment per facility, hemodialysis session per
week per patients, hours per session (Model R-square = 15.7%)
Model B: adjusted additionally for ecological factors including median household
income, unemployment rate among 16+, proportion of person in poverty/county,
proportion of black patients per county, proportion of Hispanic patients per county,
rurality, region, competition index (Model R-square = 17%)
Model C: adjusted additionally for patients factor including per facility average
distance from facility, average age of patients, proportion of male patients, proportion
of black patients, proportion of Hispanic patients, proportion of ≥ 2 comorbidities,
proportion of obese, proportion of Medicaid insured, proportion of uninsured,
proportion with catheter at the time of treatment initiation, proportion of pre-ESRD
nephrologist care, proportion of smokers, average hemoglobin level, average
glomerular filtration rate (Model R-square = 25.1%)
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APPENDIX F: ADJUSTED HAZARD RATIOS OF 1-YEAR
MORTALITY OF PATIENT BY PATIENT, FACILITY AND COUNTY
CHARACTERISTICS FROM FINAL ADJUSTED MODEL, CALENDAR
YEAR 2013
Characteristics

Parameter
estimate

SE

ChiSquare

p-value Hazard
95%
ratio Confidence
Limits

Patient factors
Sex (Ref=Female)
Male
Age at ESRD
incidence
Race (Ref= White
non-Hispanics)
Black NonHispanic
Hispanic only
Others
Vascular access
treatment (ref=
AVF/AVG)
Catheters
Others
Distance (Ref=
<1.9 miles)
≥1.9- <6.9 miles
≥6.9- <15.0
miles
≥15.0 miles
Insurance
Medicaid
(ref=No)

0.05
0.03

0.02
0.00

4.91
846.92

0.0266
<.0001

1.05
1.03

1.01
1.03

1.09
1.03

-0.36

0.03

146.97

<.0001

0.70

0.66

0.74

-0.53

0.04

156.74

<.0001

0.59

0.54

0.64

-0.56

0.06

85.65

<.0001

0.57

0.51

0.64

0.38
0.41

0.07
0.22

32.13
3.40

<.0001
0.065

1.46
1.51

1.28
0.98

1.66
2.35

0.05
0.03

0.03
0.03

2.96
1.02

0.0851
0.3118

1.05
1.03

0.99
0.97

1.12
1.09

0.08

0.03

8.45

0.0037

1.09

1.03

1.15

0.11

0.03

16.49

<.0001

1.12

1.06

1.18
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Characteristics
Private insurance
(ref=No)
No insurance
(ref=No)
Employment status
(Ref= Employed)
not employed
Retired
Basal metabolic
index (Ref= Normal
Weight)
Obese
Overweight
Underweight
Primary disease
causing ESRD (Ref=
Others)
Diabetes
Hypertension
Glomerulonephritis
Severity of
comorbidities (Ref=
0-1 comorbidities)
2 comorbidities
3 comorbidities
≥4 comorbidities
Comorbidities
diabetes (Ref= No)
ASHD (Ref= No)
CHF (Ref= No)
COPD (Ref= No)
Hypertension
(Ref= No)
CVA/TIA (Ref=
No)
PVD (Ref= No)
Comorbidity
(REF=No)
Current smoker
(Ref= No)

Parameter
estimate

SE

ChiSquare

0.03

13.66

0.46

0.07

44.04 <.0001

1.59

1.39

1.83

0.48
0.53

0.07
0.07

48.97
63.54

<.0001
<.0001

1.61
1.70

1.41
1.49

1.84
1.94

-0.18
-0.10
0.24

0.03
0.03
0.05

46.85
14.22
27.13

<.0001
0.0002
<.0001

0.90
0.83
1.28

0.86
0.79
1.16

0.95
0.88
1.40

-0.28
-0.25
-0.31

0.03
0.03
0.06

68.54
68.00
31.05

<.0001
<.0001
<.0001

0.76
0.78
0.74

0.71
0.73
0.66

0.81
0.82
0.82

0.22
0.34
0.72

0.04 31.50
0.04 65.43
0.05 257.92

<.0001
<.0001
<.0001

1.25
1.41
2.07

1.16
1.30
1.89

1.35
1.54
2.26

-0.11
-0.08
0.15
0.06
-0.47

0.03 14.50
0.03
8.52
0.02 37.30
0.03
3.50
0.03 234.24

0.0001
0.0035
<.0001
0.0614
<.0001

0.90
0.92
1.16
1.06
0.63

0.85
0.87
1.11
1.00
0.59

0.95
0.97
1.21
1.12
0.67

-0.05

0.03

2.06

0.1507

0.95

0.89

1.02

0.02
0.42

0.03
0.10

0.57
17.10

0.449
<.0001

1.02
1.52

0.96
1.25

1.09
1.86

-0.05

0.04

1.46

0.2264

0.95

0.87

1.03

-0.13
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p- Hazard
value ratio
0.0002

95%
Confidence
Limits
0.88 0.83 0.94

Characteristics
Pre ESRD care
Nephrologist care
(Ref= No)
Yes
Not reported
Dietary care
(Ref=No)
Yes
Not reported
Presence of mature
AVF/AVG (Ref= No)
Yes
Not reported
Received Epoetin
(Ref= No)
Yes
Not reported

Parameter
estimate

SE

ChiSquare

p- Hazard
value ratio

95%
Confidence
Limits

-0.20
0.06

0.03
0.04

54.80
1.80

<.0001
0.1797

0.82
1.06

0.78
0.97

0.86
1.15

0.01
-0.03

0.05
0.04

0.02
0.69

0.8977
0.4076

1.01
0.97

0.91
0.91

1.11
1.04

-0.32
-0.46

0.03 126.86
0.07 38.83

<.0001
<.0001

0.73
0.63

0.69
0.55

0.77
0.73

0.00
0.09

0.04
0.03

0.02
8.29

0.8899
0.004

1.00
1.09

0.93
1.03

1.07
1.16

-0.15

0.06

7.30

0.0069

0.86

0.77

0.96

-0.11

0.05

5.62

0.0178

0.90

0.82

0.98

0.02

0.04

0.27

0.6013

1.02

0.95

1.10

-0.12

0.08

2.28

0.131

0.89

0.76

1.04

-0.10

0.04

6.73

0.0095

0.91

0.84

0.98

0.05

0.04

1.82

0.1767

1.05

0.98

1.14

-0.01
0.03
0.06

0.04
0.03
0.05

0.10
1.34
1.58

0.7495
0.2471
0.2087

0.99
1.03
1.07

0.91
0.98
0.97

1.07
1.09
1.18

Facility Factors
Size (ref=small)
Medium (11-25
stations
Large (>25
stations)
Chain affiliation
(ref= No chains)
Chain 1: Large forprofit
Chain 2: Large not
for-profit
Chain 3: Large forprofit
Chain 4: Others
Dialysis treatments
(ref=>10,000)
<4000
4000-9999
For-profit (ref= No)
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Characteristics

Parameter
estimate

Offer Peritoneal
dialysis (ref= No)
Offer Home
Hemodialysis (ref=
No)
Offer Late shift
(ref= No)
Low volume
(ref=No)
Hemodialysis hours
per session
Hemodialysis
session per week
Patient Care
Technicians
Registered Nurses

SE

ChiSquare

p- Hazard
value ratio

0.01

0.02

0.10

0.7519

1.01

95%
Confidence
Limits
0.96 1.06

-0.07

0.03

5.84

0.0157

0.94

0.89

0.99

0.02

0.03

0.60

0.4388

1.02

0.97

1.08

0.01

0.08

0.01

0.9088

1.01

0.87

1.18

-0.013

0.023

0.348

0.5554

0.987 0.944 1.032

-0.032

0.056

0.331

0.5652

0.968 0.867 1.081

-0.004

0.003

1.134

0.287

0.996 0.990 1.003

0.014

0.005

9.379

0.0022

1.014 1.005 1.023

-0.03
0.06
-0.09

0.04
0.04
0.04

0.57
3.28
5.05

0.4495
0.0703
0.0246

0.97
1.07
0.91

0.91
1.00
0.85

1.04
1.15
0.96

0.02
-0.04
-0.09

0.04
0.10
0.07

0.19
0.21
1.76

0.665
0.6468
0.1842

1.02
0.96
0.92

0.94
0.79
0.80

1.10
1.16
1.04

0.001

0.001

1.904

0.1676

1.001 0.999 1.003

0.002
-0.004

0.001
0.007

2.445
0.308

0.1179
0.5787

1.002 1.000 1.004
0.996 0.983 1.010

-0.005

0.004

1.448

0.2288

0.995 0.987 1.003

0.000

0.000

0.799

0.3714

1.000 1.000 1.000

Patient’s county factors
Regions (ref=
Northeast)
Midwest
South
West
Rurality (ref=
Urban)
Micropolitan rural
Remote rural
Small adjacent
rural
proportion of
Hispanic
proportion of blacks
Unemployment
Rate, 16+
Percent Persons in
Poverty
Median Household
Income
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